

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2002**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

22nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2002

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

Cumulative Supplement 12

December 2002

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes	iv
1.3 Waived Exclusivity	vi
1.4 Tramadol Hydrochloride Tablets	vi
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Change Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

CUMULATIVE SUPPLEMENT 12
December 2002

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 22nd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 22nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 23rd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

DANBURY PHARMACEUTICALS INC
(DANBURY PHARMA)

WATSON LABORATORIES INC
(WATSON LABS)

DURAMED PHARMACEUTICALS INC
(DURAMED)

DURAMED PHARMACEUTICALS INC SUB OF BARR
LABORATORIES INC
(DURAMED PHARM BARR)

DERMIK LABORATORIES INC
(DERMIK LABS)

DERMIK LABORATORIES DIVISION OF AVENTIS
PHARMACEUTICALS INC
(DERMIK LABS)

DERMIK LABORATORIES INC SUB RORER
(DERMIK LABS)

DERMIK LABORATORIES DIVISION OF AVENTIS
PHARMACEUTICALS INC
(DERMIK LABS)

JANSSEN RESEARCH FDN
(JANSSEN)

JANSSEN PHARMACEUTICA PRODUCTS LP
(JANSSEN PHARMA)

JANSSEN RESEARCH FDN DIV
JOHNSON AND JOHNSON
(JANSSEN)

JANSSEN PHARMACEUTICA PRODUCTS LP
(JANSSEN PHARMA)

JOHNSON AND JOHNSON PHARMACEUTICAL
RESEARCH AND DEVELOPMENT LLC
(JOHNSON AND JOHNSON)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

MCNEIL CONSUMER HEALTHCARE DIVISION
(MCNEIL CONS)

MCNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS
DIVISION MCNEIL PPC
(MCNEIL CONS SPECLT)

MOVA PHARMACEUTICALS CORPORATION
(MOVA)

CLONMEL HEALTHCARE LTD
(CLONMEL HLTH)

NMC LABORATORIES INC

ALPHARMA US PHARMACEUTICAL DIV
(ALPHARMA US PAHRM)

PARKE DAVIS PHARMACEUTICALS LTD
(PARKE DAVIS PHARMS)

PFIZER PHARMACEUTICALS LTD
(PFIZER PHARM LTD)

RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
(JOHNSON RW)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

RW JOHNSON PHARMACEUTICAL RESEARCH
INSTITUTE DIV ORTHO PHARMACEUTICAL CORP
(JOHNSON RW)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

THAMES PHARMACAL COMPANY INC
(THAMES)

TARO PHARMACEUTICALS NORTH AMERICA INC
(TARO PHARMS US)

WHITEHALL LABORATORIES INC DIV AMERICAN HOME
PRODUCTS CORP
(WHITEHALL LABS)

WYETH CONSUMER HEALTHCARE
(WYETH CONS)

WHITEHALL ROBINS HEALTHCARE
(WHITEHALL LABS)

WYETH CONSUMER HEALTHCARE
(WYETH CONS)

1.3 WAIVED EXCLUSIVITY

Waived exclusivity - If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book.

However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

1.4 TRAMADOL HYDROCHLORIDE TABLETS. Tramadol Hydrochloride 50 mg tablet products approved under section 505(j) are marked with a (*) because there are special considerations governing the substitution of these products. The tramadol hydrochloride 50 mg tablets marked with a (*) are therapeutically equivalent (AB) to RW Johnson's Ultram (Tramadol Hydrochloride) 50 mg tablets. However, because of RW Johnson's exclusivity and patent protection for the 25 mg titration dosing regimen, tramadol hydrochloride drug products approved under section 505(j) may not carry the labeling for the 25 mg titration dosing regimen. Ultram 50 mg tablets are scored for use in the 25 mg titration schedule; tramadol hydrochloride 50 mg tablets approved under 505(j) are not scored. Prescribers and dispensers should be aware of this scoring difference between Ultram and other tramadol hydrochloride tablets and take it into account when writing a prescription or practicing drug product selection.

1.5 AVAILABILITY OF THE EDITION

The 22nd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is \$105.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the hard copy monthly supplement is at <http://www.fda.gov/cder/orange/supplement/cspreface.htm>. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 22nd annual edition of the 2001 Orange Book Patent and Exclusivity List is at <http://www.fda.gov/cder/orange/22bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:

<http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.html>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2001) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product

activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2001</u>	<u>JUN 2002</u>	<u>SEP 2002</u>	<u>DEC 2002</u>
DRUG PRODUCTS LISTED	10166	10193	10329	10465
SINGLE SOURCE	2665 (26.2%)	2400 (23.5%)	2399 (23.2%)	2420 (23.1%)
MULTISOURCE	7391 (72.7%)	7687 (75.4%)	7824 (75.7%)	7939 (75.9%)
THERAPEUTICALLY	7105 (69.9%)	7402 (72.6%)	7549 (73.1%)	7659 (73.2%)
EQUIVALENT				
NOT THERAPEUTICALLY	286 (2.8%)	285 (2.8%)	275 (2.7%)	280 (2.7%)
EQUIVALENT				
EXCEPTIONS ¹	110 (1.1%)	106 (1.1%)	106 (1.0%)	106 (1.0%)
NEW MOLECULAR ENTITIES	10	5	5	6
APPROVED				
NUMBER OF APPLICANTS	574	574	582	598

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS2	Change. Miscellaneous deletion
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 22ND EDITION
RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - DEC 2002

1-1

ACARBOSE

TABLET; ORAL

PRECOSE

>D>	BAYER	25MG	N20482 004	MAY 29, 1997	DEC	CAHN
>D>		50MG	N20482 001	SEP 06, 1995	DEC	CAHN
>D>	+	100MG	N20482 002	SEP 06, 1995	DEC	CAHN
>A>	BAYER PHARMS	25MG	N20482 004	MAY 29, 1997	DEC	CAHN
>A>		50MG	N20482 001	SEP 06, 1995	DEC	CAHN
>A>	+	100MG	N20482 002	SEP 06, 1995	DEC	CAHN

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

SECTRAL

AB	ESP PHARMA	EQ 200MG BASE	N18917 001	DEC 28, 1984	JUL	CAHN
AB	+	EQ 400MG BASE	N18917 003	DEC 28, 1984	JUL	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE

AB	VINTAGE PHARMS	325MG;50MG;40MG;30MG	N75929 001	APR 22, 2002	APR	NEWA
----	----------------	----------------------	------------	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

PHENAPHEN W/ CODEINE NO. 2

@	ROBINS AH	325MG;15MG	N84444 001		MAY	DISC
---	-----------	------------	------------	--	-----	------

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+	ALPHARMA	120MG/5ML;12MG/5ML	N85861 001		MAY	CRLD
----	---	----------	--------------------	------------	--	-----	------

TYLENOL W/ CODEINE

@	JOHNSON RW	120MG/5ML;12MG/5ML	N85057 001		MAY	DISC
---	------------	--------------------	------------	--	-----	------

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	ABLE	300MG;30MG	N40452 001	AUG 01, 2002	AUG	NEWA	
AA		300MG;60MG	N40459 001	AUG 01, 2002	AUG	NEWA	
	@	PUREPAC PHARM	300MG;60MG	N86683 001		MAY	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	KV PHARM	500MG/15ML;7.5MG/15ML	N40366 001	JAN 23, 2002	JAN	NEWA
----	----------	-----------------------	------------	--------------	-----	------

TABLET; ORAL

AA	ABLE	325MG;7.5MG	N40464 001	OCT 23, 2002	OCT	NEWA	
AA		325MG;10MG	N40464 002	OCT 23, 2002	OCT	NEWA	
AA		325MG;5MG	N40478 001	NOV 08, 2002	NOV	NEWA	
AA		500MG;10MG	N40473 001	NOV 06, 2002	NOV	NEWA	
AA		500MG;5MG	N40477 001	NOV 06, 2002	NOV	NEWA	
AA		650MG;10MG	N40476 001	OCT 23, 2002	OCT	NEWA	
AA		750MG;7.5MG	N40469 001	OCT 25, 2002	OCT	NEWA	
AA	+	MALLINCKRODT	660MG;10MG	N40084 003	JUL 29, 1996	JUL	CTNA
AA		750MG;10MG	N40468 001	OCT 31, 2002	OCT	NEWA	
AA	UCB	500MG;10MG	N40210 001	AUG 13, 1997	JUN	CAHN	
AA	+	WATSON LABS	750MG;10MG	N40094 004	MAR 22, 1999	OCT	CFTG

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

NORCO

AA + WATSON LABS 325MG;5MG N40099 001 JUN 25, 1997 MAY CTNA

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HCL

AB AMIDE PHARM 650MG;EQ 25MG BASE N76202 001 AUG 02, 2002 AUG NEWA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET

@ AAIPHARMA LLC

325MG;32.5MG

N16844 001 JUN CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

AB + AAIPHARMA LLC 650MG;100MG N17122 002 JUN CAHN

DARVOCET-N 50

AB AAIPHARMA LLC 325MG;50MG N17122 001 JUN CAHN

ACYCLOVIR

>A> CREAM; TOPICAL

>A> ZOVIRAX

>A> + GLAXOSMITHKLINE 5% N21478 001 DEC 30, 2002 DEC NEWA

TABLET; ORAL

ACYCLOVIR

AB NEOSAN PHARMS 400MG N74946 001 NOV 19, 1997 JUL CAHN

AB 800MG N74946 002 NOV 19, 1997 JUL CAHN

ADEFOVIR DIPIVOXIL

TABLET; ORAL

HEPSERA

+ GILEAD 10MG N21449 001 SEP 20, 2002 SEP NEWA

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

@ ISO TEX

100uCi/VIAL

N17835 001 JUN DISC

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

@ MALLINCKRODT

6.67uCi/ML

N17844 003 JUN DISC

@

100uCi/ML

N17844 002 JUN DISC

ALBUTEROL

AEROSOL, METERED; INHALATION

PROVENTIL

BN + SCHERING 0.09MG/INH N17559 001 JUN CRLD

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROVENTIL-HFA

BX +	3M	EQ 0.09MG BASE/INH	N20503 001	AUG 15, 1996	MAR	CTEC
------	----	--------------------	------------	--------------	-----	------

VENTOLIN HFA

BX +	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	MAR	CTEC
------	-----------------	--------------------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

AB	SIDMAK LABS	EQ 4MG BASE	N76130 002	SEP 26, 2002	SEP	NEWA
----	-------------	-------------	------------	--------------	-----	------

AB		EQ 8MG BASE	N76130 003	SEP 26, 2002	SEP	NEWA
----	--	-------------	------------	--------------	-----	------

VOLMAX

AB +	MURO	EQ 4MG BASE	N19604 002	DEC 23, 1992	SEP	CFTG
------	------	-------------	------------	--------------	-----	------

AB +		EQ 8MG BASE	N19604 001	DEC 23, 1992	SEP	CFTG
------	--	-------------	------------	--------------	-----	------

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP +	GD SEARLE LLC	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986	JUL	CAHN
------	---------------	------------------	------------	--------------	-----	------

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

a GENZYME

10 UNITS/ML

N20057 004	MAY 08, 1992	JUN	DISC
------------	--------------	-----	------

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

+ DSM PHARMS

EQ 500MG BASE/VIAL

N20298 001	MAY 17, 1996	JUN	CAHN
------------	--------------	-----	------

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN;DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATESODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION

INFUVITE ADULT

+ SABEX 2002

2 IU/ML;20MG/ML;12UGM/ML;40

IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/M

L;0.8MG/ML;0.72MG/ML;0.6MG/ML;600

IU/ML

N21163 001	MAY 18, 2000	AUG	CTNA
------------	--------------	-----	------

MULTI-12

+ SABEX 2002

2 IU/ML;20MG/ML;12UGM/ML;40

IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/M

L;0.8MG/ML;0.72MG/ML;0.6MG/ML;600

IU/ML

N21163 001	MAY 18, 2000	APR	CAHN
------------	--------------	-----	------

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

PHARMACIA AND UPJOHN

0.01MG/VIAL

N21212 001	JUN 11, 2002	JUN	NEWA
------------	--------------	-----	------

0.02MG/VIAL

N21212 002	JUN 11, 2002	JUN	NEWA
------------	--------------	-----	------

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HCL

AA CAROLINA MEDCL 50MG/5ML

N75819 001 SEP 11, 2002 SEP NEWA

TABLET; ORAL

>A> AB USL PHARMA 100MG

N76186 001 DEC 16, 2002 DEC NEWA

SYMMETREL

>D> + ENDO PHARMS 100MG

N18101 001 DEC CFTG

>A> AB + 100MG

N18101 001 DEC CFTG

AMCINONIDE

LOTION; TOPICAL

AMCINONIDE

AB ALTANA 0.1%

N76329 001 NOV 06, 2002 NOV NEWA

CYCLOCORT

AB + FUJISAWA HLTHCARE 0.1%

N19729 001 JUN 13, 1988 NOV CFTG

OINTMENT; TOPICAL

AMCINONIDE

AB ALTANA 0.1%

N76096 001 NOV 19, 2002 NOV NEWA

CYCLOCORT

AB + FUJISAWA HLTHCARE 0.1%

N18498 001 NOV CFTG

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

@ MEDIMMUNE ONCOLOGY 375MG/VIAL

N20221 002 SEP 10, 1999 JUN DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 7%

@ ABBOTT 7% (7GM/100ML)

N17673 002 JUN DISC

AMINOSYN 8.5%

@ ABBOTT 8.5% (8.5GM/100ML)

N17673 004 JUN DISC

AMINOSYN II 3.5%

@ ABBOTT 3.5% (3.5GM/100ML)

N19438 001 APR 03, 1986 JUN DISC

BRANCHAMIN 4%

@ BAXTER HLTHCARE 4% (4GM/100ML)

N18678 001 SEP 28, 1984 JUN DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP ABBOTT 50MG/ML

N75955 001 OCT 18, 2002 OCT NEWA

AP AM PHARM PARTNERS 50MG/ML

N75761 001 OCT 15, 2002 OCT NEWA

AP BEDFORD 50MG/ML

N76018 001 OCT 15, 2002 OCT NEWA

AP BEDFORD LABS 50MG/ML

N76299 001 OCT 24, 2002 OCT NEWA

AP BEN VENUE 50MG/ML

N76088 001 OCT 15, 2002 OCT NEWA

>A> AP BIONICHE (CANADA) 50MG/ML

N76217 001 OCT 15, 2002 DEC CAHN

AP FAULDING 50MG/ML

N76108 001 OCT 15, 2002 OCT NEWA

>D> AP PHARMAFORCE 50MG/ML

N76217 001 OCT 15, 2002 DEC CAHN

AP 50MG/ML

N76217 001 OCT 15, 2002 OCT NEWA

CORDARONE

AP + WYETH AYERST 50MG/ML

N20377 001 AUG 03, 1995 OCT CFTG

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HCL

AB	+	EON	400MG	N75315 002	JUN 30, 2000	NOV	CFTG
		+	400MG	N75315 002	JUN 30, 2000	OCT	CRLD
>A>		+	TARO	N75424 002	DEC 18, 2002	DEC	NEWA
AB			400MG	N76362 001	NOV 29, 2002	NOV	NEWA
		CORDARONE					
AB		WYETH AYERST	200MG	N18972 001	DEC 24, 1985	OCT	CRLD

AMLEXANOX

PASTE; DENTAL

APHTHASOL

+	GLAXOSMITHKLINE CONS	5%	N20511 001	DEC 17, 1996	JUL	CAHN
---	----------------------	----	------------	--------------	-----	------

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

	NOVARTIS	EQ 5MG BASE;20MG	N20364 004	MAR 03, 1995	AUG	CRLD
+		EQ 10MG BASE;20MG	N20364 005	JUN 20, 2002	AUG	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB		CLAY PARK	EQ 12% BASE	N75774 001	MAY 01, 2002	MAY	NEWA
		LAC-HYDRIN					
AB	+	WESTWOOD SQUIBB	EQ 12% BASE	N20508 001	AUG 29, 1996	MAY	CFTG
		LOTION; TOPICAL					
		AMMONIUM LACTATE					
AB		PADDOCK	EQ 12% BASE	N75575 001	JUN 11, 2002	JUN	NEWA
		LAC-HYDRIN					
AB	+	WESTWOOD SQUIBB	EQ 12% BASE	N19155 001	APR 24, 1985	JUN	CFTG

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB		RANBAXY	200MG/5ML	N65113 001	NOV 29, 2002	NOV	NEWA
AB			400MG/5ML	N65113 002	NOV 29, 2002	NOV	NEWA
>A>		TEVA	200MG/5ML	N65119 001	DEC 04, 2002	DEC	NEWA
>A>			400MG/5ML	N65119 002	DEC 04, 2002	DEC	NEWA

AMOXIL

AB		GLAXOSMITHKLINE	200MG/5ML	N50760 001	APR 15, 1999	NOV	CFTG
AB	+		400MG/5ML	N50760 002	APR 15, 1999	NOV	CFTG

TABLET, CHEWABLE; ORAL

AMOXICILLIN

	@	APOTHECON	125MG	N64131 001	MAY 06, 1996	JUL	DISC
	@		250MG	N64131 002	MAY 06, 1996	JUL	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	GENEVA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65066 001	JUN 05, 2002	JUN	NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	N65066 002	JUN 05, 2002	JUN	NEWA
>A>	AB	LEK SVCS	200MG/5ML;EQ 28.5MG BASE/5ML	N65098 001	DEC 16, 2002	DEC NEWA
>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	N65098 002	DEC 16, 2002	DEC NEWA

AUGMENTIN '200'

AB	GLAXOSMITHKLINE	200MG/5ML;EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996	JUN	CFTG
----	-----------------	------------------------------	------------	--------------	-----	------

AUGMENTIN '400'

AB	GLAXOSMITHKLINE	400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	JUN	CFTG
		400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	FEB	CRLD

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	GENEVA PHARMS	500MG;EQ 125MG BASE	N65064 001	MAR 15, 2002	MAR	NEWA
AB		875MG;EQ 125MG BASE	N65063 001	MAR 14, 2002	MAR	NEWA
AB	LEK SVCS	875MG;EQ 125MG BASE	N65093 001	NOV 21, 2002	NOV	NEWA
AB	RANBAXY	500MG;EQ 125MG BASE	N65109 001	NOV 04, 2002	NOV	NEWA
AB		875MG;EQ 125MG BASE	N65102 001	SEP 17, 2002	SEP	NEWA
AB	TEVA	500MG;EQ 125MG BASE	N65101 001	OCT 30, 2002	OCT	NEWA
AB		875MG;EQ 125MG BASE	N65096 001	OCT 29, 2002	OCT	NEWA

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	LEK SVCS	500MG;EQ 125MG BASE	N65117 001	NOV 27, 2002	NOV	NEWA
----	----------	---------------------	------------	--------------	-----	------

AUGMENTIN '500'

AB	GLAXOSMITHKLINE	500MG;EQ 125MG BASE	N50564 002	AUG 06, 1984	MAR	CFTG
----	-----------------	---------------------	------------	--------------	-----	------

AUGMENTIN '875'

AB +	GLAXOSMITHKLINE	875MG;EQ 125MG BASE	N50720 001	FEB 13, 1996	MAR	CFTG
------	-----------------	---------------------	------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	GENEVA PHARMS	200MG;EQ 28.5MG BASE	N65065 001	APR 18, 2002	APR	NEWA
AB		400MG;EQ 57MG BASE	N65065 002	APR 18, 2002	APR	NEWA

AUGMENTIN '200'

AB	GLAXOSMITHKLINE	200MG;EQ 28.5MG BASE	N50726 001	MAY 31, 1996	APR	CFTG
----	-----------------	----------------------	------------	--------------	-----	------

AUGMENTIN '400'

AB +	GLAXOSMITHKLINE	400MG;EQ 57MG BASE	N50726 002	MAY 31, 1996	APR	CFTG
------	-----------------	--------------------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

AUGMENTIN XR

+	GLAXOSMITHKLINE	1GM;62.5MG	N50785 001	SEP 25, 2002	SEP	NEWA
---	-----------------	------------	------------	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

SHIRE PHARM	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001	AUG	CAHN
-------------	-------------------------	------------	--------------	-----	------

ADDERALL XR 15

SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N21303 006	MAY 22, 2002	JUN	NEWA
------------	-----------------------------	------------	--------------	-----	------

SHIRE PHARM	3.75MG;3.75MG;3.75MG;3.75MG	N21303 006	MAY 22, 2002	AUG	CAHN
-------------	-----------------------------	------------	--------------	-----	------

ADDERALL XR 20

SHIRE PHARM	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	AUG	CAHN
-------------	-----------------	------------	--------------	-----	------

ADDERALL XR 25

SHIRE LABS	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	JUN	NEWA
------------	-----------------------------	------------	--------------	-----	------

SHIRE PHARM	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	AUG	CAHN
-------------	-----------------------------	------------	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;
DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 30

+	SHIRE PHARM	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001	AUG	CAHN
---	-------------	-------------------------	------------	--------------	-----	------

ADDERALL XR 5

	SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N21303 005	MAY 22, 2002	JUN	NEWA
--	------------	-----------------------------	------------	--------------	-----	------

	SHIRE PHARM	1.25MG;1.25MG;1.25MG;1.25MG	N21303 005	MAY 22, 2002	AUG	CAHN
--	-------------	-----------------------------	------------	--------------	-----	------

TABLET; ORAL

ADDERALL 10

AB	SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007	FEB 13, 1996	FEB	CFTG
----	------------	-------------------------	------------	--------------	-----	------

ADDERALL 20

AB	SHIRE LABS	5MG;5MG;5MG;5MG	N11522 008	FEB 13, 1996	FEB	CFTG
----	------------	-----------------	------------	--------------	-----	------

ADDERALL 30

AB	+	SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N11522 010	MAY 12, 1997	FEB	CFTG
----	---	------------	-------------------------	------------	--------------	-----	------

ADDERALL 5

AB	SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N11522 009	MAY 12, 1997	FEB	CFTG
----	------------	-----------------------------	------------	--------------	-----	------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	N40422 001	FEB 11, 2002	FEB	NEWA
----	------	-----------------------------	------------	--------------	-----	------

AB		2.5MG;2.5MG;2.5MG;2.5MG	N40422 002	FEB 11, 2002	FEB	NEWA
----	--	-------------------------	------------	--------------	-----	------

AB		5MG;5MG;5MG;5MG	N40422 003	FEB 11, 2002	FEB	NEWA
----	--	-----------------	------------	--------------	-----	------

AB		7.5MG;7.5MG;7.5MG;7.5MG	N40422 004	FEB 11, 2002	FEB	NEWA
----	--	-------------------------	------------	--------------	-----	------

AB	COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	N40444 001	JUN 19, 2002	JUN	NEWA
----	------------	-----------------------------	------------	--------------	-----	------

AB		2.5MG;2.5MG;2.5MG;2.5MG	N40444 002	JUN 19, 2002	JUN	NEWA
----	--	-------------------------	------------	--------------	-----	------

AB		5MG;5MG;5MG;5MG	N40444 003	JUN 19, 2002	JUN	NEWA
----	--	-----------------	------------	--------------	-----	------

AB		7.5MG;7.5MG;7.5MG;7.5MG	N40444 004	JUN 19, 2002	JUN	NEWA
----	--	-------------------------	------------	--------------	-----	------

AB	EON	1.25MG;1.25MG;1.25MG;1.25MG	N40470 001	SEP 27, 2002	SEP	NEWA
----	-----	-----------------------------	------------	--------------	-----	------

AB		2.5MG;2.5MG;2.5MG;2.5MG	N40439 001	JUN 14, 2002	JUN	NEWA
----	--	-------------------------	------------	--------------	-----	------

AB		5MG;5MG;5MG;5MG	N40439 002	JUN 14, 2002	JUN	NEWA
----	--	-----------------	------------	--------------	-----	------

AB		7.5MG;7.5MG;7.5MG;7.5MG	N40439 003	JUN 14, 2002	JUN	NEWA
----	--	-------------------------	------------	--------------	-----	------

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+	ELAN PHARMS	5MG/ML	N50724 001	NOV 20, 1995	JAN	CAHN
---	-------------	--------	------------	--------------	-----	------

+	ENZON	5MG/ML	N50724 001	NOV 20, 1995	NOV	CAHN
---	-------	--------	------------	--------------	-----	------

SUSPENSION; ORAL

FUNGIZONE

Q	BRISTOL MYERS SQUIBB	100MG/ML	N50341 003		JUN	DISC
---	----------------------	----------	------------	--	-----	------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	ESI LEDERLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074 001	MAR 19, 2002	MAR	NEWA
----	-------------	-------------------------------------	------------	--------------	-----	------

AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074 002	MAR 19, 2002	MAR	NEWA
----	--	-----------------------------------	------------	--------------	-----	------

AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076 001	MAR 19, 2002	MAR	NEWA
----	--	------------------------------------	------------	--------------	-----	------

UNASYN

AP	+	PFIZER	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N50608 002	DEC 31, 1986	MAR	CFTG
----	---	--------	-------------------------------------	------------	--------------	-----	------

AP	+		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N50608 001	DEC 31, 1986	MAR	CFTG
----	---	--	-----------------------------------	------------	--------------	-----	------

AP	+		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N50608 005	DEC 10, 1993	MAR	CFTG
----	---	--	------------------------------------	------------	--------------	-----	------

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

@ GLAXOSMITHKLINE

50MG

N21007 001 APR 15, 1999 MAY DISC

@

150MG

N21007 002 APR 15, 1999 MAY DISC

SOLUTION; ORAL

@ GLAXOSMITHKLINE

15MG/ML

N21039 001 APR 15, 1999 MAY DISC

ARIPIRAZOLE

TABLET; ORAL

ABILIFY

OTSUKA

2MG

N21436 006 NOV 15, 2002 NOV NEWA

5MG

N21436 005 NOV 15, 2002 NOV NEWA

10MG

N21436 001 NOV 15, 2002 NOV NEWA

15MG

N21436 002 NOV 15, 2002 NOV NEWA

20MG

N21436 003 NOV 15, 2002 NOV NEWA

+

30MG

N21436 004 NOV 15, 2002 NOV NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SABEX 2002

80MG/VIAL;0.02MG/VIAL;400

IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14M

G/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIA

L;1.2MG/VIAL;7 IU/VIAL;2,300

IU/VIAL;0.2MG/VIAL

N21265 001 FEB 21, 2001 APR CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ AAIPHARMA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;

5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17

MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/V

IAL;EQ 1.2MG

BASE/VIAL;0.7MG/VIAL;7MG/VIAL

N18920 001 SEP 21, 2000 JUL CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

AP + AAIPHARMA

10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/
ML;20

IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.3

6MG/ML;0.3MG/ML;330 UNITS/ML;1

IU/ML

N08809 004 AUG 08, 1985 JUL CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL					
DARVON COMPOUND					
+	AAIPHARMA LLC	389MG;32.4MG;32MG	N10996 006	MAR 08, 1983	JUN CAHN
DARVON COMPOUND-65					
AA +	AAIPHARMA LLC	389MG;32.4MG;65MG	N10996 007	MAR 08, 1983	JUN CAHN

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL					
TALWIN COMPOUND					
@	SANOFI SYNTHELABO	325MG;EQ 12.5MG BASE	N16891 001		JUN DISC

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL					
DARVON W/ ASA					
+	AAIPHARMA LLC	325MG;65MG	N10996 005		JUN CAHN

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL					
DARVON-N W/ ASA					
@	AAIPHARMA LLC	325MG;100MG	N16829 001		JUN CAHN
TABLET; ORAL					
@	AAIPHARMA LLC	325MG;100MG	N16863 001		JUN CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL					
STRATTERA					
	LILLY	5MG	N21411 001	NOV 26, 2002	NOV NEWA
		10MG	N21411 002	NOV 26, 2002	NOV NEWA
		18MG	N21411 003	NOV 26, 2002	NOV NEWA
		25MG	N21411 004	NOV 26, 2002	NOV NEWA
		40MG	N21411 005	NOV 26, 2002	NOV NEWA
+		60MG	N21411 006	NOV 26, 2002	NOV NEWA

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR					
ATNAA					
+	@ US ARMY	2.1MG/0.7ML;600MG/2ML	N21175 001	JAN 17, 2002	JAN NEWA
	@	2.1MG/0.7ML;600MG/2ML	N21175 001	JAN 17, 2002	FEB NEWA

AZELAIC ACID

>A>	GEL; TOPICAL				
>A>	FINACEA				
>A>	+	BERLEX	15%	N21470 001	DEC 24, 2002 DEC NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC					
OPTIVAR					
+	MURO	0.05%	N21127 001	MAY 22, 2000	MAY CAHN

AZITHROMYCIN DIHYDRATE

TABLET; ORAL

ZITHROMAX

+ PFIZER EQ 500MG BASE

N50784 001 MAY 24, 2002 MAY NEWA

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

a BRISTOL MYERS SQUIBB 500MG/VIAL

N50580 001 DEC 31, 1986 JUN DISC

a 1GM/VIAL

N50580 002 DEC 31, 1986 JUN DISC

a 2GM/VIAL

N50580 003 DEC 31, 1986 JUN DISC

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

>A> AP AM PHARM PARTNERS 50,000 UNITS/VIAL

N65116 001 DEC 03, 2002 DEC NEWA

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT ALTANA 500 UNITS/GM; 10,000 UNITS/GM

N65022 001 FEB 27, 2002 FEB NEWA

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

VANCENASE AQ

a SCHERING EQ 0.084MG DIPROP/SPRAY

N20469 001 JUN 26, 1996 OCT DISC

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

a APOTHECON 10MG

N12164 003 JUN DISC

NATURETIN-5

+ APOTHECON 5MG

N12164 002 JUN CRLD

BENZONATATE

CAPSULE; ORAL

TESSALON

+ FOREST LABS 200MG

N11210 003 JUN 25, 1999 MAR NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

DUAC

+ STIEFEL 5%;EQ 1% BASE

N50741 001 AUG 26, 2002 AUG NEWA

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA COREPHARMA 0.5MG

N72264 001 FEB 27, 1989 MAY CAHN

AA 1MG

N72265 001 FEB 27, 1989 MAY CAHN

AA 2MG

N72266 001 FEB 27, 1989 MAY CAHN

AA + PAR PHARM 0.5MG

N88877 001 APR 11, 1985 AUG CRLD

AA + 1MG

N88894 001 APR 11, 1985 AUG CRLD

AA +	COGENTIN	2MG	N88895 001	APR 11, 1985	AUG	CRLD
	@ MERCK	0.5MG	N09193 004		AUG	DISC
	@	1MG	N09193 003		AUG	DISC
	@	2MG	N09193 002		AUG	DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+	SCHWARZ PHARMA	60UMOLAR	N50114 001		JUL	CAHN
---	----------------	----------	------------	--	-----	------

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB +	FOUGERA	EQ 0.05% BASE	N19141 001	SEP 04, 1984	AUG	CRLD
	DIPROSONE					
	@ SCHERING	EQ 0.05% BASE	N17691 001		AUG	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ALPHARMA US PHARM	EQ 0.05% BASE;1%	N76002 001	AUG 02, 2002	AUG	NEWA
----	-------------------	------------------	------------	--------------	-----	------

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

@ LOREX	5MG;12.5MG	N19807 001	OCT 30, 1992	JUN	DISC
@	10MG;12.5MG	N19807 002	OCT 30, 1992	JUN	DISC

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

@ ALCON	EQ 0.25% BASE;1.75%	N20619 001	APR 17, 1997	JUN	DISC
---------	---------------------	------------	--------------	-----	------

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

@ ABBOTT	5MG/ML	N12418 002		JUN	DISC
----------	--------	------------	--	-----	------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	MUTUAL PHARM	5MG	N75474 001	OCT 25, 2002	OCT	NEWA
AB		10MG	N75474 002	OCT 25, 2002	OCT	NEWA

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

@ SANOFI SYNTHELABO	0.37MG/INH	N18770 001	DEC 28, 1984	JUN	DISC
---------------------	------------	------------	--------------	-----	------

SOLUTION; INHALATION

@ SANOFI SYNTHELABO	0.2%	N19548 001	FEB 19, 1992	JUN	DISC
---------------------	------	------------	--------------	-----	------

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

a ALLERGAN

0.2%

N20613 001 SEP 06, 1996 AUG DISC

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB LEK SVCS

EQ 2.5MG BASE

N74631 001 JAN 13, 1998 JAN CMFD

PARLODEL

AB + NOVARTIS

EQ 2.5MG BASE

N17962 001 JAN CFTG

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

BROMANYL

a ALPHARMA

12.5MG/5ML; 10MG/5ML

N88343 001 AUG 15, 1984 MAY DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

a ALPHARMA

2MG/5ML; 10MG/5ML; 30MG/5ML

N88722 001 MAR 07, 1985 OCT DISC

BROMFED-DM

AA VERUM PHARMS

2MG/5ML; 10MG/5ML; 30MG/5ML

N89681 001 DEC 22, 1988 NOV CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HCL KIT

a ABBOTT

0.075%

N19978 001 SEP 03, 1992 JUN DISC

a

0.114%

N19978 002 SEP 03, 1992 JUN DISC

a

0.23%

N19978 003 SEP 03, 1992 JUN DISC

BUPIVACAINE HCL PRESERVATIVE FREE

AP INTL MEDICATED

0.25%

N76012 001 JAN 09, 2002 JAN NEWA

AP

0.5%

N76012 002 JAN 09, 2002 JAN NEWA

AP

0.75%

N76012 003 JAN 09, 2002 JAN NEWA

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBUTEX

RECKITT BENCKISER

EQ 2MG BASE

N20732 002 OCT 08, 2002 OCT NEWA

+

EQ 8MG BASE

N20732 003 OCT 08, 2002 OCT NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER

2MG; 0.5MG

N20733 001 OCT 08, 2002 OCT NEWA

+

8MG; 2MG

N20733 002 OCT 08, 2002 OCT NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN SR

GLAXOSMITHKLINE

150MG

N20358 003 OCT 04, 1996 JUL CRLD

+

200MG

N20358 004 JUN 14, 2002 JUL NEWA

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

@ BRISTOL MYERS SQUIBB

5MG

N21190 001 DEC 20, 2000 JUN DISC

@

7.5MG

N21190 002 DEC 20, 2000 JUN DISC

@

10MG

N21190 003 DEC 20, 2000 JUN DISC

@

15MG

N21190 004 DEC 20, 2000 JUN DISC

TABLET; ORAL

BUSPIRONE HCL

AB EGIS

5MG

N75119 001 MAR 14, 2002 MAR NEWA

AB

10MG

N75119 002 MAR 14, 2002 MAR NEWA

AB

GENEVA PHARMS

5MG

N75413 001 MAR 19, 2002 MAR NEWA

AB

10MG

N75413 002 MAR 19, 2002 MAR NEWA

AB

15MG

N75413 003 MAR 19, 2002 MAR NEWA

AB

KV PHARM

5MG

N75572 001 FEB 27, 2002 FEB NEWA

AB

10MG

N75572 002 FEB 27, 2002 FEB NEWA

AB

15MG

N75572 003 FEB 27, 2002 FEB NEWA

AB

MYLAN

5MG

N75272 001 MAR 01, 2002 MAR NEWA

AB

10MG

N75272 002 MAR 01, 2002 MAR NEWA

AB

30MG

N76008 001 JUN 28, 2001 MAY CAHN

AB

PAR PHARM

5MG

N75467 001 FEB 28, 2002 FEB NEWA

AB

10MG

N75467 003 FEB 28, 2002 FEB NEWA

AB

15MG

N75467 004 FEB 28, 2002 FEB NEWA

AB

PHARMEX PRODS

5MG

N75388 001 MAY 09, 2002 MAY NEWA

AB

10MG

N75388 002 MAY 09, 2002 MAY NEWA

AB

15MG

N75388 003 MAY 09, 2002 MAY NEWA

AB

TEVA

5MG

N75022 001 FEB 28, 2002 FEB NEWA

AB

10MG

N75022 002 FEB 28, 2002 FEB NEWA

AB

15MG

N75022 003 FEB 28, 2002 FEB NEWA

AB

TORPHARM

5MG

N75521 001 APR 05, 2002 APR NEWA

AB

10MG

N75521 002 APR 05, 2002 APR NEWA

AB

15MG

N75521 003 APR 05, 2002 APR NEWA

AB

ZENITH GOLDLINE

5MG

N75385 001 MAR 01, 2002 MAR NEWA

AB

10MG

N75385 002 MAR 01, 2002 MAR NEWA

AB

15MG

N75385 003 MAR 01, 2002 MAR NEWA

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

@ WALLACE LABS

15MG

N00793 002 OCT DISC

@

100MG

N00793 005 OCT DISC

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

+ BERTEK

1%

N21408 001 OCT 17, 2002 OCT NEWA

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

>A>

AB

NOVEX

1MG/SPRAY

N75499 001 DEC 04, 2002 DEC NEWA

AB

ROXANE

1MG/SPRAY

N75824 001 MAR 12, 2002 MAR NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERCATAB

+	GENEVA PHARMS	100MG;1MG	N84294 001	JUN	CTEC
	WIGRAINE				
@	ORGANON	100MG;1MG	N86562 001	JUN	DISC

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

@	ORGANON	0.02MG	N18312 001	JUN	DISC
@		0.05MG	N18312 002	JUN	DISC

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

+	BRISTOL MYERS SQUIBB	0.005%	N20273 001	DEC 29, 1993	FEB	CAHN
	SOLUTION; TOPICAL					
+	BRISTOL MYERS SQUIBB	0.005%	N20611 001	MAR 03, 1997	FEB	CAHN

CALCITRIOL

INJECTABLE; INJECTION

CALCIJEX

>D>	+	ABBOTT	0.001MG/ML	N18874 001	SEP 25, 1986	DEC	CFTG
>A>	AP	+	0.001MG/ML	N18874 001	SEP 25, 1986	DEC	CFTG
>D>	+		0.002MG/ML	N18874 002	SEP 25, 1986	DEC	CFTG
>A>	AP	+	0.002MG/ML	N18874 002	SEP 25, 1986	DEC	CFTG
>A>		CALCITRIOL					
>A>	AP	AM PHARM PARTNERS	0.001MG/ML	N75836 001	DEC 31, 2002	DEC	NEWA
>A>	AP		0.002MG/ML	N75836 002	DEC 31, 2002	DEC	NEWA

CALCIUM CHLORIDE; ICODextrin; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

EXTRANEAL

>A>	+	BAXTER HLTHCARE	25.7MG/100ML;7.5GM/100ML;5.08MG/100ML;535MG/100ML;448MG/100ML	N21321 001	DEC 20, 2002	DEC	NEWA
-----	---	-----------------	---	------------	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB	PAR PHARM	12.5MG	N18343 005	JAN 17, 1985	MAY	CAHN
AB		25MG	N18343 002		MAY	CAHN
	@	37.5MG	N18343 006	SEP 17, 1986	MAY	CAHN
AB		50MG	N18343 001		MAY	CAHN
	@	75MG	N18343 007	JUN 13, 1995	MAY	CAHN
AB	+	100MG	N18343 003		MAY	CAHN
	@	150MG	N18343 004	JUN 13, 1995	MAY	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

@	SHIRE LABS	100MG	N20712 003	DEC 22, 1999	JUL	DISC
---	------------	-------	------------	--------------	-----	------

	@	200MG	N20712 001	SEP 30, 1997	JUL	DISC
	@	300MG	N20712 002	SEP 30, 1997	JUL	DISC
	+ SHIRE PHARM	100MG	N20712 003	SEP 30, 1997	SEP	CMFD
	+	200MG	N20712 001	SEP 30, 1997	SEP	CMFD
	+	300MG	N20712 002	SEP 30, 1997	SEP	CMFD
	SUSPENSION; ORAL					
	CARBAMAZEPINE					
AB	MORTON GROVE	100MG/5ML	N75714 001	JUN 05, 2002	JUN	NEWA
	TABLET; ORAL					
AB	APOTEX	200MG	N75948 001	FEB 27, 2002	FEB	NEWA
	TABLET, CHEWABLE; ORAL					
	+ TARO PHARM INDS	200MG	N75687 002	JUL 29, 2002	JUL	NEWA
	<u>CARTEOLOL HYDROCHLORIDE</u>					
	SOLUTION/DROPS; OPHTHALMIC					
	CARTEOLOL HCL					
AT	NOVEX	1%	N76097 001	FEB 06, 2002	FEB	NEWA
	<u>CEFACTOR</u>					
	TABLET, EXTENDED RELEASE; ORAL					
	CECLOR CD					
	@ LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996	JUN	DISC
	CEFACTOR					
	TEVA	EQ 375MG BASE	N65058 001	SEP 04, 2002	SEP	NEWA
AB		EQ 500MG BASE	N65058 002	SEP 04, 2002	SEP	NEWA
	<u>CEFADROXIL/CEFADROXIL HEMIHYDRATE</u>					
	CAPSULE; ORAL					
	DURICEF					
	@ GALEN CHEM	EQ 250MG BASE	N50512 002		MAY	CAHN
	@ WARNER CHILCOTT	EQ 250MG BASE	N50512 002		JUL	CAHN
AB	+	EQ 500MG BASE	N50512 001		JUL	CAHN
	FOR SUSPENSION; ORAL					
	GALEN CHEM	EQ 125MG BASE/5ML	N50527 002		MAY	CAHN
		EQ 250MG BASE/5ML	N50527 003		MAY	CAHN
	+	EQ 500MG BASE/5ML	N50527 001		MAY	CAHN
	WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527 002		JUL	CAHN
		EQ 250MG BASE/5ML	N50527 003		JUL	CAHN
	+	EQ 500MG BASE/5ML	N50527 001		JUL	CAHN
	TABLET; ORAL					
AB	+ GALEN CHEM	EQ 1GM BASE	N50528 001		MAY	CAHN
AB	+ WARNER CHILCOTT	EQ 1GM BASE	N50528 001		JUL	CAHN
	<u>CEFAMANDOLE NAFATE</u>					
	INJECTABLE; INJECTION					
	MANDOL					
	@ LILLY	EQ 10GM BASE/VIAL	N50504 004		JUN	DISC
	<u>CEFORANIDE</u>					
	INJECTABLE; INJECTION					
	PRECEF					
	@ BRISTOL	500MG/VIAL	N50554 001	MAY 24, 1984	JUN	DISC
	@	1GM/VIAL	N50554 002	MAY 24, 1984	JUN	DISC

@	2GM/VIAL	N50554 003	MAY 24, 1984	JUN	DISC
@	10GM/VIAL	N50554 004	MAY 24, 1984	JUN	DISC
@	20GM/VIAL	N50554 005	MAY 24, 1984	JUN	DISC

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

AP	HIKMA	EQ 500MG BASE/VIAL	N65072 001	NOV 20, 2002	NOV	NEWA
AP		EQ 1GM BASE/VIAL	N65072 002	NOV 20, 2002	NOV	NEWA
AP		EQ 2GM BASE/VIAL	N65072 003	NOV 20, 2002	NOV	NEWA
AP		EQ 10GM BASE/VIAL	N65071 001	NOV 20, 2002	NOV	NEWA

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AB	RANBAXY	EQ 50MG BASE/5ML	N65082 001	MAY 31, 2002	MAY	NEWA
AB		EQ 100MG BASE/5ML	N65082 002	MAY 31, 2002	MAY	NEWA
	VANTIN					
AB	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N50675 001	AUG 07, 1992	MAY	CFTG
AB +		EQ 100MG BASE/5ML	N50675 002	AUG 07, 1992	MAY	CFTG

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

@	FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001	SEP 15, 1983	JUL	DISC
---	-------------------	--------------------	------------	--------------	-----	------

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

@	HLR	EQ 500MG BASE/VIAL;1%	N50585 007	MAY 08, 1996	JUN	DISC
@		EQ 1GM BASE/VIAL;1%	N50585 006	MAY 08, 1996	JUN	DISC

CEFUROXIME AXETIL

TABLET; ORAL

CEFTIN

AB	GLAXOSMITHKLINE	EQ 125MG BASE	N50605 001	DEC 28, 1987	FEB	CFTG
AB		EQ 250MG BASE	N50605 002	DEC 28, 1987	FEB	CFTG
AB +		EQ 500MG BASE	N50605 003	DEC 28, 1987	FEB	CFTG
	CEFUROXIME AXETIL					
AB	APOTEX	EQ 250MG BASE	N65069 001	OCT 02, 2002	OCT	NEWA
AB		EQ 500MG BASE	N65069 002	OCT 02, 2002	OCT	NEWA
AB	RANBAXY	EQ 125MG BASE	N65043 003	FEB 15, 2002	FEB	NEWA
AB		EQ 250MG BASE	N65043 002	FEB 15, 2002	FEB	NEWA
AB		EQ 500MG BASE	N65043 001	FEB 15, 2002	FEB	NEWA

CELECOXIB

CAPSULE; ORAL

CELEBREX

	GD SEARLE LLC	200MG	N20998 002	DEC 31, 1998	AUG	CRLD
+		400MG	N20998 003	AUG 29, 2002	AUG	NEWA

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

@ TEVA	EQ 125MG BASE/5ML	N62873 001	MAY 23, 1988	APR	DISC
@	EQ 250MG BASE/5ML	N62867 001	APR 15, 1988	APR	DISC

TABLET; ORAL

TEVA	EQ 500MG BASE	N63024 001	JAN 12, 1989	JUN	CTEC
KEFLET					
@ LILLY	EQ 500MG BASE	N50440 001		JUN	DISC
@	EQ 1GM BASE	N50440 002		JUL	DISC

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

@ LILLY	250MG	N50219 001		MAY	DISC
---------	-------	------------	--	-----	------

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

KEFLIN

@ LILLY	EQ 20GM BASE/VIAL	N50482 007		JUN	DISC
---------	-------------------	------------	--	-----	------

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON	EQ 500MG BASE/VIAL	N62961 001	SEP 20, 1988	JUN	DISC
@	EQ 1GM BASE/VIAL	N62961 002	SEP 20, 1988	JUN	DISC
@	EQ 2GM BASE/VIAL	N62961 003	SEP 20, 1988	JUN	DISC
@	EQ 4GM BASE/VIAL	N62961 004	SEP 20, 1988	JUN	DISC

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

@ BAYER	0.2MG	N20740 003	JUN 26, 1997	JAN	DISC
@	0.3MG	N20740 004	JUN 26, 1997	JAN	DISC
@	0.4MG	N20740 005	MAY 24, 1999	JAN	DISC
@	0.8MG	N20740 006	JUL 24, 2000	JAN	DISC

CHLORAMPHENICOL

FOR SOLUTION; OPHTHALMIC

CHLOROMYCETIN

@ PARKEDALE	25MG/VIAL	N50143 001		JUL	DISC
-------------	-----------	------------	--	-----	------

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

@ PARKE DAVIS	EQ 150MG BASE/5ML	N50152 001		JUN	DISC
---------------	-------------------	------------	--	-----	------

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

@ PARKEDALE	12.5MG/VIAL;25MG/VIAL	N50202 001		JUL	DISC
-------------	-----------------------	------------	--	-----	------

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

a SANOFI SYNTHELABO

100MG

N11467 003

JUN DISC

a

200MG

N11467 005

JUN DISC

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

a WEST WARD

250MG;0.125MG

N88557 001 DEC 22, 1983 AUG DISC

a

500MG;0.125MG

N88365 001 DEC 22, 1983 AUG DISC

CHLOROTHIAZIDE-RESERPINE

a MYLAN

250MG;0.125MG

N87744 001 MAY 06, 1982 AUG DISC

a

500MG;0.125MG

N87745 001 MAY 06, 1982 AUG DISC

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

a PHARMACIA AND UPJOHN

400MG

N14217 002

JUN DISC

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

a GLAXOSMITHKLINE

30MG

N11120 016

JUN DISC

a

75MG

N11120 017

JUN DISC

a

150MG

N11120 018

JUN DISC

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

a LEDERLE

100MG

N89561 001 SEP 04, 1987 MAY DISC

a

250MG

N89562 001 SEP 04, 1987 MAY DISC

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

a LEDERLE

1%

N50404 001

JUN DISC

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HCL AND CHLORTHALIDONE

a PAR PHARM

15MG;0.3MG

N71142 001 DEC 16, 1987 OCT DISC

a

15MG;0.2MG

N71178 001 DEC 16, 1987 OCT DISC

a

15MG;0.1MG

N71179 001 DEC 16, 1987 OCT DISC

CLORPRES

+ MYLAN

15MG;0.3MG

N71325 001 FEB 09, 1987 OCT CRLD

COMBIPRES

a BOEHRINGER INGELHEIM

15MG;0.1MG

N17503 001 OCT DISC

a

15MG;0.2MG

N17503 002 OCT DISC

a

15MG;0.3MG

N17503 003 APR 10, 1984 OCT DISC

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

@ AVENTIS PHARMS

25MG;0.125MG

N15103 002

JUL DISC

REGROTON

@ AVENTIS PHARMS

50MG;0.25MG

N15103 001

JUL DISC

CHOLESTYRAMINE

TABLET; ORAL

QUESTRAN

@ APOTHECON

EQ 800MG RESIN

N73403 002 DEC 27, 1999 JUN DISC

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

+ SERONO INC

0.25MG/VIAL

N21149 001 SEP 20, 2000 FEB CAHN

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

@ ABBOTT

4,000 UNITS/VIAL

N18663 002 AUG 21, 1984 JUN DISC

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ZOLYSE

@ ALCON

750 UNITS/VIAL

N11903 001

JUN DISC

CICLOPIROX

SOLUTION; TOPICAL

PENLAC

+ DERMIK LABS

8%

N21022 001 DEC 17, 1999 JUN CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

AB LEK LJUBLJANA

300MG

N74250 002 JUN 29, 1995 FEB CMFD

AB

400MG

N74250 003 JUN 29, 1995 FEB CMFD

AB

800MG

N74250 004 JUN 29, 1995 FEB CMFD

CINOXACIN

CAPSULE; ORAL

CINOBAC

@ LILLY

250MG

N18067 001

JUN DISC

@

500MG

N18067 002

JUN DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

>A> TABLET, EXTENDED RELEASE; ORAL

>A> CIPRO XR

>A> + BAYER PHARMS

212.6MG;EQ 287.5MG BASE

N21473 001 DEC 13, 2002 DEC NEWA

>A>	<u>CITRIC ACID; UREA, C-13</u>						
>A>	FOR SOLUTION; TABLET, FOR SOLUTION; ORAL						
>A>	IDKIT:HP						
>A>	+	ORIDION	4GM;75MG	N21314 001	DEC 17, 2002	DEC	NEWA
 <u>CLADRIBINE</u>							
	INJECTABLE; INJECTION						
	LEUSTATIN						
	+	ORTHO BIOTECH	1MG/ML	N20229 001	FEB 26, 1993	MAR	CAHN
 <u>CLARITHROMYCIN</u>							
	FOR SUSPENSION; ORAL						
	BIAXIN						
	@	ABBOTT	187MG/5ML	N50698 003	SEP 30, 1998	JUN	DISC
 <u>CLINDAMYCIN PHOSPHATE</u>							
	GEL; TOPICAL						
	CLINDAGEL						
BT		GALDERMA LABS LP	EQ 1% BASE	N50782 001	NOV 27, 2000	OCT	CTNA
	LOTION; TOPICAL						
	CLEOCIN T						
AB	+	PHARMACIA AND UPJOHN	EQ 1% BASE	N50600 001	MAY 31, 1989	JAN	CFTG
	CLINDAMYCIN PHOSPHATE						
AB		ALTANA	EQ 1% BASE	N65067 001	JAN 31, 2002	JAN	NEWA
	SWAB; TOPICAL						
AT		CLAY PARK	EQ 1% BASE	N65049 001	MAY 25, 2000	FEB	CDFR
 <u>CLOBETASOL PROPIONATE</u>							
	GEL; TOPICAL						
	EMBELINE						
AB		HEALTHPOINT	0.05%	N76141 001	APR 12, 2002	APR	NEWA
 <u>CLOFAZIMINE</u>							
	CAPSULE; ORAL						
	LAMPRENE						
	@	NOVARTIS	100MG	N19500 001	DEC 15, 1986	JUN	DISC
 <u>CLONAZEPAM</u>							
	TABLET; ORAL						
	KLONOPIN						
	@	ROCHE	0.125MG	N17533 005	APR 09, 1997	JUN	DISC
	@		0.25MG	N17533 006	APR 09, 1997	JUN	DISC
	TABLET, ORALLY DISINTEGRATING; ORAL						
	KLONOPIN RAPIDLY DISINTEGRATING						
	@	ROCHE	0.125MG	N20813 001	DEC 23, 1997	JUN	DISC
	@		0.25MG	N20813 002	DEC 23, 1997	JUN	DISC
	@		0.5MG	N20813 003	DEC 23, 1997	JUN	DISC
	@		1MG	N20813 004	DEC 23, 1997	JUN	DISC
	@		2MG	N20813 005	DEC 23, 1997	JUN	DISC

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

>D>	+	BOEHRINGER INGELHEIM	0.1MG/24HR	N18891 001	OCT 10, 1984	DEC	CRLD
>A>			0.1MG/24HR	N18891 001	OCT 10, 1984	DEC	CRLD

CATAPRES-TTS-2

>D>	+	BOEHRINGER INGELHEIM	0.2MG/24HR	N18891 002	OCT 10, 1984	DEC	CRLD
>A>			0.2MG/24HR	N18891 002	OCT 10, 1984	DEC	CRLD

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@	OVATION PHARMS	3.75MG	N17105 001	SEP	CAHN
@		7.5MG	N17105 002	SEP	CAHN
@		15MG	N17105 003	SEP	CAHN

TABLET; ORAL

AB	OVATION PHARMS	3.75MG	N17105 006	SEP	CAHN
AB		7.5MG	N17105 007	SEP	CAHN
AB	+	15MG	N17105 008	SEP	CAHN
	TRANXENE SD				
	OVATION PHARMS	11.25MG	N17105 005	SEP	CAHN
	+	22.5MG	N17105 004	SEP	CAHN

CLOZAPINE

TABLET; ORAL

CLOZAPINE

AB	CARACO	25MG	N75713 001	NOV 15, 2002	NOV	NEWA
AB		100MG	N75713 002	NOV 15, 2002	NOV	NEWA

CLOZARIL

AB	NOVARTIS	25MG	N19758 001	SEP 26, 1989	MAY	CRLD
AB	+	100MG	N19758 002	SEP 26, 1989	MAY	CRLD

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

BP	+	WATSON LABS	0.5MG;500MG	N84279 001	JUN	CRLD
----	---	-------------	-------------	------------	-----	------

COLBENEMID

@	MERCK	0.5MG;500MG	N12383 001	JUN	DISC
---	-------	-------------	------------	-----	------

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

WELCHOL

@	SANKYO	375MG	N21141 001	MAY 26, 2000	JUN	DISC
---	--------	-------	------------	--------------	-----	------

CORTICOTROPIN

INJECTABLE; INJECTION

CORTICOTROPIN

+	ORGANICS LAGRANGE	40 UNITS/ML	N10831 001	AUG	CRLD
	H.P. ACTHAR GEL				
@	QUESTCOR PHARMS	40 UNITS/ML	N08372 006	JUL	DISC

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTONE

@ MERCK

25MG/ML

N07110 002

JUN DISC

@

50MG/ML

N07110 003

JUN DISC

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

AN NOVEX

10MG/ML

N75333 001 APR 30, 2002 APR NEWA

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A

DICOPAC KIT

@ AMERSHAM HLTH

N/A;N/A;N/A

N17406 001

FEB DISC

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

@ MALLINCKRODT

0.1MG;0.5uCi;60MG

N16635 001

JUN DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL

@ MCNEIL CONS SPECLT

5MG

N17821 001

JUN CAHN

AB +

10MG

N17821 002

JUN CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP BAXTER HLTHCARE

100MG/VIAL

N88371 001 JUL 03, 1986 JUN CAHN

AP 200MG/VIAL

N88372 001 JUL 03, 1986 JUN CAHN

AP 500MG/VIAL

N88373 001 JUL 03, 1986 JUN CAHN

AP 1GM/VIAL

N88374 001 SEP 24, 1986 JUN CAHN

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1 ABBOTT

25MG

N65003 001 MAY 12, 2000 MAY CTEC

BX 50MG

N65003 002 MAY 12, 2000 MAY CTEC

AB1 100MG

N65003 003 MAY 12, 2000 MAY CTEC

AB1 EON

25MG

N65017 002 JAN 13, 2000 MAY CTEC

AB1 100MG

N65017 001 JAN 13, 2000 MAY CTEC

AB1 SIDMAK LABS

25MG

N65044 002 DEC 20, 2000 MAY CTEC

AB1 100MG

N65044 001 DEC 20, 2000 MAY CTEC

AB2 TORPHARM

25MG

N65040 001 MAY 09, 2002 MAY CTEC

AB2 100MG

N65040 002 MAY 09, 2002 MAY NEWA

NEORAL

AB1 NOVARTIS

25MG

N50715 001 JUL 14, 1995 MAY CTEC

AB1 + 100MG

N50715 002 JUL 14, 1995 MAY CTEC

SANDIMMUNE

AB2 NOVARTIS

25MG

N50625 001 MAR 02, 1990 MAY CTEC

AB2 +	100MG	N50625 002	MAR 02, 1990	MAY	CTEC
>A> EMULSION; OPHTHALMIC					
>A> RESTASIS					
>A> + ALLERGAN	0.05%	N21023 001	DEC 23, 2002	DEC	NEWA
SOLUTION; ORAL					
CYCLOSPORINE					
AB ABBOTT	100MG/ML	N65025 001	MAR 03, 2000	JAN	CMFD
<u>CYPROHEPTADINE HYDROCHLORIDE</u>					
TABLET; ORAL					
CYPROHEPTADINE HCL					
AA + IVAX PHARMS	4MG	N87056 001		NOV	CRLD
PERIACTIN					
@ MERCK	4MG	N12649 001		NOV	DISC
<u>CYTARABINE</u>					
INJECTABLE; INJECTION					
CYTARABINE					
+ FAULDING	100MG/ML	N75383 001	NOV 22, 1999	AUG	CPOT
<u>DACARBAZINE</u>					
INJECTABLE; INJECTION					
DACARBAZINE					
AP BEDFORD	500MG/VIAL	N75812 002	OCT 31, 2002	NOV	NEWA
AP + GENSLA SICOR PHARMS	500MG/VIAL	N75259 001	SEP 22, 2000	OCT	CRLD
<u>DALFOPRISTIN; QUINUPRISTIN</u>					
INJECTABLE; IV (INFUSION)					
SYNERCID					
+ AVENTIS	350MG/VIAL; 150MG/VIAL	N50748 001	SEP 21, 1999	JUN	CRLD
@	420MG/VIAL; 180MG/VIAL	N50748 002	AUG 24, 2000	JUN	DISC
<u>DANAPAROID SODIUM</u>					
INJECTABLE; INJECTION					
ORGARAN					
@ ORGANON	750 UNITS/0.6ML	N20430 001	DEC 24, 1996	JUN	DISC
<u>DEFEROXAMINE MESYLATE</u>					
INJECTABLE; INJECTION					
DESFERAL					
+ NOVARTIS	2GM/VIAL	N16267 002	MAY 25, 2000	FEB	CPOT
<u>DEMECARIUM BROMIDE</u>					
SOLUTION/DROPS; OPHTHALMIC					
HUMORSOL					
@ MERCK	0.125%	N11860 002		JUN	DISC
@	0.25%	N11860 001		JUN	DISC
<u>DEMECLOCYCLINE HYDROCHLORIDE</u>					
TABLET; ORAL					
DECLOMYCIN					
@ LEDERLE	75MG	N50261 001		JUN	DISC

DESLOMATADINE

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

+ SCHERING

5MG

N21312 001 JUN 26, 2002 JUN NEWA

DESMOPRESSIN ACETATE

SOLUTION; NASAL

CONCENTRAID

a FERRING

0.01%

N19776 001 DEC 26, 1990 JUN DISC

DDAVP

+ AVENTIS

0.01%

N17922 001 SEP CTEC

SPRAY; NASAL

DESMOPRESSIN ACETATE

+ FERRING

0.1MG/SPRAY

N21333 001 SEP 16, 2002 SEP NEWA

SPRAY; METERED; NASAL

DDAVP

a AVENTIS

0.01MG/SPRAY

N17922 002 FEB 06, 1989 MAY DISC

DESMOPRESSIN ACETATE

AB + BAUSCH AND LOMB

0.01MG/SPRAY

N74830 001 JAN 25, 1999 MAY CRLD

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

KARIVA

AB BARR

0.15MG;0.02MG;0.01MG

N75863 001 APR 05, 2002 APR NEWA

MIRCETTE

AB + ORGANON

0.15MG;0.02MG;0.01MG

N20713 001 APR 22, 1998 APR CFTG

DESONIDE

LOTION; TOPICAL

DESONIDE

AB ALTANA

0.05%

N75860 001 MAR 19, 2002 MAR NEWA

DESOWEN

AB + GALDERMA LABS LP

0.05%

N72354 001 JAN 24, 1992 MAR CFTG

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

a ALTANA

0.25%

N73440 001 APR 01, 1998 MAY DISC

DEXAMETHASONE

AEROSOL; TOPICAL

DECASPRAY

a MERCK

0.04%

N12731 002 JUN DISC

TABLET; ORAL

DEXAMETHASONE

a WATSON LABS

0.25MG

N85455 001 AUG DISC

a

0.5MG

N85458 001 AUG DISC

a

1.5MG

N85456 001 AUG DISC

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

Ⓢ MERCK	EQ 8MG BASE/ML	N16675 001		APR	DISC
---------	----------------	------------	--	-----	------

DEXAMETHASONE ACETATE

Ⓢ STERIS	EQ 8MG BASE/ML	N84315 001		APR	DISC
----------	----------------	------------	--	-----	------

Ⓢ	EQ 16MG BASE/ML	N87711 001	MAY 24, 1982	APR	DISC
---	-----------------	------------	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DECADRON

Ⓢ MERCK	EQ 4MG PHOSPHATE/ML	N12071 002		OCT	DISC
---------	---------------------	------------	--	-----	------

Ⓢ	EQ 24MG PHOSPHATE/ML	N12071 004		OCT	DISC
---	----------------------	------------	--	-----	------

DEXAMETHASONE

Ⓢ AM PHARM PARTNERS	EQ 10MG PHOSPHATE/ML	N88469 001	JAN 25, 1984	OCT	DISC
---------------------	----------------------	------------	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

AP +	GENSIA SICOR PHARMS	EQ 10MG PHOSPHATE/ML	N81126 001	AUG 31, 1990	OCT	CRLD
------	---------------------	----------------------	------------	--------------	-----	------

AP +	LUITPOLD	EQ 4MG PHOSPHATE/ML	N87440 001	JUL 21, 1982	OCT	CRLD
------	----------	---------------------	------------	--------------	-----	------

Ⓢ STERIS	EQ 4MG PHOSPHATE/ML	N89169 001	APR 09, 1986	OCT	DISC
----------	---------------------	------------	--------------	-----	------

Ⓢ	EQ 10MG PHOSPHATE/ML	N87668 001	JUL 01, 1982	OCT	DISC
---	----------------------	------------	--------------	-----	------

HEXADROL

Ⓢ ORGANON	EQ 4MG PHOSPHATE/ML	N14694 002		OCT	DISC
-----------	---------------------	------------	--	-----	------

Ⓢ	EQ 10MG PHOSPHATE/ML	N14694 003		OCT	DISC
---	----------------------	------------	--	-----	------

OINTMENT; OPHTHALMIC

MAXIDEX

Ⓢ ALCON	EQ 0.05% PHOSPHATE	N83342 001		JUN	DISC
---------	--------------------	------------	--	-----	------

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DECADRON W/ XYLOCAINE

Ⓢ MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N13334 002		JUN	DISC
---------	-----------------------------	------------	--	-----	------

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB +	GLAXOSMITHKLINE	5MG	N17078 001		JAN	CFTG
------	-----------------	-----	------------	--	-----	------

AB +		10MG	N17078 002		JAN	CFTG
------	--	------	------------	--	-----	------

AB +		15MG	N17078 003		JAN	CFTG
------	--	------	------------	--	-----	------

DEXTROAMPHETAMINE SULFATE

AB	BARR	5MG	N76137 001	JAN 18, 2002	JAN	NEWA
----	------	-----	------------	--------------	-----	------

AB		10MG	N76137 002	JAN 18, 2002	JAN	NEWA
----	--	------	------------	--------------	-----	------

AB		15MG	N76137 003	JAN 18, 2002	JAN	NEWA
----	--	------	------------	--------------	-----	------

TABLET; ORAL

AA	KV PHARM	5MG	N40365 001	OCT 31, 2002	OCT	NEWA
----	----------	-----	------------	--------------	-----	------

AA		10MG	N40367 001	OCT 31, 2002	OCT	NEWA
----	--	------	------------	--------------	-----	------

AA	MALLINCKRODT	5MG	N40436 001	JAN 29, 2002	JAN	NEWA
----	--------------	-----	------------	--------------	-----	------

AA		10MG	N40436 002	JAN 29, 2002	JAN	NEWA
----	--	------	------------	--------------	-----	------

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

DIATRIZOATE MEGLUMINE

Ⓢ BRACCO	76%	N10040 017		JUN	DISC
----------	-----	------------	--	-----	------

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOVIST

@ BRACCO 34.3%;35%

N10040 020

JUN DISC

RENOVIST II

@ BRACCO 28.5%;29.1%

N10040 019

JUN DISC

DIATRIZOATE SODIUM

INJECTABLE; INJECTION

HYPAQUE

@ AMERSHAM HLTH 25%

N09561 003

JUN DISC

SOLUTION; ORAL, RECTAL

@ AMERSHAM HLTH 40%

N11386 003

JUL DISC

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

@ AMERSHAM HLTH 20%

N09561 002

JUN DISC

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

AP + ABBOTT 5MG/ML

N71583 001 OCT 13, 1987 OCT CRLD

VALIUM

@ ROCHE 5MG/ML

N16087 001

OCT DISC

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

@ BAKER NORTON 50MG

N17425 001

JUN DISC

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB MUTUAL PHARM 50MG

N75470 001 FEB 21, 2002 FEB NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+ BIOGLAN PHARMA 3%

N21005 001 OCT 16, 2000 JUL CAHN

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB ALPHAPHARM 50MG

N75281 002 FEB 12, 2002 FEB NEWA

AB 75MG

N75281 003 FEB 12, 2002 FEB NEWA

TABLET, EXTENDED RELEASE; ORAL

AB DEXCEL LTD 100MG

N76201 001 NOV 06, 2002 NOV NEWA

AB PUREPAC PHARM 100MG

N75910 001 JAN 07, 2002 JAN NEWA

DICUMAROL

TABLET; ORAL

DICUMAROL

@ ABBOTT 25MG

N05545 003

JUN DISC

DIENESTROL

CREAM; VAGINAL

DIENESTROL

+ ORTHO MCNEIL

0.01%

N06110 005

JUN CAHN

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

>D> AB ALTANA

0.05%

N75187 001 MAR 30, 2008 DEC CTEC

>A> AB1

0.05%

N75187 001 MAR 30, 2008 DEC CTEC

>A> AB2

0.05%

N76263 001 DEC 20, 2002 DEC NEWA

>D> AB TARO

0.05%

N75508 001 APR 24, 2000 DEC CTEC

>A> AB1

0.05%

N75508 001 APR 24, 2000 DEC CTEC

FLORONE E

>D> BX + PHARMACIA AND UPJOHN

0.05%

N19259 001 AUG 28, 2005 DEC CTEC

>A> AB2 +

0.05%

N19259 001 AUG 28, 2005 DEC CTEC

PSORCON

>D> AB + DERMIK LABS

0.05%

N20205 001 NOV 20, 2002 DEC CTEC

>A> AB1 +

0.05%

N20205 001 NOV 20, 2002 DEC CTEC

DIGOXIN

TABLET; ORAL

DIGOXIN

AB STEVENS J

0.125MG

N76268 001 JUL 26, 2002 JUL NEWA

AB

0.25MG

N76268 002 JUL 26, 2002 JUL NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

XCEL PHARMS

1MG/ML

N05929 001

JUN CAHN

SPRAY, METERED; NASAL

MIGRANAL

+ XCEL PHARM

0.5MG/INH

N20148 001 DEC 08, 1997 JUL CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

AP + BIOVAIL

5MG/ML

N20027 001 OCT 24, 1991 JUN CAHN

+

25MG/VIAL

N20027 003 AUG 18, 1995 JUN CAHN

DILTIAZEM HCL

>A> AP ABBOTT

100MG/VIAL

N75853 001 DEC 17, 2002 DEC NEWA

+ GENSIA SICOR PHARMS

10MG/ML

N74894 002 APR 19, 2002 APR NEWA

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

+ BIOVAIL

EQ 180MG HCL;5MG

N20507 001 OCT 04, 1996 JUN CAHN

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

AT BIONICHE (CANADA)

50%

N76185 001 NOV 29, 2002 NOV NEWA

DIMETHYL SULFOXIDESOLUTION; INTRAVESICAL
RIMSO-50

AT + RES INDS 50% N17788 001 NOV CFTG

DIMYRISTOYL LECITHIN; PERFLEXANEINJECTABLE; INTRAVENOUS
IMAGENT

+ ALLIANCE PHARM 0.92MG/VIAL;0.092MG/VIAL N21191 001 MAY 31, 2002 MAY NEWA

DIPHENHYDRAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

AP AM PHARM PARTNERS 50MG/ML N40466 001 MAY 28, 2002 MAY NEWA

DIPHENIDOL HYDROCHLORIDETABLET; ORAL
VONTROL

@ GLAXOSMITHKLINE EQ 25MG BASE N16033 001 JUN DISC

DIPYRIDAMOLEINJECTABLE; INJECTION
DIPYRIDAMOLE

AP APOTEX 5MG/ML N75769 001 NOV 27, 2002 NOV NEWA

DISULFIRAMTABLET; ORAL
ANTABUSE

>D>	ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983	DEC	CRLD
>A>	+	250MG	N88482 001	DEC 08, 1983	DEC	CRLD
>D>	+	500MG	N88483 001	DEC 08, 1983	DEC	DISC
>A>	@	500MG	N88483 001	DEC 08, 1983	DEC	DISC

DIVALPROEX SODIUMTABLET, EXTENDED RELEASE; ORAL
DEPAKOTE ER

ABBOTT EQ 250MG VALPROIC ACID N21168 002 MAY 31, 2002 JUL NEWA

DONEPEZIL HYDROCHLORIDETABLET; ORAL
ARICEPT

	EISAI MEDCL RES	5MG	N20690 002	NOV 25, 1996	MAY	CAHN
+		10MG	N20690 001	NOV 25, 1996	MAY	CAHN

DOXEPIN HYDROCHLORIDECAPSULE; ORAL
DOXEPIN HCL

@	LEDERLE	EQ 10MG BASE	N71685 001	JAN 05, 1988	MAY	DISC
@		EQ 25MG BASE	N71686 001	JAN 05, 1988	MAY	DISC
@		EQ 50MG BASE	N71673 001	JAN 05, 1988	MAY	DISC
@		EQ 75MG BASE	N71674 001	JAN 05, 1988	MAY	DISC

	@	EQ 100MG BASE	N71675 001	JAN 05, 1988	MAY	DISC
	@	EQ 150MG BASE	N71676 001	JAN 05, 1988	MAY	DISC
	CREAM; TOPICAL					
	ZONALON					
	+	BIOGLAN PHARMS	5%	N20126 001	APR 01, 1994	JUN CAHN
	<u>DOXYCYCLINE</u>					
	TABLET; ORAL					
	DOXYCYCLINE					
>A>		PAR PHARM	EQ 75MG BASE	N65070 003	DEC 30, 2002	DEC NEWA
	<u>DOXYCYCLINE HYCLATE</u>					
	CAPSULE; ORAL					
	PERIOSTAT					
	@	COLLAGENEX	EQ 20MG BASE	N50744 001	SEP 30, 1998	JUN DISC
	<u>DROPERIDOL; FENTANYL CITRATE</u>					
	INJECTABLE; INJECTION					
	FENTANYL CITRATE AND DROPERIDOL					
	+	ABBOTT	2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001	MAY 04, 1988	JUN CTEC
	@	ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	N72026 001	APR 13, 1989	JUN DISC
	<u>DUTASTERIDE</u>					
	CAPSULE; ORAL					
	AVODART					
	+	GLAXOSMITHKLINE	0.5MG	N21319 001	NOV 20, 2001	OCT CTNA
	<u>ECHOTHIOPHATE IODIDE</u>					
	FOR SOLUTION; OPHTHALMIC					
	PHOSPHOLINE IODIDE					
	@	AYERST	0.03%	N11963 002		JUN DISC
	@		0.06%	N11963 004		JUN DISC
	@		0.25%	N11963 003		JUN DISC
	<u>ECONAZOLE NITRATE</u>					
	CREAM; TOPICAL					
	ECONAZOLE NITRATE					
AB		ALTANA	1%	N76075 001	NOV 26, 2002	NOV NEWA
AB		TARO	1%	N76005 001	NOV 26, 2002	NOV NEWA
	SPECTAZOLE					
AB	+	JOHNSON AND JOHNSON	1%	N18751 001	DEC 23, 1982	NOV CFTG
	<u>EDETATE DISODIUM</u>					
	INJECTABLE; INJECTION					
	EDETATE DISODIUM					
AP		APOTEX	150MG/ML	N40376 001	NOV 04, 2002	NOV NEWA
>A>	AP	BIONICHE (CANADA)	150MG/ML	N40437 001	JUL 09, 2002	DEC CAHN
>D>	AP	PHARMAFORCE	150MG/ML	N40437 001	JUL 09, 2002	DEC CAHN
AP			150MG/ML	N40437 001	JUL 09, 2002	JUL NEWA

EFAVIRENZ

TABLET; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB	300MG
+	600MG

N21360 001	FEB 01, 2002	FEB	NEWA
N21360 002	FEB 01, 2002	FEB	NEWA

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+	WOMEN FIRST HLTHCARE	13.9%
---	----------------------	-------

N21145 001	JUL 27, 2000	JUL	CAHN
------------	--------------	-----	------

>A> ELETRIPTAN HYDROBROMIDE

>A> TABLET; ORAL

>A> RELPAX

>A>	PFIZER	EQ 20MG BASE
>A>	+	PFIZER IRELAND
		EQ 40MG BASE

N21016 001	DEC 26, 2002	DEC	NEWA
N21016 002	DEC 26, 2002	DEC	NEWA

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

AB	BIOVAIL	2.5MG
AB		5MG
AB		10MG
AB	+	20MG

N18998 005	JUL 26, 1988	MAY	CAHN
N18998 001	DEC 24, 1985	MAY	CAHN
N18998 002	DEC 24, 1985	MAY	CAHN
N18998 003	DEC 24, 1985	MAY	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB	BIOVAIL	5MG;12.5MG
AB	+	10MG;25MG

N19221 003	JUL 12, 1995	MAY	CAHN
N19221 001	OCT 31, 1986	MAY	CAHN

ENALAPRILAT

INJECTABLE; INJECTION

VASOTEC

AP	+	BIOVAIL	1.25MG/ML
----	---	---------	-----------

N19309 001	FEB 09, 1988	MAY	CAHN
------------	--------------	-----	------

ENOXACIN

TABLET; ORAL

PENETREX

@	AVENTIS	200MG
@		400MG

N19616 004	DEC 31, 1991	JUN	DISC
N19616 005	DEC 31, 1991	JUN	DISC

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

@	AVENTIS	90MG/0.6ML
---	---------	------------

N20164 006	JUN 02, 2000	JUN	DISC
------------	--------------	-----	------

EPINEPHRINE

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

@	FORREST LABS	1.5MG/AMP
@		5MG/ML

N07942 003	FEB 05, 1999	JUN	DISC
N07942 001		JUN	DISC

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

@ MERIDIAN MEDCL TECHN 0.15MG/DELIVERY

N19430 004 AUG 03, 1995 JUN DISC

EPIPEN E Z PEN

@ MERIDIAN MEDCL TECHN 0.3MG/DELIVERY

N19430 003 AUG 03, 1995 JUN DISC

EPLERENONE

TABLET; ORAL

INSPRA

GD SEARLE LLC

25MG

N21437 001 SEP 27, 2002 SEP NEWA

50MG

N21437 002 SEP 27, 2002 SEP NEWA

+

100MG

N21437 003 SEP 27, 2002 SEP NEWA

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

BIOVAIL PHARMS

EQ 300MG BASE

N20738 004 DEC 22, 1997 JUN CAHN

EQ 400MG BASE

N20738 005 DEC 22, 1997 JUN CAHN

+

EQ 600MG BASE

N20738 006 MAY 27, 1999 JUN CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

BIOVAIL PHARMS

600MG;12.5MG

N21268 001 NOV 01, 2001 JUN CAHN

+

600MG;25MG

N21268 002 NOV 01, 2001 JUN CAHN

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+ MILLENNIUM PHARMS

2MG/ML

N20718 001 MAY 18, 1998 FEB CAHN

+

75MG/100ML

N20718 002 MAY 18, 1998 FEB CAHN

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

@ NOVARTIS

1MG

N18706 001 JAN 18, 1983 JUN DISC

SOLUTION; ORAL

HYDERGINE

@ NOVARTIS

1MG/ML

N18418 001 JUN DISC

ERYTHROMYCIN

GEL; TOPICAL

E-GLADES

AT GLADES PHARMS

2%

N65009 001 MAR 18, 2002 MAR NEWA

ESCITALOPRAM OXALATE

SOLUTION; ORAL

LEXAPRO

+ FOREST LABS EQ 5MG BASE/5ML N21365 001 NOV 27, 2002 NOV NEWA

TABLET; ORAL

FOREST LABS 5MG N21323 001 AUG 14, 2002 AUG NEWA

10MG N21323 002 AUG 14, 2002 AUG NEWA

+ 20MG N21323 003 AUG 14, 2002 AUG NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ALORA

BX WATSON LABS 0.025MG/24HR N20655 004 APR 05, 2002 MAY CMS1

BX 0.025MG/24HR N20655 004 APR 16, 2002 APR NEWA

FEMPATCH

@ PARKE DAVIS 0.025MG/24HR N20417 001 DEC 03, 1996 NOV WDGB

TABLET; ORAL

ESTRADIOL

AB USL PHARMA 0.5MG N40297 001 APR 17, 2002 APR NEWA

AB 1MG N40297 002 APR 17, 2002 APR NEWA

AB 2MG N40297 003 APR 17, 2002 APR NEWA

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTADIOL

>D> AO + PHARMACIA AND UPJOHN 2MG/ML;50MG/ML N17968 001 DEC CTEC

>A> + 2MG/ML;50MG/ML N17968 001 DEC CTEC

>D> TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

>D> AO STERIS 2MG/ML;50MG/ML N85603 001 MAR 13, 1986 DEC DISC

>A> @ 2MG/ML;50MG/ML N85603 001 MAR 13, 1986 DEC DISC

>D> ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

>D> INJECTABLE; INJECTION

>D> DITATE-DS

>D> + SAVAGE LABS 8MG/ML;180MG/ML N86423 001 DEC DISC

>A> @ 8MG/ML;180MG/ML N86423 001 DEC DISC

>D> TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

>D> + STERIS 4MG/ML;90MG/ML N85865 001 DEC DISC

>A> @ 4MG/ML;90MG/ML N85865 001 DEC DISC

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

+ NOVO NORDISK 1MG;0.5MG N20907 001 NOV 18, 1998 JUN CTNA

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ORTHO-PREFEST

+ KING PHARMS 1MG;1MG;0.09MG N21040 001 OCT 22, 1999 MAY CAHN

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

DURAMED 0.3MG

N20992 001 JUN 21, 2002 AUG CAHN

DURAMED PHARM BARR 0.3MG

N20992 001 JUN 21, 2002 JUL NEWA

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

@ WYETH AYERST 0.625MG;0.625MG;5MG

N20303 002 DEC 30, 1994 JUN DISC

PREMPRO (PREMARIN;CYCRIN)

@ WYETH AYERST 0.625MG;0.625MG;2.5MG;2.5MG

N20303 001 DEC 30, 1994 JUN DISC

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

PMB 200

@ WYETH AYERST 0.45MG;200MG

N10971 005 JUN DISC

PMB 400

@ WYETH AYERST 0.45MG;400MG

N10971 003 JUN DISC

ETHCHLORVYNOL

CAPSULE; ORAL

PLACIDYL

@ ABBOTT 200MG

N10021 007 JUN DISC

@ 500MG

N10021 002 JUN DISC

@ 750MG

N10021 010 JUN DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB + WYETH AYERST 0.02MG;0.1MG

N20683 001 MAR 27, 1997 MAR CTEC

AB1 + 0.02MG;0.1MG

N20683 001 MAR 27, 1997 MAY CTEC

AVIANE-21

AB1 DURAMED PHARM BARR 0.02MG;0.1MG

N75796 002 APR 30, 2001 MAR CTEC

LESSINA-21

AB2 BARR 0.02MG;0.1MG

N75803 001 MAR 20, 2002 MAR NEWA

LEVLITE

AB2 + BERLEX LABS 0.02MG;0.1MG

N20860 001 JUL 13, 1998 MAR CTEC

PORTIA-21

AB BARR 0.03MG;0.15MG

N75866 001 MAY 23, 2002 MAY NEWA

TABLET; ORAL-28

ALESSE

AB1 WYETH AYERST 0.02MG;0.1MG

N20683 002 MAR 27, 1997 MAR CTEC

AVIANE-28

AB1 DURAMED PHARM BARR 0.02MG;0.1MG

N75796 001 APR 30, 2001 MAR CTEC

LESSINA-28

AB BARR 0.02MG;0.1MG

N75803 002 MAR 20, 2002 MAR NEWA

LEVLITE

AB BERLEX LABS 0.02MG;0.1MG

N20860 002 JUL 13, 1998 MAR CTEC

PORTIA-28

AB BARR 0.03MG;0.15MG

N75866 002 MAY 23, 2002 MAY NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	NORTREL 0.5/35-21						
AB	BARR	0.035MG;0.5MG	N72692 001	FEB 28, 1992	AUG	CTNA	
	NORTREL 1/35-21						
AB	BARR	0.035MG;1MG	N72693 001	FEB 28, 1992	AUG	CTNA	
	NORTREL 7/7/7						
AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N75478 001	AUG 30, 2002	AUG	NEWA	
	ORTHO-NOVUM 7/7/7-21						
AB +	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N18985 001	APR 04, 1984	AUG	CFTG	

TABLET; ORAL-28

	NORTREL 0.5/35-28						
AB	BARR	0.035MG;0.5MG	N72695 001	FEB 28, 1992	AUG	CTNA	
	NORTREL 1/35-28						
AB	BARR	0.035MG;1MG	N72696 001	FEB 28, 1992	AUG	CTNA	
	NORTREL 7/7/7						
AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N75478 002	AUG 30, 2002	AUG	NEWA	
	ORTHO-NOVUM 7/7/7-28						
AB	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N18985 002	APR 04, 1984	AUG	CFTG	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

ESTROSTEP 21

@	PARKE DAVIS	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 001	OCT 09, 1996	JUN	DISC	
---	-------------	-----------------------------------	------------	--------------	-----	------	--

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO CYCLEN-28

AB +	ORTHO MCNEIL PHARM	0.035MG;0.25MG	N19653 002	DEC 29, 1989	SEP	CFTG	
------	--------------------	----------------	------------	--------------	-----	------	--

ORTHO TRI-CYCLEN

>D>	+	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N19697 001	JUL 03, 1992	DEC	CFTG
-----	---	--------------------	---	------------	--------------	-----	------

>A>	AB +		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N19697 001	JUL 03, 1992	DEC	CFTG
-----	------	--	---	------------	--------------	-----	------

	+		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N19697 001	JUL 03, 1992	SEP	CRLD
--	---	--	---	------------	--------------	-----	------

ORTHO TRI-CYCLEN LO

+	JOHNSON AND JOHNSON	0.025MG,0.025MG,0.025MG;0.18MG,0.25MG,0.215MG	N21241 001	AUG 22, 2002	AUG	NEWA	
---	---------------------	---	------------	--------------	-----	------	--

SPRINTEC

AB	BARR	0.035MG;0.25MG	N75804 001	SEP 25, 2002	SEP	NEWA	
----	------	----------------	------------	--------------	-----	------	--

TRI-SPRINTEC

>A>	AB	BARR	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N75808 001	DEC 18, 2002	DEC	NEWA
-----	----	------	---	------------	--------------	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	BANNER PHARMACAPS	250MG	N40430 001	OCT 28, 2002	OCT	NEWA
ZARONTIN						
AB +	PARKE DAVIS	250MG	N12380 001		OCT	CFTG

ETHOTOIN

TABLET; ORAL

PEGANONE

+	ABBOTT	250MG	N10841 001		JUN	CRLD
@		500MG	N10841 003		JUN	DISC

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

@	ASTRAZENECA	1%	N17751 005		SEP	DISC
---	-------------	----	------------	--	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AB	NEOSAN PHARMS	300MG	N74929 001	JAN 30, 1998	JUL	CAHN
----	---------------	-------	------------	--------------	-----	------

TABLET; ORAL

>A>	AB	APOTEX	400MG	N76004 001	DEC 03, 2002	DEC	NEWA
>A>	AB		500MG	N76004 002	DEC 03, 2002	DEC	NEWA
	AB	NEOSAN PHARMS	400MG	N74927 001	OCT 30, 1997	JUL	CAHN
TABLET, EXTENDED RELEASE; ORAL							
	AB	EON	400MG	N75943 001	JUL 26, 2002	JUL	NEWA
	AB		500MG	N75943 002	JUL 26, 2002	JUL	NEWA
	AB		600MG	N75943 003	JUL 26, 2002	JUL	NEWA

EZETIMIBE

TABLET; ORAL

ZETIA

+	MSP SINGAPORE	10MG	N21445 001	OCT 25, 2002	OCT	NEWA
---	---------------	------	------------	--------------	-----	------

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	APOTEX	10MG/ML	N75942 001	AUG 02, 2002	AUG	NEWA
AP	BAXTER HLTHCARE	10MG/ML	N75799 001	APR 30, 2002	APR	NEWA
FAMOTIDINE PRESERVATIVE FREE						
AP	APOTEX	10MG/ML	N76324 001	NOV 27, 2002	NOV	NEWA
	@ APOTHECON	10MG/ML	N75708 001	APR 16, 2001	MAR	WDAG
AP	BAXTER HLTHCARE	10MG/ML	N75789 001	APR 30, 2002	APR	NEWA
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)						
AP	APOTEX	10MG/ML	N76322 001	NOV 27, 2002	NOV	NEWA

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB	TEVA	67MG	N75753 001	SEP 03, 2002	SEP	NEWA
----	------	------	------------	--------------	-----	------

AB		134MG	N75753 002	APR 09, 2002	APR	NEWA
AB		200MG	N75753 003	APR 09, 2002	APR	NEWA
TRICOR (MICRONIZED)						
AB	ABBOTT	67MG	N19304 002	FEB 09, 1998	SEP	CFTG
AB		134MG	N19304 003	JUN 30, 1999	APR	CFTG
AB	+	200MG	N19304 004	JUN 30, 1999	APR	CFTG

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

AB	+	RANBAXY	EQ 300MG BASE	N17604 002		JUN	CAHN
NALFON 200							
AB		RANBAXY	EQ 200MG BASE	N17604 003		JUN	CAHN
TABLET; ORAL							
FENOPROFEN CALCIUM							
AB	+	MYLAN	EQ 600MG BASE	N72267 001	AUG 17, 1988	NOV	CRLD
NALFON							
		@ DISTA	EQ 600MG BASE	N17710 001		NOV	DISC

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL

FENTANYL

@	ANESTA	EQ 0.1MG BASE	N20195 007	OCT 30, 1995	JUN	DISC
@		EQ 0.2MG BASE	N20195 001	OCT 04, 1993	JUN	DISC
@		EQ 0.3MG BASE	N20195 002	OCT 04, 1993	JUN	DISC
@		EQ 0.4MG BASE	N20195 003	OCT 04, 1993	JUN	DISC

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

@	AMERSHAM HLTH	600MG/PACKET	N20292 001	OCT 14, 1997	JUL	DISC
---	---------------	--------------	------------	--------------	-----	------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	BARR	50MG	N75882 001	OCT 28, 2002	OCT	NEWA
AB		100MG	N75882 002	OCT 28, 2002	OCT	NEWA
AB		150MG	N75882 003	OCT 28, 2002	OCT	NEWA
AB	GENEVA PHARMS TECH	50MG	N76030 001	OCT 28, 2002	OCT	NEWA
AB		100MG	N76030 002	OCT 28, 2002	OCT	NEWA
AB		150MG	N76030 003	OCT 28, 2002	OCT	NEWA

FLOXURIDINE

INJECTABLE; INJECTION

FUDR

AP	+	FAULDING	500MG/VIAL	N16929 001		APR	CAHN
----	---	----------	------------	------------	--	-----	------

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F 18

@	DOWNSTATE CLINCL	4-40mCi/ML	N20306 001	AUG 19, 1994	JUL	DISC
---	------------------	------------	------------	--------------	-----	------

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

AB +	KING PHARMS	0.1MG	N10060 001		MAR	CFTG
	FLUDROCORTISONE ACETATE					
AB	IMPAX LABS	0.1MG	N40431 001	MAR 18, 2002	MAR	NEWA

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

AB	BAUSCH AND LOMB	0.025MG/SPRAY	N74805 001	FEB 20, 2002	FEB	NEWA
	NASALIDE					
AB +	IVAX RES	0.025MG/SPRAY	N18148 001		FEB	CTEC

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR-HP

@ MEDICIS

0.2%

N16161 002 JUN DISC

SOLUTION; TOPICAL

FLUONID

@ ALLERGAN HERBERT

0.01%

N87158 001 MAR 17, 1983 MAY DISC

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

+ HILL DERMAC 0.01%;4%;0.05%

N21112 001 JAN 18, 2002 JAN NEWA

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

AB	TEVA	0.05%	N72490 001	FEB 07, 1989	AUG	CTNA
----	------	-------	------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

AB	ALPHAPHARM	EQ 10MG BASE	N75577 001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75577 002	JAN 29, 2002	JAN	NEWA
AB	BARR	EQ 10MG BASE	N74803 002	JAN 30, 2002	JAN	NEWA
AB	CARLSBAD	EQ 10MG BASE	N76022 001	JAN 30, 2002	JAN	NEWA
AB		EQ 20MG BASE	N76022 002	JAN 30, 2002	JAN	NEWA
AB	DR REDDYS LABS INC	EQ 10MG BASE	N75465 001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75465 002	JAN 29, 2002	JAN	NEWA
AB	EON	EQ 10MG BASE	N75807 001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75807 002	JAN 29, 2002	JAN	NEWA
AB	IVAX PHARMS	EQ 10MG BASE	N75245 002	JAN 31, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75245 001	JAN 31, 2002	JAN	NEWA
AB	MALLINCKRODT	EQ 10MG BASE	N75658 001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75658 002	JAN 29, 2002	JAN	NEWA
AB	MUTUAL PHARMA	EQ 10MG BASE	N75787 001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75787 002	JAN 29, 2002	JAN	NEWA
AB	MYLAN	EQ 10MG BASE	N75207 001	JAN 30, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75207 002	JAN 30, 2002	JAN	NEWA

AB	RANBAXY	EQ 10MG BASE	N76165 001	FEB 01, 2002	FEB	NEWA
AB		EQ 20MG BASE	N76165 002	FEB 01, 2002	FEB	NEWA
AB	SIDMAK LABS	EQ 10MG BASE	N76001 001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N76001 002	JAN 29, 2002	JAN	NEWA
AB	SIEGFRIED	EQ 10MG BASE	N75464 001	JAN 30, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75464 002	JAN 30, 2002	JAN	NEWA
AB	TEVA	EQ 10MG BASE	N75452 001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75452 002	JAN 29, 2002	JAN	NEWA
AB		EQ 40MG BASE	N75452 003	JAN 29, 2002	JAN	NEWA
AB	WATSON LABS	EQ 10MG BASE	N75662 001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75662 002	JAN 29, 2002	JAN	NEWA
FLUOXETINE HCL						
AB	GENEVA PHARMS	EQ 20MG BASE	N75049 002	JAN 29, 2002	JAN	NEWA
AB		EQ 40MG BASE	N75049 003	JAN 29, 2002	JAN	NEWA
SOLUTION; ORAL						
FLUOXETINE						
AA	ALPHARMA	EQ 20MG BASE/5ML	N75690 001	JAN 31, 2002	JAN	NEWA
AA	MALLINCKRODT	EQ 20MG BASE/5ML	N75920 001	JAN 29, 2002	JAN	NEWA
AA	NOVEX	EQ 20MG BASE/5ML	N75292 001	FEB 07, 2002	FEB	NEWA
AA	PHARM ASSOC	EQ 20MG BASE/5ML	N76015 001	JAN 30, 2002	JAN	NEWA
FLUOXETINE HCL						
AA	HI TECH PHARMA	EQ 20MG BASE/5ML	N75525 001	JUN 27, 2002	JUN	NEWA
AA	MORTON GROVE	EQ 20MG BASE/5ML	N75514 001	AUG 29, 2002	AUG	NEWA
TABLET; ORAL						
AB	BARR	EQ 10MG BASE	N75810 001	FEB 01, 2002	FEB	NEWA
AB	DR REDDYS LABS INC	EQ 10MG BASE	N76006 001	JAN 30, 2002	JAN	NEWA
AB	EON	EQ 10MG BASE	N76024 001	JAN 29, 2002	JAN	NEWA
AB	TEVA	EQ 10MG BASE	N75872 001	JAN 29, 2002	JAN	NEWA
AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865 001	FEB 28, 2002	FEB	NEWA
<u>FLUPHENAZINE ENANTHATE</u>						
INJECTABLE; INJECTION						
PROLIXIN ENANTHATE						
	@ APOTHECON	25MG/ML	N16110 001		JUN	DISC
<u>FLUPHENAZINE HYDROCHLORIDE</u>						
TABLET; ORAL						
PERMITIL						
	@ SCHERING	2.5MG	N12034 004		NOV	WDGB
	@	5MG	N12034 005		NOV	WDGB
<u>FLUVOXAMINE MALEATE</u>						
TABLET; ORAL						
FLUVOXAMINE MALEATE						
AB	+ EON	100MG	N75888 003	NOV 29, 2000	MAY	CRLD
AB	MUTUAL PHARM	25MG	N76125 001	APR 29, 2002	APR	NEWA
AB		50MG	N76125 002	APR 29, 2002	APR	NEWA
AB		100MG	N76125 003	APR 29, 2002	APR	NEWA
AB	TEVA	25MG	N75893 001	SEP 10, 2002	SEP	NEWA
AB		50MG	N75893 002	SEP 10, 2002	SEP	NEWA
AB		100MG	N75893 003	SEP 10, 2002	SEP	NEWA
LUVOX						
	@ SOLVAY	25MG	N20243 001	DEC 05, 1994	MAY	DISC

@	50MG	N20243 002	DEC 05, 1994	MAY	DISC
@	100MG	N20243 003	DEC 05, 1994	MAY	DISC
<u>FOLIC ACID</u>					
TABLET; ORAL					
FOLIC ACID					
AA + WATSON LABS	1MG	N80680 001		FEB	CAHN
<u>FOLLITROPIN ALFA/BETA</u>					
INJECTABLE; INJECTION					
GONAL-F					
@ SERONO	37.5 IU/VIAL	N20378 003	MAY 25, 2000	JUN	DISC
<u>FULVESTRANT</u>					
INJECTABLE; INTRAMUSCULAR					
FASLODEX					
+ ASTRAZENECA	50MG/ML	N21344 001	APR 25, 2002	APR	NEWA
<u>FURAZOLIDONE</u>					
SUSPENSION; ORAL					
FUROXONE					
@ SHIRE LABS	50MG/15ML	N11323 002		JUL	DISC
TABLET; ORAL					
@ SHIRE LABS	100MG	N11270 002		JUL	DISC
<u>GALLIUM CITRATE, GA-67</u>					
INJECTABLE; INJECTION					
NEOSCAN					
@ AMERSHAM HLTH	2mCi/ML	N17655 001		JUN	DISC
<u>GALLIUM NITRATE</u>					
INJECTABLE; INJECTION					
GANITE					
>D> @ GENTA	25MG/ML	N19961 002	JAN 17, 1991	DEC	CMFD
>A> +	25MG/ML	N19961 002	JAN 17, 1991	DEC	CMFD
@	25MG/ML	N19961 002	JAN 17, 1991	JUL	CAHN
<u>GATIFLOXACIN</u>					
INJECTABLE; INJECTION					
TEQUIN					
>A> BRISTOL MYERS SQUIBB	2MG /ML (200MG/100ML)	N21062 001	DEC 17, 1999	DEC	CPOT
>A>	2MG /ML (400MG/200ML)	N21062 002	DEC 17, 1999	DEC	CPOT
>A>	10MG /ML (200MG)	N21062 003	DEC 17, 1999	DEC	NEWA
>A> +	10MG /ML (400MG)	N21062 004	DEC 17, 1999	DEC	NEWA
>D> +	200MG/VIAL	N21062 001	DEC 17, 1999	DEC	CPOT
>D> +	400MG/VIAL	N21062 002	DEC 17, 1999	DEC	CPOT
<u>GLATIRAMER ACETATE</u>					
FOR SOLUTION; SUBCUTANEOUS					
COPAXONE					
+ TEVA	20MG/VIAL	N20622 001	DEC 20, 1996	JUN	CDFR
INJECTABLE; SUBCUTANEOUS					
+ TEVA	20MG/ML	N20622 002	FEB 12, 2002	JUN	NEWA

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL

GLUCOTROL XL

PFIZER	2.5MG
	5MG

N20329 003	AUG 10, 1999	FEB	CRLD
N20329 001	APR 26, 1994	FEB	CRLD

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

METAGLIP

BRISTOL MYERS SQUIBB	2.5MG;250MG
	2.5MG;500MG
+	5MG;500MG

N21460 001	OCT 21, 2002	OCT	NEWA
N21460 002	OCT 21, 2002	OCT	NEWA
N21460 003	OCT 21, 2002	OCT	NEWA

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

Q LILLY	EQ 1MG BASE/VIAL
---------	------------------

N12122 001		JUN	DISC
------------	--	-----	------

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB	AMIDE PHARM	1.5MG
AB		3MG
AB		6MG
AB	COREPHARMA	1.25MG
AB		2.5MG
AB		5MG

N75947 001	NOV 14, 2002	NOV	NEWA
N75947 002	NOV 14, 2002	NOV	NEWA
N75947 003	NOV 14, 2002	NOV	NEWA
N76257 001	JUN 27, 2002	JUN	NEWA
N76257 002	JUN 27, 2002	JUN	NEWA
N76257 003	JUN 27, 2002	JUN	NEWA

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

Q FERRING	0.8MG/VIAL
Q	3.2MG/VIAL

N19687 001	OCT 10, 1989	JUL	DISC
N19687 002	OCT 10, 1989	JUN	DISC

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

Q WYETH AYERST	EQ 0.5MG BASE/VIAL
----------------	--------------------

N18123 003	SEP 30, 1982	JUN	DISC
------------	--------------	-----	------

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

Q WYETH AYERST	20,000 UNITS/VIAL
----------------	-------------------

N17055 003		JUN	DISC
------------	--	-----	------

CHORIONIC GONADOTROPIN

Q STERIS	2,000 UNITS/VIAL
----------	------------------

N17016 011	FEB 16, 1990	JUN	DISC
------------	--------------	-----	------

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL

KYTRIL

Q ROCHE	EQ 2MG BASE/10ML
---------	------------------

N21238 001	JUN 27, 2001	JUN	DISC
------------	--------------	-----	------

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

GRISACTIN

@ WYETH AYERST	500MG	N60212 001		MAY	DISC
----------------	-------	------------	--	-----	------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

GRISACTIN ULTRA

@ WYETH AYERST	165MG	N62438 001	NOV 17, 1983	MAY	DISC
----------------	-------	------------	--------------	-----	------

@	330MG	N62438 002	NOV 17, 1983	MAY	DISC
---	-------	------------	--------------	-----	------

GUANADREL SULFATE

TABLET; ORAL

HYLOREL

@ PHARMACIA AND UPJOHN	10MG	N18104 001	DEC 29, 1982	JUN	DISC
------------------------	------	------------	--------------	-----	------

@	25MG	N18104 002	DEC 29, 1982	JUN	DISC
---	------	------------	--------------	-----	------

GUANETHIDINE MONOSULFATE

TABLET; ORAL

ISMELIN

@ NOVARTIS	EQ 10MG SULFATE	N12329 001		JUN	DISC
------------	-----------------	------------	--	-----	------

@	EQ 25MG SULFATE	N12329 002		JUN	DISC
---	-----------------	------------	--	-----	------

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

TENEX

AB	ESP PHARMA	EQ 1MG BASE	N19032 001	OCT 27, 1986	APR	CAHN
----	------------	-------------	------------	--------------	-----	------

AB	+	EQ 2MG BASE	N19032 002	NOV 07, 1988	APR	CAHN
----	---	-------------	------------	--------------	-----	------

@	EQ 3MG BASE	N19032 003	NOV 07, 1988	APR	CAHN
---	-------------	------------	--------------	-----	------

HALOPERIDOL

TABLET; ORAL

HALDOL

@ ORTHO MCNEIL	0.5MG	N15921 001		AUG	DISC
----------------	-------	------------	--	-----	------

@	1MG	N15921 002		AUG	DISC
---	-----	------------	--	-----	------

@	2MG	N15921 003		AUG	DISC
---	-----	------------	--	-----	------

@	5MG	N15921 004		AUG	DISC
---	-----	------------	--	-----	------

@	10MG	N15921 005		AUG	DISC
---	------	------------	--	-----	------

@	20MG	N15921 006	FEB 02, 1982	AUG	DISC
---	------	------------	--------------	-----	------

HALOPERIDOL

+	GENEVA PHARMS	20MG	N71211 001	MAR 11, 1988	AUG	CRLD
---	---------------	------	------------	--------------	-----	------

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

@ ORTHO MCNEIL	EQ 2MG BASE/ML	N15922 001		AUG	DISC
----------------	----------------	------------	--	-----	------

HALOPERIDOL

@ ALPHARMA	EQ 2MG BASE/ML	N70318 001	APR 11, 1986	MAY	DISC
------------	----------------	------------	--------------	-----	------

AA	+	TEVA	EQ 2MG BASE/ML	N71015 001	AUG 25, 1987	AUG	CRLD
----	---	------	----------------	------------	--------------	-----	------

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

@ WYETH AYERST

99.99%

N11338 001

APR DISC

HALOTHANE

AN + ABBOTT

99.99%

N83254 001

APR CTEC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP-LOCK

AP + ELKINS SINN

10 UNITS/ML

N17037 007

JUN CRLD

AP +

100 UNITS/ML

N17037 006

JUN CRLD

HEPARIN LOCK FLUSH

@ WYETH AYERST

10 UNITS/ML

N17007 008

JUN DISC

@

100 UNITS/ML

N17007 009

JUN DISC

HEPARIN SODIUM

AP + ABBOTT

2,500 UNITS/ML

N88099 001 APR 28, 1983

JUN CRLD

AP + AM PHARM PARTNERS

20,000 UNITS/ML

N17029 004

JUN CRLD

@ WYETH AYERST

1,000 UNITS/ML

N17007 001

JUN DISC

@

2,500 UNITS/ML

N17007 007

JUN DISC

@

5,000 UNITS/ML

N17007 002

JUN DISC

@

5,000 UNITS/0.5ML

N17007 010

JUN DISC

@

7,500 UNITS/ML

N17007 003

JUN DISC

@

10,000 UNITS/ML

N17007 004

JUN DISC

@

20,000 UNITS/ML

N17007 006

JUN DISC

HEXACHLOROPHENE

SOAP; TOPICAL

GAMOPHEN

@ ARBROOK

2%

N06270 003

JUN DISC

SPONGE; TOPICAL

E-Z SCRUB

@ BECTON DICKINSON

450MG

N17452 001

JUN DISC

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

@ SHIRE LABS

EQ 0.2MG BASE/ML

N19836 001 DEC 24, 1991 JUL DISC

@

EQ 0.5MG BASE/ML

N19836 002 DEC 24, 1991 JUL DISC

@

EQ 1MG BASE/ML

N19836 003 DEC 24, 1991 JUL DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB VINTAGE PHARMS

12.5MG

N75907 001 SEP 17, 2002 SEP NEWA

TABLET; ORAL

ESIDRIX

AB + NOVARTIS

100MG

N11793 009

MAR CRLD

@

100MG

N11793 009

SEP DISC

HYDROCHLOROTHIAZIDE

AB + IVAX PHARMS

100MG

N85022 001

SEP CRLD

@ LEDERLE

100MG

N87060 001

SEP DISC

AB	VINTAGE PHARMS	25MG	N40412 001	MAR 29, 2002	MAR	NEWA
AB		50MG	N40412 002	MAR 29, 2002	MAR	NEWA
	Ⓢ WATSON LABS	100MG	N81190 001	JAN 24, 1992	SEP	DISC
	HYDRODIURIL					
	Ⓢ MERCK	25MG	N11835 003		MAR	DISC
	Ⓢ	50MG	N11835 006		MAR	DISC
	Ⓢ	100MG	N11835 007		MAR	DISC
	ORETIC					
	Ⓢ ABBOTT	25MG	N11971 001		SEP	DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	EON	12.5MG;10MG	N76262 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76262 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76262 003	JUL 01, 2002	JUL	NEWA
AB	GENEVA PHARMS TECH	12.5MG;10MG	N75926 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75926 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75926 003	JUL 01, 2002	JUL	NEWA
AB	IVAX PHARMS	12.5MG;10MG	N75776 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75776 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75776 003	JUL 01, 2002	JUL	NEWA
AB	MYLAN	12.5MG;10MG	N76113 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76113 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76113 003	JUL 01, 2002	JUL	NEWA
AB	PUREPAC PHARM	12.5MG;10MG	N76230 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76230 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76230 003	JUL 01, 2002	JUL	NEWA
AB	RANBAXY	12.5MG;10MG	N76007 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76007 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76007 003	JUL 01, 2002	JUL	NEWA
AB	TEVA	12.5MG;10MG	N75869 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75869 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75869 003	JUL 01, 2002	JUL	NEWA
AB	WATSON LABS	12.5MG;20MG	N76194 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;10MG	N76194 003	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76194 002	JUL 01, 2002	JUL	NEWA
AB	WEST WARD	12.5MG;10MG	N76265 001	JUL 08, 2002	JUL	NEWA
AB		12.5MG;20MG	N76265 002	JUL 08, 2002	JUL	NEWA
AB		25MG;20MG	N76265 003	JUL 08, 2002	JUL	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIRETIC

	SCHWARZ PHARMA	12.5MG;15MG	N20729 003	FEB 14, 2002	JUN	NEWA
--	----------------	-------------	------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

Ⓢ WYETH AYERST	50MG;120MG	N19059 002	JUL 03, 1985	JUN	DISC
----------------	------------	------------	--------------	-----	------

INDERIDE LA 160/50

Ⓢ WYETH AYERST	50MG;160MG	N19059 003	JUL 03, 1985	JUN	DISC
----------------	------------	------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 80/50

@ WYETH AYERST

50MG;80MG

N19059 001 JUL 03, 1985 JUN DISC

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROPRES 25

@ MERCK

25MG;0.125MG

N11958 002

JUN DISC

HYDROPRES 50

@ MERCK

50MG;0.125MG

N11958 003

JUN DISC

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

@ ALPHARMA

5MG/5ML;25MG/5ML

N75103 001 SEP 29, 2000 SEP DISC

HYCOMINE

@ ENDO PHARMS

5MG/5ML;25MG/5ML

N19410 001 AUG 17, 1990 SEP DISC

HYCOMINE PEDIATRIC

@ ENDO PHARMS

2.5MG/5ML;12.5MG/5ML

N19411 001 AUG 17, 1990 SEP DISC

HYDROCORTISONE

TABLET; ORAL

CORTEF

+ PHARMACIA AND UPJOHN

5MG

N08697 003

MAY CRLD

5MG

N08697 003

OCT CRLD

BP +

10MG

N08697 001

MAY CRLD

BP

10MG

N08697 001

OCT CRLD

BP +

20MG

N08697 002

MAY CRLD

HYDROCORTISONE ACETATE

CREAM; TOPICAL

MICORT-HC

+ FERNDAL LABS

2%

N40398 001 MAR 29, 2002 MAR NEWA

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

+ STERIS

25MG/ML

N83128 001

JUN CRLD

@

25MG/ML

N83128 001

OCT DISC

HYDROCORTONE

@ MERCK

25MG/ML

N08228 001

JUN DISC

@

50MG/ML

N08228 004

JUN DISC

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

+ FERNDAL LABS

0.1%

N18514 001 MAR 31, 1982 MAR CAHN

LOCOID LIPOCREAM

+ FERNDAL LABS

0.1%

N20769 001 SEP 08, 1997 MAR CAHN

OINTMENT; TOPICAL

LOCOID

+ FERNDAL LABS

0.1%

N18652 001 OCT 29, 1982 MAR CAHN

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

ACHROMYCIN

@ LEDERLE

1.5%;1%

N50272 001

JUN DISC

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

>D> AB + SHIRE 50MG

N11949 001

DEC CAHN

>A> AB + SHIRE LABS 50MG

N11949 001

DEC CAHN

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE AND HYDROFLUMETHIAZIDE

@ PAR PHARM

50MG;0.125MG

N88907 001 SEP 20, 1985 AUG DISC

SALUTENSIN

>D> + SHIRE 50MG;0.125MG

N12359 003

DEC CAHN

>A> + SHIRE LABS 50MG;0.125MG

N12359 003

DEC CAHN

SALUTENSIN-DEMI

>D> @ SHIRE 25MG;0.125MG

N12359 004

DEC CAHN

>A> @ SHIRE LABS 25MG;0.125MG

N12359 004

DEC CAHN

@ 25MG;0.125MG

N12359 004

JUL DISC

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIE

@ AKORN

1%

N00004 004

JUN DISC

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

@ STERIS

250MG/ML

N17439 002

JUN DISC

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HCL

AA VINTAGE PHARMS 10MG/5ML

N40391 001 APR 10, 2002 APR NEWA

IBUPROFEN

SUSPENSION/DROPS; ORAL

MOTRIN

@ MCNEIL

40MG/ML

N20476 001 MAY 25, 1995 JUN DISC

TABLET; ORAL

@ MCNEIL CONS SPECLT

100MG

N20418 001 NOV 16, 1994 JUN DISC

TABLET, CHEWABLE; ORAL

@ MCNEIL CONS SPECLT

50MG

N20135 001 NOV 16, 1994 JUN DISC

@ 100MG

N20135 002 NOV 16, 1994 JUN DISC

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

AP + PHARMACIA AND UPJOHN 5MG/VIAL

N50661 002 SEP 27, 1990 MAY CFTG

	@	5MG/VIAL	N50661 002	SEP 27, 1990	JUN	DISC
AP	+	10MG/VIAL	N50661 001	SEP 27, 1990	MAY	CFTG
	@	10MG/VIAL	N50661 001	SEP 27, 1990	JUN	DISC
AP	+	20MG/VIAL	N50661 003	APR 25, 1995	MAY	CFTG
	@	20MG/VIAL	N50661 003	APR 25, 1995	JUN	DISC
IDAMYCIN PFS						
AP	+	PHARMACIA AND UPJOHN 1MG/ML	N50734 001	FEB 17, 1997	MAY	CFTG
IDARUBICIN HCL						
AP		GENSIA SICOR PHARMS 5MG/VIAL	N65037 003	MAY 01, 2002	MAY	NEWA
	+	10MG/VIAL	N65037 002	MAY 01, 2002	JUN	CRLD
AP		10MG/VIAL	N65037 002	MAY 01, 2002	MAY	NEWA
	+	20MG/VIAL	N65037 001	MAY 01, 2002	JUN	CRLD
AP		20MG/VIAL	N65037 001	MAY 01, 2002	MAY	NEWA
IDARUBICIN HCL PFS						
AP		GENSIA SICOR PHARMS 1MG/ML	N65036 001	MAY 01, 2002	MAY	NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

+	AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	AUG	CRLD
		1GM/VIAL	N76078 001	MAY 28, 2002	MAY	NEWA
+		3GM/VIAL	N76078 002	MAY 28, 2002	MAY	NEWA

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+	GENSIA SICOR PHARMS	1GM /20ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 001	FEB 26, 2002	FEB	NEWA
+		3GM /60ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 002	FEB 26, 2002	FEB	NEWA

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE

AP	+	ABBOTT	EQ 5MG BASE/ML	N74616 001	AUG 03, 1998	JUN	CRLD
		INOCOR					
	@	SANOFI SYNTHELABO	EQ 5MG BASE/ML	N18700 001	JUL 31, 1984	JUN	DISC

INDOCYANINE GREEN

INJECTABLE; INJECTION

CARDIO-GREEN

@	AKORN	50MG/VIAL	N11525 002		JUN	DISC
---	-------	-----------	------------	--	-----	------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB		PAR PHARM	25MG	N18829 002	AUG 06, 1984	JUL	CAHN
AB			50MG	N18829 001	AUG 06, 1984	JUL	CAHN
CAPSULE, EXTENDED RELEASE; ORAL							
AB		ABLE	75MG	N76114 001	FEB 06, 2002	FEB	NEWA
SUPPOSITORY; RECTAL							
		INDOCIN					
	@	MERCK	50MG	N17814 001	AUG 13, 1984	MAY	DISC

INDOMETHACIN

SUPPOSITORY; RECTAL

INDOMETHEGAN

+ G AND W LABS

50MG

N73314 001 AUG 31, 1992 MAY CRLD

INSULIN PORK

INJECTABLE; INJECTION

ILETIN I

@ LILLY

500 UNITS/ML

N17931 001 JUN DISC

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

@ BRACCO

10.3%

N09321 007 JUN DISC

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

@ AMERSHAM HLTH

55%

N20808 001 AUG 29, 1997 JUN DISC

VISIPAQUE 320

@ AMERSHAM HLTH

65.2%

N20808 002 AUG 29, 1997 JUN DISC

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION

HIPPIRAN I 131

@ MALLINCKRODT

0.25mCi/ML

N16666 001 JUN DISC

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE

@ IMP

1mCi/ML

N19432 001 DEC 24, 1987 JUN DISC

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 210

@ AMERSHAM HLTH

45.3%

N18956 006 JUN 30, 1989 JUN DISC

SOLUTION; URETHRAL

OMNIPAQUE 70

@ AMERSHAM HLTH

15.1%

N18956 007 JUN 01, 1994 JUN DISC

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

@ FAULDING

61%

N74734 001 DEC 10, 1996 JUL DISC

@

76%

N74734 002 DEC 10, 1996 JUL DISC

ISOVUE-128

@ BRACCO

26%

N18735 005 OCT 21, 1986 JUN DISC

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+	BERLEX LABS	300MG/ML
+		370MG/ML

N21425 001 SEP 20, 2002 SEP NEWA

N21425 002 SEP 20, 2002 SEP NEWA

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

CONRAY 325

a MALLINCKRODT 54.3%

N17685 001

JUN DISC

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET 62%

N20316 001 DEC 21, 1995 JUN CAHN

OXILAN-350

GUERBET 73%

N20316 002 DEC 21, 1995 JUN CAHN

IPODATE SODIUM

CAPSULE; ORAL

ORAGRAFIN SODIUM

a BRACCO 500MG

N12967 001

JUN DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPATROPIUM BROMIDE

AN ROXANE 0.02%

N75867 001 JUL 22, 2002 JUL NEWA

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL

a 3M 0.12MG/INH

N10375 004

JUN DISC

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

a 3M 0.08MG/INH

N10375 003

JUN DISC

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

a ALCON 100GM/220ML

N17063 001

JUN DISC

ISOSORBIDE DINITRATE

TABLET; ORAL

SORBITRATE

a ASTRAZENECA 5MG

N16192 001 APR 01, 1996 SEP DISC

a 10MG

N16192 002 APR 01, 1996 SEP DISC

TABLET, CHEWABLE; ORAL

a ASTRAZENECA 5MG

N16776 002 APR 01, 1996 SEP DISC

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

AB	ESP PHARMA	20MG	N19091 001	DEC 30, 1991	JUL	CAHN
----	------------	------	------------	--------------	-----	------

ISOTRETINOIN

CAPSULE; ORAL

AC CUTANE

AB	HLR	10MG	N18662 002	MAY 07, 1982	NOV	CFTG
----	-----	------	------------	--------------	-----	------

AB	+	20MG	N18662 004	MAR 28, 1983	NOV	CFTG
----	---	------	------------	--------------	-----	------

AB	+	40MG	N18662 003	MAY 07, 1982	NOV	CFTG
----	---	------	------------	--------------	-----	------

AMNESTEEM

AB	GENPHARM	10MG	N75945 001	NOV 08, 2002	NOV	NEWA
----	----------	------	------------	--------------	-----	------

AB		20MG	N75945 002	NOV 08, 2002	NOV	NEWA
----	--	------	------------	--------------	-----	------

AB		40MG	N75945 003	NOV 08, 2002	NOV	NEWA
----	--	------	------------	--------------	-----	------

ISOTRETINOIN

>A>	AB	RANBAXY	10MG	N76041 001	DEC 24, 2002	DEC	NEWA
-----	----	---------	------	------------	--------------	-----	------

>A>	AB		20MG	N76041 002	DEC 24, 2002	DEC	NEWA
-----	----	--	------	------------	--------------	-----	------

>A>	AB		40MG	N76041 003	DEC 24, 2002	DEC	NEWA
-----	----	--	------	------------	--------------	-----	------

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN

>A>	AP	AM PHARM PARTNERS	EQ 500MG BASE/2ML	N65111 001	DEC 17, 2002	DEC	NEWA
-----	----	-------------------	-------------------	------------	--------------	-----	------

>A>	AP		EQ 1GM BASE/3ML	N65111 002	DEC 17, 2002	DEC	NEWA
-----	----	--	-----------------	------------	--------------	-----	------

KANTREX

>D>	+	APOTHECON	EQ 500MG BASE/2ML	N61901 001		DEC	CFTG
-----	---	-----------	-------------------	------------	--	-----	------

>A>	AP	+	EQ 500MG BASE/2ML	N61901 001		DEC	CFTG
-----	----	---	-------------------	------------	--	-----	------

>D>	+		EQ 1GM BASE/3ML	N61901 002		DEC	CFTG
-----	---	--	-----------------	------------	--	-----	------

>A>	AP	+	EQ 1GM BASE/3ML	N61901 002		DEC	CFTG
-----	----	---	-----------------	------------	--	-----	------

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

AP	BIONICHE (CANADA)	EQ 100MG BASE/ML	N76092 003	OCT 25, 2002	OCT	NEWA
----	-------------------	------------------	------------	--------------	-----	------

KETOCONAZOLE

CREAM; TOPICAL

KETOZOLE

>A>	AB	TARO	2%	N75638 001	DEC 18, 2002	DEC	NEWA
-----	----	------	----	------------	--------------	-----	------

TABLET; ORAL

KETOCONAZOLE

AB	NEOSAN PHARMS	200MG	N75341 001	JUL 27, 1999	JUL	CAHN
----	---------------	-------	------------	--------------	-----	------

AB	TORPHARM	200MG	N75912 001	JAN 10, 2002	JAN	NEWA
----	----------	-------	------------	--------------	-----	------

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

AB	MYLAN	100MG	N75679 003	FEB 20, 2002	FEB	NEWA
----	-------	-------	------------	--------------	-----	------

AB		150MG	N75679 002	FEB 20, 2002	FEB	NEWA
----	--	-------	------------	--------------	-----	------

AB		200MG	N75679 001	FEB 20, 2002	FEB	NEWA
----	--	-------	------------	--------------	-----	------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	AM PHARM PARTNERS	15MG/ML	N75784 001	JAN 11, 2002	JAN	NEWA
AP		30MG/ML	N75784 002	JAN 11, 2002	JAN	NEWA

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GAS GENERATOR

@ AMERSHAM HLTH N/A

N18088 001 JUL DISC

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

AP	APOTEX	5MG/ML	N76051 001	JUL 05, 2002	JUL	NEWA
----	--------	--------	------------	--------------	-----	------

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	NOVEX	10GM/15ML	N75911 001	FEB 21, 2002	FEB	NEWA
----	-------	-----------	------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

CEPHULAC

@ AVENTIS PHARMS 10GM/15ML

N17657 001 JUL DISC

ENULOSE

AA +	ALPHARMA	10GM/15ML	N71548 001	AUG 15, 1988	JUL	CRLD
------	----------	-----------	------------	--------------	-----	------

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

LAMICTAL CD

+ GLAXOSMITHKLINE 25MG

N20764 002 AUG 24, 1998 MAR CRLD

@ 100MG

N20764 003 AUG 24, 1998 MAR DISC

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL

PREVACID

TAP PHARM 15MG

N21428 001 AUG 30, 2002 AUG NEWA

+ 30MG

N21428 002 AUG 30, 2002 AUG NEWA

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL

LEUCOVORIN CALCIUM

>D>	@ IMMUNEX	EQ 60MG BASE/VIAL	N08107 003	JAN 30, 1987	DEC	CAHN
-----	-----------	-------------------	------------	--------------	-----	------

>A>	@ XANODYNE PHARM	EQ 60MG BASE/VIAL	N08107 003	JAN 30, 1987	DEC	CAHN
-----	------------------	-------------------	------------	--------------	-----	------

INJECTABLE; INJECTION

>D>	@ IMMUNEX	EQ 3MG BASE/ML	N08107 001		DEC	CAHN
-----	-----------	----------------	------------	--	-----	------

>D>	AP +	EQ 50MG BASE/VIAL	N08107 002		DEC	CAHN
-----	------	-------------------	------------	--	-----	------

>D>	AP +	EQ 100MG BASE/VIAL	N08107 004	MAY 23, 1988	DEC	CAHN
-----	------	--------------------	------------	--------------	-----	------

>D>	AP +	EQ 350MG BASE/VIAL	N08107 005	APR 05, 1989	DEC	CAHN
-----	------	--------------------	------------	--------------	-----	------

>A>	@ XANODYNE PHARM	EQ 3MG BASE/ML	N08107 001		DEC	CAHN
-----	------------------	----------------	------------	--	-----	------

>A>	AP +	EQ 50MG BASE/VIAL	N08107 002		DEC	CAHN
-----	------	-------------------	------------	--	-----	------

>A>	AP +	EQ 100MG BASE/VIAL	N08107 004	MAY 23, 1988	DEC	CAHN
-----	------	--------------------	------------	--------------	-----	------

>A>	AP +	EQ 350MG BASE/VIAL	N08107 005	APR 05, 1989	DEC	CAHN
-----	------	--------------------	------------	--------------	-----	------

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

BX	XANODYNE PHARM	EQ 5MG BASE	N18459 001	JAN 30, 1986	AUG	CAHN
AB		EQ 10MG BASE	N71962 001	NOV 19, 1987	AUG	CAHN
AB		EQ 15MG BASE	N71104 001	MAR 04, 1987	JUN	CAHN

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

+	ATRIX	7.5MG/VIAL	N21343 001	JAN 23, 2002	JAN	NEWA
+		22.5MG/VIAL	N21379 001	JUL 24, 2002	JUL	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

+	SEPRACOR	EQ 0.0105% BASE	N20837 003	JAN 30, 2002	JUN	NEWA
---	----------	-----------------	------------	--------------	-----	------

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR

	@ SIGMA TAU	1GM/10ML	N18948 002	APR 27, 1988	JUN	DISC
+		1GM/10ML	N19257 001	APR 10, 1986	JUL	CMFD
	@	1GM/10ML	N19257 001	APR 10, 1986	JUN	DISC

LEVODOPA

TABLET; ORAL

LARODOPA

	@ ROCHE	100MG	N16912 005		JUN	DISC
	@	250MG	N16912 003		JUN	DISC
	@	500MG	N16912 004		JUN	DISC

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

BX	MOVA	0.025MG	N21342 001	MAR 01, 2002	MAR	NEWA
BX		0.05MG	N21342 002	MAR 01, 2002	MAR	NEWA
BX		0.075MG	N21342 003	MAR 01, 2002	MAR	NEWA
BX		0.088MG	N21342 004	MAR 01, 2002	MAR	NEWA
BX		0.1MG	N21342 005	MAR 01, 2002	MAR	NEWA
BX		0.112MG	N21342 006	MAR 01, 2002	MAR	NEWA
BX		0.125MG	N21342 007	MAR 01, 2002	MAR	NEWA
BX		0.15MG	N21342 008	MAR 01, 2002	MAR	NEWA
BX		0.175MG	N21342 009	MAR 01, 2002	MAR	NEWA
BX		0.2MG	N21342 010	MAR 01, 2002	MAR	NEWA
BX	+	0.3MG	N21342 011	MAR 01, 2002	MAR	NEWA
	LEVOTHYROXINE SODIUM					
AB	MYLAN	0.025MG	N76187 001	JUN 05, 2002	JUN	NEWA
AB		0.05MG	N76187 002	JUN 05, 2002	JUN	NEWA
AB		0.075MG	N76187 003	JUN 05, 2002	JUN	NEWA

AB		0.088MG	N76187 004	JUN 05, 2002	JUN	NEWA
AB		0.1MG	N76187 005	JUN 05, 2002	JUN	NEWA
AB		0.112MG	N76187 006	JUN 05, 2002	JUN	NEWA
AB		0.125MG	N76187 007	JUN 05, 2002	JUN	NEWA
AB		0.15MG	N76187 008	JUN 05, 2002	JUN	NEWA
AB		0.175MG	N76187 009	JUN 05, 2002	JUN	NEWA
AB		0.2MG	N76187 010	JUN 05, 2002	JUN	NEWA
AB		0.3MG	N76187 011	JUN 05, 2002	JUN	NEWA
NOVOTHYROX						
BX	GENPHARM	0.025MG	N21292 001	MAY 31, 2002	MAY	NEWA
BX		0.05MG	N21292 002	MAY 31, 2002	MAY	NEWA
BX		0.075MG	N21292 003	MAY 31, 2002	MAY	NEWA
BX		0.088MG	N21292 004	MAY 31, 2002	MAY	NEWA
BX		0.1MG	N21292 005	MAY 31, 2002	MAY	NEWA
BX		0.112MG	N21292 006	MAY 31, 2002	MAY	NEWA
BX		0.125MG	N21292 007	MAY 31, 2002	MAY	NEWA
BX		0.137MG	N21292 008	MAY 31, 2002	MAY	NEWA
BX		0.15MG	N21292 009	MAY 31, 2002	MAY	NEWA
BX		0.175MG	N21292 010	MAY 31, 2002	MAY	NEWA
BX		0.2MG	N21292 011	MAY 31, 2002	MAY	NEWA
BX +		0.3MG	N21292 012	MAY 31, 2002	MAY	NEWA
SYNTHROID						
BX	ABBOTT	0.025MG	N21402 001	JUL 24, 2002	JUL	NEWA
BX		0.05MG	N21402 002	JUL 24, 2002	JUL	NEWA
BX		0.075MG	N21402 003	JUL 24, 2002	JUL	NEWA
BX		0.088MG	N21402 004	JUL 24, 2002	JUL	NEWA
BX		0.1MG	N21402 005	JUL 24, 2002	JUL	NEWA
BX		0.112MG	N21402 006	JUL 24, 2002	JUL	NEWA
BX		0.125MG	N21402 007	JUL 24, 2002	JUL	NEWA
BX		0.137MG	N21402 008	JUL 24, 2002	JUL	NEWA
BX		0.15MG	N21402 009	JUL 24, 2002	JUL	NEWA
BX		0.175MG	N21402 010	JUL 24, 2002	JUL	NEWA
BX		0.2MG	N21402 012	JUL 24, 2002	AUG	NEWA
BX +		0.3MG	N21402 011	JUL 24, 2002	JUL	NEWA
THYRO-TABS						
BX	LLOYD	0.025MG	N21116 001	OCT 24, 2002	OCT	NEWA
BX		0.05MG	N21116 002	OCT 24, 2002	OCT	NEWA
BX		0.075MG	N21116 003	OCT 24, 2002	OCT	NEWA
BX		0.088MG	N21116 010	OCT 24, 2002	OCT	NEWA
BX		0.1MG	N21116 004	OCT 24, 2002	OCT	NEWA
BX		0.112MG	N21116 011	OCT 24, 2002	OCT	NEWA
BX		0.125MG	N21116 005	OCT 24, 2002	OCT	NEWA
BX		0.15MG	N21116 006	OCT 24, 2002	OCT	NEWA
BX		0.175MG	N21116 007	OCT 24, 2002	OCT	NEWA
BX		0.2MG	N21116 008	OCT 24, 2002	OCT	NEWA
BX +		0.3MG	N21116 009	OCT 24, 2002	OCT	NEWA
UNITHROID						
AB	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	JUN	CRLD
AB		0.05MG	N21210 002	AUG 21, 2000	JUN	CRLD
AB		0.075MG	N21210 003	AUG 21, 2000	JUN	CRLD
AB		0.088MG	N21210 004	AUG 21, 2000	JUN	CRLD
AB		0.1MG	N21210 005	AUG 21, 2000	JUN	CRLD
AB		0.112MG	N21210 006	AUG 21, 2000	JUN	CRLD

AB		0.125MG	N21210 007	AUG 21, 2000	JUN	CRLD
AB		0.15MG	N21210 008	AUG 21, 2000	JUN	CRLD
AB		0.175MG	N21210 009	AUG 21, 2000	JUN	CRLD
AB		0.2MG	N21210 010	AUG 21, 2000	JUN	CRLD
AB +		0.3MG	N21210 011	AUG 21, 2000	JUN	CRLD

LIDOCAINE

AEROSOL; ORAL						
XYLOCAINE						
	@ ASTRAZENECA	10%	N14394 001		JUN	DISC
FILM, EXTENDED RELEASE; BUCCAL						
LIDOCAINE						
	@ NOVEN	23MG/PATCH	N20575 001	MAY 21, 1996	JUN	DISC
OINTMENT; TOPICAL						
AT +	FOUGERA	5%	N80198 001		SEP	CRLD
XYLOCAINE						
	@ ASTRAZENECA	5%	N08048 001		SEP	DISC

LIDOCAINE HYDROCHLORIDE

INJECTABLE; SPINAL

LIDOCAINE HCL 5% AND DEXTROSE 7.5%

+	ABBOTT	5%	N83914 001		SEP	CRLD
XYLOCAINE 5% W/ GLUCOSE 7.5%						
	@ ASTRAZENECA	5%	N10496 002	JUL 07, 1982	SEP	DISC

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN

@	PHARMACIA AND UPJOHN	EQ 250MG BASE	N50316 001		JUN	DISC
@		EQ 500MG BASE	N50316 002		JUN	DISC

LINEZOLID

TABLET; ORAL

ZYVOX

@	PHARMACIA AND UPJOHN	400MG	N21130 001	APR 18, 2000	JUN	DISC
---	----------------------	-------	------------	--------------	-----	------

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	APOTEX	2.5MG	N76102 001	SEP 30, 2002	SEP	NEWA
AB		5MG	N76102 002	SEP 30, 2002	SEP	NEWA
AB		10MG	N76102 003	SEP 30, 2002	SEP	NEWA
AB		20MG	N76102 004	SEP 30, 2002	SEP	NEWA
AB		30MG	N76102 005	SEP 30, 2002	SEP	NEWA
AB		40MG	N76102 006	SEP 30, 2002	SEP	NEWA
AB	EON	2.5MG	N75994 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75994 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75994 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75994 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75994 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75994 006	JUL 01, 2002	JUL	NEWA
AB	GENEVA PHARMS TECH	2.5MG	N75903 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75903 002	JUL 01, 2002	JUL	NEWA

AB		10MG	N75903 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75903 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75903 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75903 006	JUL 01, 2002	JUL	NEWA
AB	IVAX PHARMS	2.5MG	N75752 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75752 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75752 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75752 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75752 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75752 006	JUL 01, 2002	JUL	NEWA
AB	LEK PHARM	2.5MG	N75999 001	JUL 01, 2002	AUG	NEWA
AB		5MG	N75999 002	JUL 01, 2002	AUG	NEWA
AB		10MG	N75999 003	JUL 01, 2002	AUG	NEWA
AB		20MG	N75999 004	JUL 01, 2002	AUG	NEWA
AB		30MG	N75999 005	JUL 01, 2002	AUG	NEWA
AB		40MG	N75999 006	JUL 01, 2002	AUG	NEWA
AB	MYLAN	2.5MG	N76071 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76071 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76071 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76071 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N76071 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N76071 006	JUL 01, 2002	JUL	NEWA
AB	PAR PHARM	2.5MG	N75743 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75743 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75743 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75743 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75743 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75743 006	JUL 01, 2002	JUL	NEWA
AB	PUREPAC PHARM	2.5MG	N76180 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76180 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76180 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76164 001	JUL 01, 2002	JUL	NEWA
AB		30MG	N76164 002	JUL 01, 2002	JUL	NEWA
AB		40MG	N76164 003	JUL 01, 2002	JUL	NEWA
AB	RANBAXY	2.5MG	N75944 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75944 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75944 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75944 004	JUL 01, 2002	JUL	NEWA
AB		40MG	N75944 005	JUL 01, 2002	JUL	NEWA
AB	TEVA	2.5MG	N75783 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75783 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75783 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75783 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75783 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75783 006	JUL 01, 2002	JUL	NEWA
AB	WATSON LABS	2.5MG	N76059 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76059 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76059 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76059 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N76059 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N76059 006	JUL 01, 2002	JUL	NEWA
AB	WEST WARD	2.5MG	N76063 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76063 002	JUL 01, 2002	JUL	NEWA

AB		10MG	N76063 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76063 004	JUL 01, 2002	JUL	NEWA
AB		40MG	N76063 005	JUL 01, 2002	JUL	NEWA
	ZESTRIL					
AB +	ASTRAZENECA	30MG	N19777 006	JAN 20, 1999	JUL	CFTG
	<u>LITHIUM CARBONATE</u>					
	CAPSULE; ORAL					
	LITHIUM CARBONATE					
AB	WEST WARD	300MG	N76243 001	JUN 27, 2002	JUN	NEWA
	TABLET, EXTENDED RELEASE; ORAL					
AB	BARR	300MG	N76170 001	JUN 10, 2002	JUN	NEWA
	LITHOBID					
AB +	SOLVAY	300MG	N18027 001		JUN	CFTG
	<u>LOMEFLOXACIN HYDROCHLORIDE</u>					
	TABLET; ORAL					
	MAXAQUIN					
+	PHARMACIA	EQ 400MG BASE	N20013 001	FEB 21, 1992	JUL	CAHN
	<u>LORATADINE</u>					
	TABLET; ORAL					
	CLARITIN					
+	SCHERING	10MG	N19658 001	APR 12, 1993	JUL	CTEC
	<u>LOVASTATIN</u>					
	TABLET; ORAL					
	LOVASTATIN					
AB	CARLSBAD	10MG	N75991 001	JUN 05, 2002	JUN	NEWA
AB		20MG	N75991 002	JUN 05, 2002	JUN	NEWA
AB		40MG	N75991 003	JUN 05, 2002	JUN	NEWA
	TABLET, EXTENDED RELEASE; ORAL					
	ALTOCOR					
	ANDRX	10MG	N21316 001	JUN 26, 2002	JUL	CAHN
		20MG	N21316 002	JUN 26, 2002	JUL	CAHN
		40MG	N21316 003	JUN 26, 2002	JUL	CAHN
+		60MG	N21316 004	JUN 26, 2002	JUL	CAHN
	AURA LABS	10MG	N21316 001	JUN 26, 2002	JUN	NEWA
		20MG	N21316 002	JUN 26, 2002	JUN	NEWA
		40MG	N21316 003	JUN 26, 2002	JUN	NEWA
+		60MG	N21316 004	JUN 26, 2002	JUN	NEWA
	<u>LOXAPINE HYDROCHLORIDE</u>					
	CONCENTRATE; ORAL					
	LOXITANE C					
	@ WATSON LABS	EQ 25MG BASE/ML	N17658 001		JUL	DISC
	INJECTABLE; INJECTION					
	LOXITANE IM					
	@ WATSON LABS	EQ 50MG BASE/ML	N18039 001		JUL	DISC

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

@ BRACCO 3.49MG/GM

N20686 001 DEC 19, 1997 JUN DISC

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

@ ASTRAZENECA 12.5GM/50ML

N89239 001 MAY 06, 1987 NOV WDGA

MASOPROCOL

CREAM; TOPICAL

ACTINEX

@ UNIV AZ CANCER CTR 10%

N19940 001 SEP 04, 1992 JUN DISC

MAZINDOL

TABLET; ORAL

MAZANOR

@ WYETH AYERST 1MG

N17980 002 APR DISC

SANOREX

NOVARTIS 1MG

N17247 001 APR CTEC

@ 1MG

N17247 001 JUN DISC

@ 2MG

N17247 002 JUN DISC

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

AMEN

@ AMARIN PHARMS 10MG

N83242 001 SEP DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

AB + ROCHE 250MG

N19591 001 MAY 02, 1989 FEB CFTG

MEFLOQUINE HCL

AB GENEVA PHARMS TECH 250MG

N76175 001 FEB 20, 2002 FEB NEWA

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB ROXANE 40MG/ML

N75997 001 FEB 15, 2002 FEB NEWA

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

PERGONAL

BX + SERONO 75 IU/AMP;75 IU/AMP

N17646 001 AUG CMFD

75 IU/AMP;75 IU/AMP

N17646 001 JUN DISC

@ 150 IU/AMP;150 IU/AMP

N17646 002 MAY 20, 1985 JUN DISC

REPRONEX

+ FERRING 75 IU/VIAL;75 IU/VIAL

N21047 001 AUG 27, 1999 JUN CRLD

BX 75 IU/VIAL;75 IU/VIAL

N21047 001 AUG 27, 1999 AUG CRLD

+ 150 IU/VIAL;150 IU/VIAL

N21047 002 AUG 27, 1999 JUN CRLD

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HCL

AA	CARACO	50MG	N40446 001	AUG 08, 2002	AUG	NEWA
AA		100MG	N40446 002	AUG 08, 2002	AUG	NEWA

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@ WYETH AYERST	25MG/ML;25MG/ML	N11730 001		JUN	DISC
----------------	-----------------	------------	--	-----	------

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

@ WYETH AYERST	EQ 15MG BASE/ML	N08248 002		JUN	DISC
----------------	-----------------	------------	--	-----	------

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

@ NOVARTIS	100MG	N06008 001		JUN	DISC
------------	-------	------------	--	-----	------

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ GALDERMA LABS	2%;0.01%	N20922 001	DEC 10, 1999	APR	CAHN
-----------------	----------	------------	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNEX

AP + BAXTER HLTHCARE	100MG/ML	N19884 001	DEC 30, 1988	MAR	CAHN
TABLET; ORAL					
+ BAXTER HLTHCARE	400MG	N20855 001	MAR 21, 2002	JUN	CAHN
+ BRISTOL MYERS SQUIBB	400MG	N20855 001	MAR 21, 2002	MAR	NEWA

MESORIDAZINE BESYLATE

INJECTABLE; INJECTION

SERENTIL

@ NOVARTIS	EQ 25MG BASE/ML	N16775 001		JUN	DISC
------------	-----------------	------------	--	-----	------

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

AB WATSON LABS	0.05MG;1MG	N16659 001		JAN	CAHN
----------------	------------	------------	--	-----	------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

@ BOEHRINGER INGELHEIM	5%	N17659 001		JUN	DISC
------------------------	----	------------	--	-----	------

METAPROTERENOL SULFATE

AN MORTON GROVE	0.4%	N75586 001	MAY 30, 2002	MAY	NEWA
AN	0.6%	N75586 002	MAY 30, 2002	MAY	NEWA

METAPROTERENOL SULFATE

TABLET; ORAL

ALUPENT

@ BOEHRINGER INGELHEIM	10MG	N15874 002		NOV	WDGB
@	20MG	N15874 001		NOV	WDGB
AB + PAR PHARM	20MG	N72025 001	JUN 28, 1988	NOV	CRLD

METAXALONE

TABLET; ORAL

SKELAXIN

+ ELAN PHARMS	400MG	N13217 001		JUN	CAHN
	400MG	N13217 001		AUG	CRLD
+	800MG	N13217 003	AUG 30, 2002	AUG	NEWA

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

AB BRISTOL MYERS SQUIBB	500MG	N20357 001	MAR 03, 1995	JAN	CFTG
AB	850MG	N20357 002	MAR 03, 1995	JAN	CFTG
AB +	1GM	N20357 005	NOV 05, 1998	JAN	CFTG

METFORMIN HCL

AB ALPHAPHARM	500MG	N75969 001	JAN 29, 2002	JAN	NEWA
AB	850MG	N75969 002	JAN 29, 2002	JAN	NEWA
AB	1GM	N75969 003	JAN 29, 2002	JAN	NEWA
AB ANDRX PHARMS	500MG	N75961 001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75961 002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75961 003	JAN 25, 2002	JAN	NEWA
AB BARR	500MG	N75971 001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75971 002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75971 003	JAN 25, 2002	JAN	NEWA
AB CARACO	500MG	N75967 001	JAN 29, 2002	JAN	NEWA
AB	850MG	N75967 002	JAN 29, 2002	JAN	NEWA
AB	1GM	N75967 003	JAN 29, 2002	JAN	NEWA
AB EON	500MG	N75965 001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75965 002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75965 003	JAN 25, 2002	JAN	NEWA
AB GENEVA PHARMS	500MG	N75985 001	JAN 25, 2002	MAY	CAHN
AB	850MG	N75985 002	JAN 25, 2002	MAY	CAHN
AB	1GM	N75985 003	JAN 25, 2002	MAY	CAHN
AB GENEVA PHARMS TECH	500MG	N75985 001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75985 002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75985 003	JAN 25, 2002	JAN	NEWA
AB GENPHARM	500MG	N75973 001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75973 002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75973 003	JAN 25, 2002	JAN	NEWA
AB GOLDLINE	500MG	N75972 001	JAN 24, 2002	JAN	NEWA
AB	625MG	N75972 005	JAN 24, 2002	JAN	NEWA
AB	750MG	N75972 004	JAN 24, 2002	JAN	NEWA
AB	850MG	N75972 002	JAN 24, 2002	JAN	NEWA
AB	1GM	N75972 003	JAN 24, 2002	JAN	NEWA
AB MUTUAL PHARMA	500MG	N76038 001	FEB 21, 2002	FEB	NEWA

AB		850MG	N76038 002	FEB 21, 2002	FEB	NEWA
AB		1GM	N76038 003	FEB 21, 2002	FEB	NEWA
AB	MYLAN	500MG	N75976 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N75976 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75976 003	JAN 24, 2002	JAN	NEWA
AB	PUREPAC PHARM	500MG	N76033 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N76033 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N76033 003	JAN 24, 2001	JAN	NEWA
AB	TEVA	500MG	N75978 001	JAN 25, 2002	JAN	NEWA
>A>	AB	500MG	N76328 001	DEC 16, 2002	DEC	NEWA
	AB	850MG	N75978 002	JAN 25, 2002	JAN	NEWA
>A>	AB	850MG	N76328 002	DEC 16, 2002	DEC	NEWA
	AB	1GM	N75978 003	NOV 05, 2002	NOV	NEWA
>A>	AB	1GM	N76328 003	DEC 16, 2002	DEC	NEWA
	AB	TORPHARM	N75984 001	APR 23, 2002	APR	NEWA
	AB	850MG	N75984 002	APR 23, 2002	APR	NEWA
	AB	1GM	N75984 003	APR 23, 2002	APR	NEWA
	AB	WATSON LABS	N75979 001	JAN 24, 2002	JAN	NEWA
	AB	850MG	N75979 002	JAN 24, 2002	JAN	NEWA
	AB	1GM	N75979 003	JAN 24, 2002	JAN	NEWA
	AB	ZENITH GOLDLINE	N75975 001	JAN 24, 2002	JAN	NEWA
	AB	625MG	N75975 004	JAN 24, 2002	JAN	NEWA
	AB	750MG	N75975 005	JAN 24, 2002	JAN	NEWA
	AB	850MG	N75975 002	JAN 24, 2002	JAN	NEWA
	AB	1GM	N75975 003	JAN 24, 2002	JAN	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

GLAXOSMITHKLINE 500MG;EQ 1MG BASE

N21410 001 OCT 10, 2002 OCT NEWA

500MG;EQ 2MG BASE

N21410 002 OCT 10, 2002 OCT NEWA

+ 500MG;EQ 4MG BASE

N21410 003 OCT 10, 2002 OCT NEWA

METHADONE HYDROCHLORIDE

SYRUP; ORAL

DOLOPHINE HCL

a ROXANE 10MG/30ML

N06134 004 JUL DISC

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

+ OVATION PHARMS 5MG

N05378 002 SEP CAHN

TABLET, EXTENDED RELEASE; ORAL

a ABBOTT 5MG

N05378 004 JUN DISC

a 10MG

N05378 003 JUN DISC

a 15MG

N05378 005 JUN DISC

a OVATION PHARMS 5MG

N05378 004 SEP CAHN

a 10MG

N05378 003 SEP CAHN

a 15MG

N05378 005 SEP CAHN

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

@ SHIRE LABS

50MG

N07390 001

JUL DISC

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+ KING PHARMS

500MG/VIAL

N11559 001

FEB CAHN

+

2.5GM/VIAL

N11559 002

FEB CAHN

+

5GM/VIAL

N11559 003

FEB CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

FOLEX

+ PHARMACIA AND UPJOHN

EQ 50MG BASE/VIAL

N87695 002 APR 08, 1983 JUN CRLD

+

EQ 100MG BASE/VIAL

N87695 003 APR 08, 1983 JUN CRLD

METHOTREXATE SODIUM

@ LEDERLE

EQ 2.5MG BASE/ML

N11719 004

JUN DISC

@

EQ 50MG BASE/VIAL

N11719 003

JUN DISC

@

EQ 100MG BASE/VIAL

N11719 006

JUN DISC

TABLET; ORAL

AB + CLONMEL HLTHCARE

EQ 2.5MG BASE

N08085 002

JUL CAHN

METHYLCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

@ WALLACE LABS

2.5MG;0.1MG

N12708 005

OCT DISC

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

@ MERCK

250MG/5ML

N18389 001

JUN DISC

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX + CELLTECH PHARMS

20MG

N21259 001 APR 03, 2001 JUN CTEC

RITALIN LA

BX NOVARTIS

20MG

N21284 001 JUN 05, 2002 JUN NEWA

30MG

N21284 002 JUN 05, 2002 JUN NEWA

+

40MG

N21284 003 JUN 05, 2002 JUN NEWA

>A> SOLUTION; ORAL

>A> METHYLIN

>A> + MALLINCKRODT BAKER

5MG/5ML

N21419 001 DEC 19, 2002 DEC NEWA

>A> +

10MG/5ML

N21419 002 DEC 19, 2002 DEC NEWA

TABLET; ORAL

METHYLPHENIDATE HCL

AB PUREPAC PHARM

5MG

N40321 001 FEB 05, 2002 FEB NEWA

AB

10MG

N40321 002 FEB 05, 2002 FEB NEWA

AB

20MG

N40321 003 FEB 05, 2002 FEB NEWA

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

+	ALZA	27MG	N21121 004	APR 01, 2002	JUN	NEWA
---	------	------	------------	--------------	-----	------

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB	GENEVA PHARMS	4MG	N40194 001	OCT 31, 1997	MAY	CAHN
----	---------------	-----	------------	--------------	-----	------

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

+	PHARMACIA AND UPJOHN	80MG/ML	N11757 004		SEP	CTEC
---	----------------------	---------	------------	--	-----	------

METHYLPREDNISOLONE ACETATE

@	STERIS	20MG/ML	N85597 001		SEP	DISC
---	--------	---------	------------	--	-----	------

@		80MG/ML	N85595 001		SEP	DISC
---	--	---------	------------	--	-----	------

METHYLTESTOSTERONE

TABLET; ORAL

METHYLTESTOSTERONE

@	LANNETT	10MG	N87092 001	NOV 05, 1982	SEP	DISC
---	---------	------	------------	--------------	-----	------

@		25MG	N87111 001	JAN 27, 1983	SEP	DISC
---	--	------	------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HCL

AA	+	TEVA	EQ 5MG BASE/5ML	N70819 001	JUL 10, 1987	NOV	CRLD
----	---	------	-----------------	------------	--------------	-----	------

REGLAN

@	ROBINS AH	EQ 5MG BASE/5ML	N18821 001	MAR 25, 1983	NOV	WDGB
---	-----------	-----------------	------------	--------------	-----	------

METRONIDAZOLE

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+	GD SEARLE LLC	500MG/100ML	N18353 002		JUL	CAHN
----	---	---------------	-------------	------------	--	-----	------

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

+	GD SEARLE LLC	EQ 500MG BASE/VIAL	N18353 001		JUL	CAHN
---	---------------	--------------------	------------	--	-----	------

MICONAZOLE NITRATE

CREAM, INSERT; TOPICAL, VAGINAL

MONISTAT DUAL- PAK

@	PERSONAL PRODS	1.2GM;2%	N20968 001	JUN 30, 1999	JUN	DISC
---	----------------	----------	------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

AP	+	ABBOTT	EQ 1MG BASE/ML	N75293 001	JUN 20, 2000	OCT	CRLD
----	---	--------	----------------	------------	--------------	-----	------

AP			EQ 1MG BASE/ML	N75857 001	JUL 22, 2002	JUL	NEWA
----	--	--	----------------	------------	--------------	-----	------

AP +	EQ 5MG BASE/ML	N75293 002	JUN 20, 2000	OCT	CRLD
AP	EQ 5MG BASE/ML	N75857 002	JUL 22, 2002	JUL	NEWA
AP ROSS LABS	EQ 1MG BASE/ML	N75856 001	JUN 13, 2002	JUN	NEWA
AP	EQ 5MG BASE/ML	N75856 002	JUN 13, 2002	JUN	NEWA
VERSED					
@ HLR	EQ 1MG BASE/ML	N18654 002	MAY 26, 1987	OCT	DISC
@	EQ 5MG BASE/ML	N18654 001	DEC 20, 1985	OCT	DISC
SYRUP; ORAL					
MIDAZOLAM HCL					
AA RANBAXY	EQ 2MG BASE/ML	N76058 001	MAR 15, 2002	MAR	NEWA
AA + ROXANE	EQ 2MG BASE/ML	N75873 001	APR 30, 2002	SEP	CRLD
AA	EQ 2MG BASE/ML	N75873 001	APR 30, 2002	APR	NEWA
VERSED					
AA + ROCHE	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	MAR	CFTG
@	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	AUG	DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

SHIRE LABS	10MG	N19815 003	MAR 20, 2002	JUL	CRLD
+	10MG	N19815 003	MAR 20, 2002	JUN	NEWA
SHIRE PHARM	2.5MG	N19815 001	SEP 06, 1996	SEP	CMFD
	5MG	N19815 002	SEP 06, 1996	JUN	CRLD
+	5MG	N19815 002	SEP 06, 1996	OCT	CRLD
	10MG	N19815 003	MAR 20, 2002	OCT	CRLD

MIFEPRISTONE

TABLET; ORAL

MIFEPREX

+ DANCO LABS LLC	200MG	N20687 001	SEP 28, 2000	OCT	CAHN
------------------	-------	------------	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP ABBOTT	EQ 1MG BASE/ML	N75884 001	MAY 28, 2002	MAY	NEWA
AP AM PHARM PARTNERS	EQ 1MG BASE/ML	N75936 001	MAY 28, 2002	MAY	NEWA
AP BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75852 001	MAY 28, 2002	MAY	NEWA
AP BEDFORD	EQ 10MG /10ML BASE (10MG/ML)	N75660 001	MAY 28, 2002	NOV	CPOT
AP	EQ 10MG 10/ML (10MG/ML)	N75660 001	MAY 28, 2002	MAY	NEWA
AP	EQ 20MG /20ML BASE (1MG/ML)	N75660 002	MAY 28, 2002	MAY	NEWA
AP	EQ 50MG /50ML BASE (1MG/ML)	N75660 003	MAY 28, 2002	MAY	NEWA
AP ESI LEDERLE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	MAY	NEWA
AP FAULDING	EQ 1MG BASE/ML	N75830 001	MAY 28, 2002	MAY	NEWA
AP INTL MEDICATED	EQ 1MG BASE/ML	N76013 001	AUG 02, 2002	AUG	NEWA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP ABBOTT	EQ 20MG BASE/100ML	N75885 001	MAY 28, 2002	MAY	NEWA
AP +	EQ 40MG BASE/200ML	N75885 002	MAY 28, 2002	MAY	NEWA
AP BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75834 001	MAY 28, 2002	MAY	NEWA
AP	EQ 40MG BASE/100ML	N75834 002	MAY 28, 2002	MAY	NEWA
AP	EQ 40MG BASE/200ML	N75834 002	MAY 28, 2002	JUN	NEWA
AP ESI LEDERLE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	MAY	NEWA
MILRINONE LACTOSE IN 5% DEXTROSE					
AP ESI LEDERLE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002	AUG	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

PRIMACOR

AP +	SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001	DEC 31, 1987	MAY	CFTG
	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CFTG
AP +		EQ 40MG BASE/100ML	N20343 004	AUG 09, 1994	MAY	CFTG
AP +		EQ 40MG BASE/200ML	N20343 004	AUG 09, 1994	JUN	CFTG

MINOCYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

MINOCIN

@ LEDERLE

EQ 50MG BASE/5ML

N50445 001

JUN DISC

MISOPROSTOL

TABLET; ORAL

CYTOTEC

AB	GD SEARLE LLC	0.1MG	N19268 003	SEP 21, 1990	JUL	CFTG
AB +		0.2MG	N19268 001	DEC 27, 1988	JUL	CFTG
	MISOPROSTOL					
AB	IVAX PHARMS	0.1MG	N76095 001	JUL 10, 2002	JUL	NEWA
AB		0.2MG	N76095 002	JUL 10, 2002	JUL	NEWA

MITOMYCIN

INJECTABLE; INJECTION

MYTOZYTREX

+ SUPERGEN

5MG/VIAL

N50763 001 NOV 14, 2002 NOV NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVANTRONE

>D>	+	IMMUNEX	EQ 2MG BASE/ML
>A>	+	SERONO INC	EQ 2MG BASE/ML

N19297 001 DEC 23, 1987 DEC CAHN

N19297 001 DEC 23, 1987 DEC CAHN

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ABBOTT

EQ 0.5MG BASE/ML

N20098 002 JAN 22, 1992 JUN DISC

MOMETASONE FUROATE

OINTMENT; TOPICAL

ELOCON

AB +	SCHERING	0.1%	N19543 001	APR 30, 1987	MAR	CFTG
	MOMETASONE FUROATE					
AB	CLAY PARK	0.1%	N76067 001	MAR 18, 2002	MAR	NEWA

MONOCTANOIN

LIQUID; PERFUSION, BILIARY

MOCTANIN

@ ETHITEK

100%

N19368 001 OCT 29, 1985 JUN DISC

MONTELUKAST SODIUM

GRANULE; ORAL

SINGULAIR

+	MERCK	EQ 4MG BASE/PACKET	N21409 001	JUL 26, 2002	JUL	NEWA
---	-------	--------------------	------------	--------------	-----	------

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

ETHMOZINE

>D>	SHIRE	200MG	N19753 001	JUN 19, 1990	DEC	CAHN
>A>	SHIRE LABS	200MG	N19753 001	JUN 19, 1990	DEC	CAHN
>D>	SHIRE	250MG	N19753 002	JUN 19, 1990	DEC	CAHN
>A>	SHIRE LABS	250MG	N19753 002	JUN 19, 1990	DEC	CAHN
>D>	+ SHIRE	300MG	N19753 003	JUN 19, 1990	DEC	CAHN
>A>	+ SHIRE LABS	300MG	N19753 003	JUN 19, 1990	DEC	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX	+	ELAN PHARM	30MG	N21260 001	MAR 20, 2002	SEP	CTEC
			30MG	N21260 001	MAR 20, 2002	MAR	NEWA
BX	+		60MG	N21260 002	MAR 20, 2002	SEP	CTEC
			60MG	N21260 002	MAR 20, 2002	MAR	NEWA
	+		90MG	N21260 003	MAR 20, 2002	SEP	CRLD
			90MG	N21260 003	MAR 20, 2002	MAR	NEWA
	+		120MG	N21260 004	MAR 20, 2002	MAR	NEWA

KADIAN

BX	+	FAULDING PHARMS	30MG	N20616 004	MAR 09, 2001	SEP	CTEC
BX	+		60MG	N20616 005	MAR 09, 2001	SEP	CTEC

TABLET, EXTENDED RELEASE; ORAL

MS CONTIN

AB	PURDUE FREDERICK	15MG	N19516 003	SEP 12, 1989	OCT	CRLD
AB		30MG	N19516 001	MAY 29, 1987	OCT	CRLD
AB		100MG	N19516 004	JAN 16, 1990	OCT	CRLD
AB		200MG	N19516 005	NOV 08, 1993	OCT	CRLD

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

>A>	CLAY PARK LABS	2%	N50788 001	DEC 04, 2002	DEC	NEWA
-----	----------------	----	------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	EON	500MG	N75280 001	FEB 25, 2002	FEB	NEWA
AB		750MG	N75280 002	FEB 25, 2002	FEB	NEWA
AB	INVAMED	500MG	N75590 001	FEB 25, 2002	FEB	NEWA
AB		750MG	N75590 002	FEB 25, 2002	FEB	NEWA

NAFCILLIN SODIUM

CAPSULE; ORAL

UNIPEN

@	WYETH AYERST	EQ 250MG BASE	N50111 001		JUN	DISC
---	--------------	---------------	------------	--	-----	------

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

@ ABBOTT

1.5MG/ML

N20200 001 MAR 12, 1993 JUL DISC

NALIDIXIC ACID

SUSPENSION; ORAL

NEGRAM

@ SANOFI SYNTHELABO

250MG/5ML

N17430 001 JUN DISC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HCL

MALLINCKRODT

25MG

N76264 001 MAR 22, 2002 MAR NEWA

AB

50MG

N76264 002 MAR 22, 2002 MAR NEWA

+

100MG

N76264 003 MAR 22, 2002 MAR NEWA

REVIA

AB + BARR PHARMS

50MG

N18932 001 NOV 20, 1984 NOV CAHN

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

@ ELAN PHARM

EQ 750MG BASE

N20353 003 JAN 05, 1996 JUN DISC

NEOMYCIN SULFATE

SOLUTION; ORAL

MYCIFRADIN

AA + PHARMACIA AND UPJOHN

EQ 87.5MG BASE/5ML

N50285 001 MAY CFTG

@

EQ 87.5MG BASE/5ML

N50285 001 JUN DISC

NEO-FRADIN

+ PHARMATEK

EQ 87.5MG BASE/5ML

N65010 001 MAY 23, 2002 JUN CRLD

AA

EQ 87.5MG BASE/5ML

N65010 001 MAY 23, 2002 MAY NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

STATROL

@ ALCON

EQ 3.5MG BASE/GM;10,000 UNITS/GM

N50344 002 JUN DISC

SOLUTION/DROPS; OPHTHALMIC

@ ALCON

EQ 3.5MG BASE/ML;16,250 UNITS/ML

N50456 001 JUN DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

@ KOS

375MG

N20381 001 JUL 28, 1997 AUG DISC

+

500MG

N20381 002 JUL 28, 1997 AUG CMFD

@

500MG

N20381 002 JUL 28, 1997 JUN DISC

NIASPAN TITRATION STARTER PACK

@ KOS

375MG;500MG;750MG

N20381 005 JUL 28, 1997 JUN DISC

NICOTINE

INHALANT; INHALATION

NICOTROL

a PHARMACIA AND UPJOHN 4MG/CARTRIDGE

N20714 001 MAY 02, 1997 NOV WDGB

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

AB1 + BAYER 90MG

N20198 003 APR 21, 1993 AUG CTEC

NIFEDIPINE

AB1 BIOVAIL 90MG

N76070 001 AUG 16, 2002 AUG NEWA

NILUTAMIDE

TABLET; ORAL

NILANDRON

a AVENTIS PHARMS 50MG

N20169 001 SEP 19, 1996 JUN DISC

+ 150MG

N20169 002 APR 30, 1999 JUL CMFD

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

+ FIRST HORIZON 10MG

N20356 001 FEB 02, 1995 MAR CAHN

20MG

N20356 002 FEB 02, 1995 MAR CAHN

+ 30MG

N20356 003 FEB 02, 1995 MAR CAHN

+ 40MG

N20356 004 FEB 02, 1995 MAR CAHN

+ WHITEHALL ROBINS 10MG

N20356 001 FEB 02, 1995 FEB CAHN

20MG

N20356 002 FEB 02, 1995 FEB CAHN

+ 40MG

N20356 004 FEB 02, 1995 FEB CAHN

NITAZOXANIDE

FOR SUSPENSION; ORAL

ALINIA

+ ROMARK 100MG/5ML

N21498 001 NOV 22, 2002 NOV NEWA

NITISINONE

CAPSULE; ORAL

ORFADIN

R R REGISTRATIONS 2MG

N21232 001 JAN 18, 2002 JAN NEWA

5MG

N21232 002 JAN 18, 2002 JAN NEWA

+ 10MG

N21232 003 JAN 18, 2002 JAN NEWA

SWEDISH ORPHAN 2MG

N21232 001 JAN 18, 2002 MAY CAHN

5MG

N21232 002 JAN 18, 2002 MAY CAHN

+ 10MG

N21232 003 JAN 18, 2002 MAY CAHN

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

+ FIRST HORIZON 25MG/5ML

N09175 001 JAN CAHN

NITROFURAZONE

CREAM; TOPICAL

FURACIN

@ SHIRE LABS 0.2%

N83789 001 JUL DISC

OINTMENT; TOPICAL

@ SHIRE LABS 0.2%

N05795 001 JUL DISC

+ SHIRE PHARM 0.2%

N05795 001 SEP CMFD

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

@ FIRST HORIZON 0.4MG/SPRAY

N18705 001 OCT 31, 1985 APR CAHN

@ POHL BOSKAMP 0.4MG/SPRAY

N18705 001 OCT 31, 1985 JUN CAHN

SPRAY, METERED; SUBLINGUAL

NITROLINGUAL PUMPSPRAY

+ FIRST HORIZON 0.4MG/SPRAY

N18705 002 JAN 10, 1997 APR CAHN

+ POHL BOSKAMP 0.4MG/SPRAY

N18705 002 JAN 10, 1997 JUN CAHN

TABLET; SUBLINGUAL

NITROSTAT

PFIZER PHARMS 0.4MG

N21134 002 MAY 01, 2000 JUN CAHN

NIZATIDINE

CAPSULE; ORAL

AXID

AB LILLY 150MG

N19508 001 APR 12, 1988 JUL CFTG

AB + 300MG

N19508 002 APR 12, 1988 JUL CFTG

AB RELIANT PHARMS 150MG

N19508 001 APR 12, 1988 AUG CAHN

AB + 300MG

N19508 002 APR 12, 1988 AUG CAHN

NIZATIDINE

AB EON 150MG

N76178 001 JUL 05, 2002 JUL NEWA

AB 300MG

N76178 002 JUL 05, 2002 JUL NEWA

AB GENPHARM 150MG

N75934 001 JUL 09, 2002 JUL NEWA

AB 300MG

N75934 002 JUL 09, 2002 JUL NEWA

AB MYLAN 150MG

N75806 001 JUL 05, 2002 JUL NEWA

AB 300MG

N75806 002 JUL 05, 2002 JUL NEWA

AB TEVA 150MG

N75668 001 SEP 12, 2002 SEP NEWA

AB 300MG

N75668 002 SEP 12, 2002 SEP NEWA

AB WATSON LABS 150MG

N75616 001 JUL 09, 2002 JUL NEWA

AB 300MG

N75616 002 JUL 09, 2002 JUL NEWA

AB ZENITH GOLDLINE 150MG

N75461 001 JUL 08, 2002 JUL NEWA

AB 300MG

N75461 002 JUL 08, 2002 JUL NEWA

NORETHINDRONE

TABLET; ORAL

NOR-QD

+ WATSON LABS (UTAH) 0.35MG

N17060 001 MAY CAHN

TABLET; ORAL-28

CAMILA

AB1 BARR 0.35MG

N76177 001 OCT 21, 2002 OCT NEWA

ERRIN

AB2 BARR 0.35MG

N76225 001 OCT 21, 2002 OCT NEWA

MICRONOR

NORETHINDRONE

TABLET; ORAL-28

MICRONOR

AB2 + ORTHO MCNEIL PHARM 0.35MG N16954 001 OCT CFTG

NOR-QD

AB1 + WATSON LABS (UTAH) 0.35MG N17060 001 OCT CFTG

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL

AVENTYL HCL

AA + RANBAXY EQ 10MG BASE/5ML N14685 001 JUN CAHN

NOVOBIOCIN SODIUM

CAPSULE; ORAL

ALBAMYCIN

@ PHARMACIA AND UPJOHN EQ 250MG BASE

N50339 001 JUN DISC

NYSTATIN

TABLET; ORAL

NILSTAT

@ LEDERLE 500,000 UNITS

N61151 001 JUN DISC

TABLET; VAGINAL

@ LEDERLE 100,000 UNITS

N61325 001 JUL DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

SANDOSTATIN LAR

NOVARTIS

EQ 10MG BASE/VIAL

N21008 001 NOV 25, 1998 NOV CRLD

EQ 20MG BASE/VIAL

N21008 002 NOV 25, 1998 NOV CRLD

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

AP + JOHNSON RW 40MG/ML

N20087 003 MAR 31, 1992 JAN CFTG

@ ORTHO MCNEIL PHARM 20MG/ML

N20087 002 MAR 31, 1992 JUL DISC

OFLOXACIN

AP BEDFORD 40MG/ML

N75762 001 JAN 16, 2002 JAN NEWA

OLANZAPINE

TABLET; ORAL

ZYPREXA

LILLY

2.5MG

N20592 001 SEP 30, 1996 OCT CRLD

OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR

SANKYO

5MG

N21286 001 APR 25, 2002 APR NEWA

20MG

N21286 003 APR 25, 2002 APR NEWA

+

40MG

N21286 004 APR 25, 2002 APR NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

>A>	AB	EON	10MG	N75791 001	DEC 23, 2002	DEC	NEWA
>A>	AB		20MG	N75791 002	DEC 23, 2002	DEC	NEWA
	AB	IMPAX LABS	10MG	N75785 001	NOV 08, 2002	NOV	NEWA
	AB		20MG	N75785 002	NOV 08, 2002	NOV	NEWA
	AB	KREMERS URBAN DEV	10MG	N75410 001	NOV 01, 2002	NOV	NEWA
	AB		20MG	N75410 002	NOV 01, 2002	NOV	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

	SANOFI	50MG/VIAL	N21492 001	AUG 09, 2002	AUG	NEWA
+		100MG/VIAL	N21492 002	AUG 09, 2002	AUG	NEWA

OXANDROLONE

TABLET; ORAL

OXANDRIN

	BIO TECH GEN	2.5MG	N13718 001		JUN	CRLD
+		10MG	N13718 002	NOV 05, 2001	JUN	NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	CARACO	600MG	N75844 001	JAN 03, 2002	JAN	NEWA
AB	IVAX PHARMS	600MG	N75846 001	MAY 13, 2002	MAY	NEWA
AB	TEVA	600MG	N75849 001	JUL 03, 2002	JUL	NEWA

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

+	PHARMACIA	600MG	N20776 001	OCT 17, 2002	OCT	NEWA
---	-----------	-------	------------	--------------	-----	------

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	ABBOTT	6MG/ML	N76131 001	MAY 08, 2002	MAY	NEWA
AP	NAPRO	6MG/ML	N76233 001	AUG 01, 2002	AUG	NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	AESGEN	30MG/VIAL	N75594 001	MAY 06, 2002	MAY	NEWA
AP		90MG/VIAL	N75594 002	MAY 06, 2002	MAY	NEWA
AP	AM PHARM PARTNERS	30MG/VIAL	N75773 001	MAY 06, 2002	MAY	NEWA
AP		30MG /10ML(3MG/ML)	N76207 001	MAY 17, 2002	MAY	NEWA
AP		90MG/VIAL	N75773 002	MAY 06, 2002	MAY	NEWA
AP		90MG /10ML(9MG/ML)	N76207 002	MAY 17, 2002	MAY	NEWA
AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAY	CDFR
AP	+	90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAY	CDFR
AP	FAULDING	30MG /10ML(3MG/ML)	N75841 001	JUN 27, 2002	JUN	NEWA

AP		60MG /10ML(6MG/ML)	N75841 002	JUN 27, 2002	JUN	NEWA
AP		90MG /10ML(9MG/ML)	N75841 003	JUN 27, 2002	JUN	NEWA
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAY	CDFR
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAY	CDFR
INJECTABLE; IV (INFUSION)						
AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAR	NEWA
AP	+	90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAR	NEWA
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAR	NEWA
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAR	NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL

COTAZYM

@ ORGANON

30,000USP UNITS;8,000USP
UNITS;30,000USP UNITS

N20580 001 DEC 09, 1996 JUN DISC

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

@ ABBOTT

150MG

N06800 003

JUN DISC

@

300MG

N06800 001

JUN DISC

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAXIL CR

GLAXOSMITHKLINE

EQ 12.5MG BASE
EQ 25MG BASE

N20936 001 FEB 16, 1999 OCT CRLD
N20936 002 FEB 16, 1999 OCT CRLD

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

AP	GENEVA PHARMS	1,000,000 UNITS/VIAL
AP		5,000,000 UNITS/VIAL
AP		20,000,000 UNITS/VIAL

N65079 001	AUG 30, 2002	AUG	NEWA
N65079 002	AUG 30, 2002	AUG	NEWA
N65079 003	AUG 30, 2002	AUG	NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PEN-VEE K

@ WYETH AYERST

EQ 125MG BASE/5ML

N60007 001

MAY DISC

@

EQ 250MG BASE/5ML

N60007 002

MAY DISC

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

@ WYETH AYERST

0.25MG/ML

N17048 001

APR DISC

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ JOHNSON AND JOHNSON

100MG

N20193 001 SEP 26, 1996 JUL CAHN

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

AB	TEVA	EQ 0.05MG BASE	N76061 001	NOV 27, 2002	NOV	NEWA
AB		EQ 0.25MG BASE	N76061 002	NOV 27, 2002	NOV	NEWA
AB		EQ 1MG BASE	N76061 003	NOV 27, 2002	NOV	NEWA
PERMAX						
AB +	LILLY	EQ 0.05MG BASE	N19385 001	DEC 30, 1988	NOV	CFTG
AB		EQ 0.25MG BASE	N19385 002	DEC 30, 1988	NOV	CFTG
AB		EQ 1MG BASE	N19385 003	DEC 30, 1988	NOV	CFTG

PHENACEMIDE

TABLET; ORAL

PHENURONE

@ ABBOTT	500MG	N07707 001		JUN	DISC
----------	-------	------------	--	-----	------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL

@ ABLE	200MG;800MG;160MG	N21105 001	JUN 26, 2001	JUN	DISC
--------	-------------------	------------	--------------	-----	------

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA	MIKART	35MG	N89452 001	OCT 30, 1991	MAR	CMFD
----	--------	------	------------	--------------	-----	------

PENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PENTERMINE HCL

AA	VINTAGE PHARMS	37.5MG	N40377 001	JAN 04, 2002	JAN	NEWA
----	----------------	--------	------------	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

@ ALLERGAN	0.12%;0.1%	N07953 001		JUN	DISC
------------	------------	------------	--	-----	------

PHENYTOIN

SUSPENSION; ORAL

PHENTYTOIN

AB	MORTON GROVE	125MG/5ML	N40420 001	APR 19, 2002	APR	NEWA
----	--------------	-----------	------------	--------------	-----	------

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC

OCUSERT PILO-40

@ AKORN	11MG	N17548 001		JUN	DISC
---------	------	------------	--	-----	------

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

@ AKORN	5MG	N17431 001		JUN	DISC
---------	-----	------------	--	-----	------

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

a ORGANON

10MG/VIAL

N19638 001 JUN 26, 1990 JUN DISC

PODOFILOX

SOLUTION; TOPICAL

CONDYLOX

AT + PADDOCK 0.5%

N19795 001 DEC 13, 1990 JAN CFTG

PODOFILOX

AT PADDOCK 0.5%

N75600 001 JAN 29, 2002 JAN NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB ANDRX PHARMS 10MEQ

N75604 001 APR 10, 2002 APR NEWA

AB 20MEQ

N75604 002 APR 10, 2002 APR NEWA

AB KV PHARM 20MEQ

N76044 001 APR 05, 2002 APR NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

BRISTOL MYERS SQUIBB 40MG

N19898 004 MAR 22, 1993 MAR CRLD

+ 80MG

N19898 008 DEC 18, 2001 MAR NEWA

PREDNICARBATE

CREAM; TOPICAL

DERMATOP

+ DERMIK LABS 0.1%

N20279 001 OCT 29, 1993 JUN CAHN

OINTMENT; TOPICAL

+ DERMIK LABS 0.1%

N19568 001 SEP 23, 1991 JUN CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA KV PHARM 15MG/5ML

N40364 001 APR 10, 2002 APR NEWA

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

METIMYD

a SCHERING 0.5%;10%

N10210 002 SEP 09, 1984 JUL DISC

VASOCIDIN

+ NOVARTIS 0.5%;10%

N88791 001 OCT 05, 1984 AUG CRLD

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

a ALCON 0.25%;10%

N87547 001 JUN DISC

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

a SCHERING 0.5%;10%

N10210 001 JUL DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

AA + ASCENT PEDS EQ 15MG BASE/5ML N75117 001 DEC 14, 2000 JUL CFTG

PEDIAPRED

AA + CELLTECH PHARMS EQ 5MG BASE/5ML N19157 001 MAY 28, 1986 JUN CFTG

PREDNISOLONE SODIUM PHOSPHATE

AA MORTON GROVE EQ 5MG BASE/5ML N75099 001 JUN 28, 2002 JUN NEWA

>A> AA PHARM ASSOC EQ 5MG BASE/5ML N76123 001 DEC 23, 2002 DEC NEWA

>A> AA WE PHARMS EQ 5MG BASE/5ML N75181 001 DEC 23, 2002 DEC NEWA

AA EQ 15MG BASE/5ML N75250 001 JUL 12, 2002 JUL NEWA

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

@ MERCK 20MG/ML N10562 001 JUN DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

@ LANNETT 5MG N80514 001 SEP DISC

AB VINTAGE PHARMS 5MG N40256 001 JUL 12, 2002 JUL NEWA

AB 10MG N40256 002 JUL 12, 2002 JUL NEWA

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

@ XCEL PHARMS 250MG/5ML N10401 001 JUL DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

@ GLAXOSMITHKLINE EQ 10MG BASE N11000 001 JUN DISC

+ EQ 10MG BASE N21019 001 OCT 06, 1999 JUN CRLD

@ EQ 15MG BASE N11000 002 JUN DISC

+ EQ 15MG BASE N21019 002 OCT 06, 1999 JUN CRLD

@ EQ 30MG BASE N11000 003 JUN DISC

PROGESTERONE

GEL; VAGINAL

CRINONE

>D> + COLUMBIA RES LABS 8% N20756 001 MAY 13, 1997 DEC CMS2

>A> 8% N20756 001 MAY 13, 1997 DEC CMS2

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

@ ALZA 38MG N17553 001 JUN DISC

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

SPARINE

@ WYETH AYERST 50MG/ML N10349 006 JUN DISC

PROMAZINE HYDROCHLORIDE

TABLET; ORAL

SPARINE

@ WYETH AYERST	25MG	N10348 001		JUN	DISC
@	50MG	N10348 002		JUN	DISC

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

AP	GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002	AUG	NEWA
AP		50MG/ML	N40454 002	AUG 22, 2002	AUG	NEWA
AP	PHARMAFORCE	25MG/ML	N40471 001	NOV 21, 2002	NOV	NEWA

SUPPOSITORY; RECTAL

PHENERGAN

AB +	WYETH AYERST	25MG	N10926 001		FEB	CTEC
------	--------------	------	------------	--	-----	------

PROMETHAZINE HCL

AB	G AND W LABS	25MG	N40428 001	FEB 05, 2002	FEB	NEWA
----	--------------	------	------------	--------------	-----	------

SYRUP; ORAL

PHENERGAN FORTIS

@ WYETH AYERST	25MG/5ML	N08381 003		JUN	DISC
----------------	----------	------------	--	-----	------

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HCL

AB	KV PHARM	150MG	N76193 001	FEB 07, 2002	FEB	NEWA
AB		225MG	N76193 002	FEB 07, 2002	FEB	NEWA
AB		300MG	N76193 003	FEB 07, 2002	FEB	NEWA
AB	VINTAGE PHARMS	150MG	N75938 001	OCT 17, 2002	OCT	NEWA
AB		225MG	N75938 002	OCT 17, 2002	OCT	NEWA
AB		300MG	N75938 003	OCT 17, 2002	OCT	NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

AA +	AAI PHARMA	32MG	N10997 001		JUN	CAHN
AA +		65MG	N10997 003		JUN	CAHN

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

+	NEOSAN PHARMS	50MG/5ML	N16861 001		JUN	CAHN
---	---------------	----------	------------	--	-----	------

TABLET; ORAL

+	AAIPHARMA LLC	100MG	N16862 002		JUN	CAHN
---	---------------	-------	------------	--	-----	------

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

@ LEDERLE	60MG	N71495 001	DEC 31, 1987	FEB	DISC
@	80MG	N70128 001	JUL 30, 1985	MAY	CAHN
@	90MG	N71496 001	DEC 31, 1987	FEB	DISC
@ PUREPAC PHARM	10MG	N70814 001	NOV 03, 1986	MAY	DISC

	20MG	N70815 001	NOV 03, 1986	MAY	DISC
	40MG	N70816 001	NOV 03, 1986	MAY	DISC
	60MG	N70817 001	NOV 03, 1986	MAY	DISC
	80MG	N70757 001	NOV 03, 1986	MAY	DISC
 <u>PYRAZINAMIDE</u>					
TABLET; ORAL					
PYRAZINAMIDE					
AB +	CLONMEL 500MG	N80157 001		JUL	CAHN
 <u>PYRIDOSTIGMINE BROMIDE</u>					
TABLET; ORAL					
MESTINON					
>D>	+ ICN 60MG	N09829 002		DEC	CFTG
>A>	AB + 60MG	N09829 002		DEC	CFTG
>A>	PYRIDOSTIGMINE BROMIDE				
>A>	AB COREPHARMA 60MG	N40457 001	DEC 26, 2002	DEC	NEWA
 <u>QUINETHAZONE</u>					
TABLET; ORAL					
HYDROMOX					
	20MG	N13264 001		APR	DISC
 <u>RABEPRAZOLE SODIUM</u>					
TABLET, DELAYED RELEASE; ORAL					
ACIPHEX					
	20MG	N20973 001	MAY 29, 2002	JUL	DISC
	20MG	N20973 002	AUG 19, 1999	MAY	CAHN
	20MG	N20973 002	AUG 19, 1999	JUL	CMFD
	20MG	N20973 002	AUG 19, 1999	JUN	DISC
 <u>RANITIDINE HYDROCHLORIDE</u>					
CAPSULE; ORAL					
RANITIDINE HCL					
AB +	GENEVA PHARMS EQ 300MG BASE	N74655 002	OCT 22, 1997	AUG	CRLD
	ZANTAC 300				
	GLAXOSMITHKLINE EQ 300MG BASE	N20095 002	MAR 08, 1994	AUG	DISC
 <u>RAPACURONIUM BROMIDE</u>					
INJECTABLE; INJECTION					
RAPLON					
	100MG/VIAL	N20984 001	AUG 18, 1999	JUN	DISC
	200MG/VIAL	N20984 002	AUG 18, 1999	JUN	DISC
 <u>RIBAVIRIN</u>					
>A>	TABLET; ORAL				
>A>	COPEGUS				
>A>	+ ROCHE 200MG	N21511 001	DEC 03, 2002	DEC	NEWA
 <u>RIMANTADINE HYDROCHLORIDE</u>					
TABLET; ORAL					
RIMANTADINE HCL					
AB	IMPAX LABS 100MG	N76132 001	AUG 30, 2002	AUG	NEWA

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

PROCTER AND GAMBLE

30MG

N20835 001 MAR 27, 1998 JUL CRLD

+

35MG

N20835 003 MAY 25, 2002 JUL NEWA

RITONAVIR

CAPSULE; ORAL

NORVIR

a ABBOTT

100MG

N20680 001 MAR 01, 1996 JUN DISC

+

100MG

N20945 001 JUN 29, 1999 JUN CRLD

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

a ORGANON

10MG/ML

N20214 002 MAR 17, 1994 JUN DISC

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+ RANBAXY

50MG

N86101 001 OCT 03, 1983 JUN CAHN

AA +

100MG

N86101 002 OCT 03, 1983 JUN CAHN

SECRETIN

FOR SOLUTION; INTRAVENOUS

SECREFO

+ CHIRHOCLIN

16UGM/VIAL

N21209 001 APR 04, 2002 APR NEWA

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HCL

AB CLONMEL HLTHCARE

5MG

N75352 001 NOV 30, 1998 JUN CAHN

TABLET; ORAL

AB CLONMEL HLTHCARE

5MG

N74641 001 AUG 02, 1996 APR CAHN

AB SIEGFRIED

5MG

N74672 001 APR 01, 1997 AUG CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELSUN

AT + CHATTEM

2.5%

N07936 001

AUG CAHN

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

a CIS

500uCi/ML

N17322 001

JUN DISC

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

AN BAXTER HLTHCARE

100%

N75895 001 JUL 02, 2002 SEP NEWA

ULTANE

AN + ABBOTT

100%

N20478 001 JUN 07, 1995 SEP CFTG

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX

a BRACCO 7.5MG/ML

N20773 001 OCT 29, 1998 JUN DISC

SIROLIMUS

TABLET; ORAL

RAPAMUNE

+ WYETH AYERST 1MG

N21110 001 AUG 25, 2000 JUN NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

a B BRAUN 100MG/ML;100MG/ML

N19530 001 DEC 23, 1987 JUN DISC

SODIUM IODIDE, I-131

CAPSULE; ORAL

IODOTOPE

a BRACCO 1-150mCi

N10929 003 JUN DISC

SOLUTION; ORAL

a BRACCO 7-106mCi/BOT

N10929 002 JUN DISC

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ ORPHAN MEDCL 500MG/ML

N21196 001 JUL 17, 2002 JUL NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

a NOVO NORDISK 4MG/VIAL

N19721 001 MAY 08, 1995 JUN DISC

a 8MG/VIAL

N19721 002 MAY 08, 1995 JUN DISC

NUTROPIN AQ PEN

BX + GENENTECH 5MG/ML

N20522 002 APR 22, 2002 JUN NEWA

SAIZEN

BX + SERONO 8.8MG/VIAL

N19764 003 AUG 29, 2000 SEP CDFR

+ 8.8MG/VIAL

N19764 003 AUG 29, 2000 NOV CTEC

SEROSTIM

BX + SERONO 4MG/VIAL

N20604 003 JUL 25, 1997 JUN CRLD

BX 6MG/VIAL

N20604 001 AUG 23, 1996 JUN CRLD

+ 8.8MG/VIAL

N20604 004 SEP 06, 2001 NOV CTEC

BX + 8.8MG/VIAL

N20604 004 SEP 06, 2001 SEP CTNA

SEROSTIM IN PLASTIC CONTAINER

BX + SERONO 8.8MG/VIAL

N20604 004 SEP 06, 2001 JUN NEWA

TEV-TROVIN

BX + BIO TECH GEN 5MG/ML

N19774 002 JAN 04, 2002 JUN NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HCL

AB APOTEX 80MG

N76140 001 SEP 26, 2002 SEP NEWA

AB 120MG

N76140 002 SEP 26, 2002 SEP NEWA

AB	160MG	N76140 003	SEP 26, 2002	SEP	NEWA
AB	240MG	N76140 004	SEP 26, 2002	SEP	NEWA

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

@ PHARMACIA AND UPJOHN EQ 4GM BASE/VIAL

N50347 002 JUN DISC

STAVUDINE

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> ZERIT XR

>A> BRISTOL MYERS SQUIBB 37.5MG

N21453 001 DEC 31, 2002 DEC NEWA

>A> 50MG

N21453 002 DEC 31, 2002 DEC NEWA

>A> 75MG

N21453 003 DEC 31, 2002 DEC NEWA

>A> + 100MG

N21453 004 DEC 31, 2002 DEC NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

QUELICIN PRESERVATIVE FREE

@ ABBOTT 50MG/ML

N08845 002 JUN DISC

SULFAMETHIZOLE

TABLET; ORAL

THIOSULFIL

@ WYETH AYERST 500MG

N08565 004 JUN DISC

SULFAMETHOXAZOLE

TABLET; ORAL

GANTANOL

@ ROCHE 500MG

N12715 002 MAY CTEC

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

BACTRIM PEDIATRIC

@ WOMEN FIRST HLTHCARE 200MG/5ML;40MG/5ML

N17560 002 APR DISC

SEPTRA

AB + MONARCH PHARMS 200MG/5ML;40MG/5ML

N17598 001 APR CRLD

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

@ LILLY 500MG

N00159 001 JUN DISC

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

AB VINTAGE PHARMS 500MG

N40349 001 JAN 11, 2002 JAN NEWA

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS

AB + PHARMACIA AND UPJOHN 500MG

N07073 002 APR 06, 1983 JAN CFTG

SULFASALAZINE

AB VINTAGE PHARMS 500MG

N75339 001 JAN 11, 2002 JAN NEWA

SULFISOXAZOLE ACETYL

SYRUP; ORAL

GANTRISIN

@ ROCHE

EQ 500MG BASE/5ML

N09182 002

JUN DISC

SUMATRIPTAN SUCCINATE

TABLET; ORAL

IMITREX

GLAXOSMITHKLINE

EQ 50MG BASE

N20132 003 JUN 01, 1995 JUN CRLD

+

EQ 100MG BASE

N20132 001 JUN 01, 1995 JUN CMFD

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC

PROFENAL

@ ALCON

1%

N19387 001 DEC 23, 1988 JUN DISC

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

+ ASTRAZENECA

EQ 20MG BASE

N17970 002 MAR 21, 1994 AUG CTEC

TAZAROTENE

CREAM; TOPICAL

AVAGE

+ ALLERGAN

0.1%

N21184 003 SEP 30, 2002 OCT NEWA

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION

MICROLITE

@ CIS

N/A

N18263 001 MAR 25, 1983 JUN DISC

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

@ AMERSHAM HLTH

N/A

N17775 001 JUL DISC

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

@ CADEMA

N/A

N20063 001 JUN 11, 1992 JUN DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

@ MALLINCKRODT

10-60mCi/ML

N17725 001 JUN DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

TECHNETIUM TC 99M GENERATOR

@ AMERSHAM HLTH

830-16600mCi/GENERATOR

N17693 001 JUN DISC

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

NOVARTIS

EQ 2MG BASE

N21200 001 JUL 24, 2002 AUG CPOT

2MG

N21200 001 JUL 24, 2002 JUL NEWA

+

EQ 6MG BASE

N21200 002 JUL 24, 2002 AUG CPOT

+

6MG

N21200 002 JUL 24, 2002 JUL NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HCL

AB RANBAXY

EQ 1MG BASE

N76021 001 AUG 22, 2002 AUG NEWA

AB

EQ 2MG BASE

N76021 002 AUG 22, 2002 AUG NEWA

AB

EQ 5MG BASE

N76021 003 AUG 22, 2002 AUG NEWA

AB

EQ 10MG BASE

N76021 004 AUG 22, 2002 AUG NEWA

TERBINAFINE

GEL; TOPICAL

LAMISIL

>D> @ NOVARTIS

1%

N20846 001 APR 29, 1998 DEC CAHN

>A> @ NOVARTIS CONS

1%

N20846 001 APR 29, 1998 DEC CAHN

@

1%

N20846 001 APR 29, 1998 JUN DISC

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL

>D> + NOVARTIS

1%

N20749 001 OCT 17, 1997 DEC CAHN

>A> + NOVARTIS CONS

1%

N20749 001 OCT 17, 1997 DEC CAHN

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

+ AAIPHARMA

1MG/ML

N18571 001

JUL CAHN

+ NEOSAN PHARMS

1MG/ML

N18571 001

FEB CAHN

TABLET; ORAL

AB AAIPHARMA

2.5MG

N17849 001

JUL CAHN

AB +

5MG

N17849 002

JUL CAHN

AB NEOSAN PHARMS

2.5MG

N17849 001

FEB CAHN

AB +

5MG

N17849 002

FEB CAHN

TERIPARATIDE ACETATE

INJECTABLE; SUBCUTANEOUS

>D> FORTERO

>D> + LILLY

EQ 0.75MG 3ML(0.25MG/ML)

N21318 001 NOV 26, 2002 DEC CTNA

>A> FORTEO

>A> + LILLY

EQ 0.75MG 3ML(0.25MG/ML)

N21318 001 NOV 26, 2002 DEC CTNA

+ LILLY

EQ 0.75MG 3ML(0.25MG/ML)

N21318 001 NOV 26, 2002 NOV NEWA

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

TESTODERM TTS

BX + ALZA

5MG/24HR

N20791 001 DEC 18, 1997 JAN CTNA

TESTOSTERONE

GEL; TOPICAL

TESTIM

+	AUXILIUM A2	1%	N21454 001	OCT 31, 2002	OCT	NEWA
---	-------------	----	------------	--------------	-----	------

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

+	ALZA	12.7MG/FIBER	N50653 001	MAR 25, 1994	FEB	CAHN
---	------	--------------	------------	--------------	-----	------

FOR SOLUTION; TOPICAL

TOPICYCLINE

@	SHIRE LABS	2.2MG/ML	N50493 001		JUL	DISC
---	------------	----------	------------	--	-----	------

INJECTABLE; INJECTION

ACHROMYCIN

@	LEDERLE	250MG/VIAL	N50273 002		JUN	DISC
---	---------	------------	------------	--	-----	------

+		500MG/VIAL	N50273 003		JUN	CRLD
---	--	------------	------------	--	-----	------

@		500MG/VIAL	N50273 003		JUL	DISC
---	--	------------	------------	--	-----	------

SUSPENSION; ORAL

ACHROMYCIN V

@	LEDERLE	125MG/5ML	N50263 002		APR	DISC
---	---------	-----------	------------	--	-----	------

SUMYCIN

+	APOTHECON	125MG/5ML	N60400 001		APR	CTEC
---	-----------	-----------	------------	--	-----	------

TABLET; ORAL

@	PAR PHARM	50MG	N61147 003		MAY	CAHN
---	-----------	------	------------	--	-----	------

@		100MG	N61147 002		MAY	CAHN
---	--	-------	------------	--	-----	------

		250MG	N61147 001		MAY	CAHN
--	--	-------	------------	--	-----	------

+		500MG	N61147 004		MAY	CAHN
---	--	-------	------------	--	-----	------

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

THEO-DUR

AB	SCHERING	100MG	N85328 001		OCT	CRLD
----	----------	-------	------------	--	-----	------

AB		200MG	N86998 001		OCT	CRLD
----	--	-------	------------	--	-----	------

AB		300MG	N85328 002		OCT	CRLD
----	--	-------	------------	--	-----	------

AB		450MG	N89131 001	JUN 25, 1986	OCT	CRLD
----	--	-------	------------	--------------	-----	------

THEOPHYLLINE

AB	+	SIDMAK LABS NJ	100MG	N89807 001	APR 30, 1990	OCT	CRLD
----	---	----------------	-------	------------	--------------	-----	------

AB	+		200MG	N89808 001	APR 30, 1990	OCT	CRLD
----	---	--	-------	------------	--------------	-----	------

AB	+		300MG	N89763 001	APR 30, 1990	OCT	CRLD
----	---	--	-------	------------	--------------	-----	------

AB	+		450MG	N81236 001	NOV 09, 1992	OCT	CRLD
----	---	--	-------	------------	--------------	-----	------

UNI-DUR

BC	SCHERING	400MG	N89822 001	JAN 04, 1995	OCT	CRLD
----	----------	-------	------------	--------------	-----	------

BC		600MG	N89823 001	JAN 04, 1995	OCT	CRLD
----	--	-------	------------	--------------	-----	------

UNIPHYL

BC	+	PURDUE FREDERICK	400MG	N87571 001	SEP 01, 1982	OCT	CRLD
----	---	------------------	-------	------------	--------------	-----	------

BC	+		600MG	N40086 001	APR 15, 1996	OCT	CRLD
----	---	--	-------	------------	--------------	-----	------

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION

TORECAN

@	NOVARTIS	5MG/ML	N12754 002		JUN	DISC
---	----------	--------	------------	--	-----	------

THIORIDAZINE

SUSPENSION; ORAL

MELLARIL-S

a NOVARTIS

EQ 25MG HCL/5ML

N17923 001

JUN DISC

a

EQ 100MG HCL/5ML

N17923 002

JUN DISC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

a NOVARTIS

30MG/ML

N11808 012

AUG DISC

a

100MG/ML

N11808 018

AUG DISC

THIORIDAZINE HCL

AA + COPLEY PHARM

30MG/ML

N89602 001 NOV 09, 1987 AUG CRLD

AA +

100MG/ML

N89603 001 NOV 09, 1987 AUG CRLD

TABLET; ORAL

MELLARIL

a NOVARTIS

10MG

N11808 003

AUG DISC

a

15MG

N11808 016

AUG DISC

a

25MG

N11808 006

AUG DISC

a

50MG

N11808 011

AUG DISC

a

100MG

N11808 009

AUG DISC

a

150MG

N11808 017

AUG DISC

a

200MG

N11808 015

AUG DISC

THIORIDAZINE HCL

AB + GENEVA PHARMS

25MG

N88133 001 AUG 30, 1983 AUG CRLD

AB +

100MG

N88135 001 NOV 20, 1984 AUG CRLD

AB +

200MG

N88137 001 SEP 17, 1986 AUG CRLD

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

AP AM PHARM PARTNERS

15MG/VIAL

N75698 001 SEP 20, 2001 FEB CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

THIOTHIXENE HCL INTENSOL

a ROXANE

EQ 5MG BASE/ML

N73494 001 JUN 30, 1992 JAN DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

+ CEPHALON

16MG

N20646 003 SEP 30, 1997 JUN CRLD

a

20MG

N20646 004 SEP 30, 1997 JUN DISC

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HCL

AB CARACO

250MG

N75526 001 SEP 26, 2002 SEP NEWA

TIMOLOL MALEATE

SOLUTION; OPHTHALMIC

TIMOLOL MALEATE

AT	HI TECH PHARMA	EQ 0.5% BASE	N75163 001	SEP 10, 2002	SEP	NEWA
----	----------------	--------------	------------	--------------	-----	------

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

+	LEO PHARM	20,000 IU/ML	N20484 001	JUL 14, 2000	APR	CAHN
+	PHARMION	20,000 IU/ML	N20484 001	JUL 14, 2000	JUL	CAHN

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANAFLEX

ELAN PHARMS

		EQ 2MG BASE	N21447 001	AUG 29, 2002	AUG	NEWA
		EQ 4MG BASE	N21447 002	AUG 29, 2002	AUG	NEWA
+		EQ 6MG BASE	N21447 003	AUG 29, 2002	AUG	NEWA

TABLET; ORAL

TIZANIDINE HCL

AB	COREPHARMA	EQ 2MG BASE	N76347 001	OCT 11, 2002	OCT	NEWA
AB		EQ 4MG BASE	N76347 002	OCT 11, 2002	OCT	NEWA
AB	DR REDDYS LABS INC	EQ 2MG BASE	N76286 001	JUL 03, 2002	JUL	NEWA
AB		EQ 4MG BASE	N76286 002	JUL 03, 2002	JUL	NEWA
AB	EON	EQ 2MG BASE	N76399 001	NOV 26, 2002	NOV	NEWA
AB		EQ 4MG BASE	N76280 002	JUN 27, 2002	JUN	NEWA
AB	PUREPAC PHARM	EQ 2MG BASE	N76283 001	JUL 12, 2002	JUL	NEWA
AB		EQ 4MG BASE	N76283 002	JUL 12, 2002	JUL	NEWA
AB	TEVA	EQ 2MG BASE	N76284 001	JUL 03, 2002	JUL	NEWA
AB		EQ 4MG BASE	N76284 002	JUL 03, 2002	JUL	NEWA
	ZANAFLEX					
AB	ELAN PHARMS	EQ 2MG BASE	N20397 002	FEB 04, 2000	AUG	CFTG
AB	+	EQ 4MG BASE	N20397 001	NOV 27, 1996	JUN	CFTG

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	NOVEX	0.3%	N65087 001	FEB 25, 2002	FEB	NEWA
----	-------	------	------------	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

AP	AM PHARM PARTNERS	EQ 10MG BASE/ML	N65122 001	NOV 29, 2002	NOV	NEWA
AP		EQ 40MG BASE/ML	N65122 002	NOV 29, 2002	NOV	NEWA
	TOBRAMYCIN (PHARMACY BULK)					
AP	AM PHARM PARTNERS	EQ 40MG BASE/ML	N65120 001	NOV 29, 2002	NOV	NEWA
	TOBRAMYCIN SULFATE					
	@ ASTRAZENECA	EQ 40MG BASE/ML	N63120 001	OCT 31, 1994	FEB	DISC
	@	EQ 40MG BASE/ML	N63122 001	OCT 31, 1994	JAN	DISC

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

@ NOVARTIS

25MG/ML

N06403 005	FEB 22, 1985	JUN	DISC
------------	--------------	-----	------

TOPIRAMATE

TABLET; ORAL

TOPAMAX

+ JOHNSON AND JOHNSON

25MG

N20505 004 DEC 24, 1996 JAN CAHN

a

50MG

N20505 005 DEC 24, 1996 JAN CAHN

100MG

N20505 001 DEC 24, 1996 JAN CAHN

200MG

N20505 002 DEC 24, 1996 JAN CAHN

a

300MG

N20505 003 DEC 24, 1996 JAN CAHN

a

400MG

N20505 006 DEC 24, 1996 JAN CAHN

TORSEMIDE

TABLET; ORAL

DEMADEX

AB ROCHE

5MG

N20136 001 AUG 23, 1993 MAY CFTG

AB

10MG

N20136 002 AUG 23, 1993 MAY CFTG

AB +

20MG

N20136 003 AUG 23, 1993 MAY CFTG

AB

100MG

N20136 004 AUG 23, 1993 MAY CFTG

TORSEMIDE

AB TEVA

5MG

N76110 001 MAY 14, 2002 MAY NEWA

AB

10MG

N76110 002 MAY 14, 2002 MAY NEWA

AB

20MG

N76110 003 MAY 14, 2002 MAY NEWA

AB

100MG

N76110 004 MAY 14, 2002 MAY NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HCL

AB ABLE

50MG*

N75963 001 JUL 03, 2002 JUL NEWA

AB ALPHAPHARM

50MG*

N75980 001 NOV 21, 2002 NOV NEWA

AB ASTA

50MG*

N75974 001 JUL 12, 2002 JUL NEWA

AB CARACO

50MG*

N75964 001 JUN 19, 2002 JUN NEWA

AB COREPHARMA

50MG*

N76003 001 JUN 20, 2002 JUN NEWA

AB EON

50MG*

N75968 001 JUN 25, 2002 JUN NEWA

AB MALLINCKRODT

50MG*

N75983 001 JUN 25, 2002 JUN NEWA

AB MUTUAL PHARM

50MG*

N76100 001 JUN 20, 2002 JUN NEWA

AB MYLAN

50MG*

N75986 001 JUN 21, 2002 JUN NEWA

AB PUREPAC PHARM

50MG*

N75960 001 JUN 19, 2002 JUN NEWA

AB SIDMAK LABS

50MG*

N75982 001 JUL 01, 2002 JUL NEWA

AB TEVA

50MG*

N75977 001 JUN 19, 2002 JUN NEWA

AB TORPHARM

50MG*

N75981 001 JUL 10, 2002 JUL NEWA

AB WATSON LABS

50MG*

N75962 001 JUN 24, 2002 JUN NEWA

ULTRAM

+ JOHNSON AND JOHNSON

50MG

N20281 002 MAR 03, 1995 FEB CAHN

a

100MG

N20281 001 MAR 03, 1995 FEB CAHN

AB + ORTHO MCNEIL PHARM

50MG

N20281 002 MAR 03, 1995 JUN CTEC

TREPROSTINIL SODIUM

INJECTABLE; SUBCUTANEOUS

REMODULIN

UNITED THERAP

1MG/ML

N21272 001 MAY 21, 2002 MAY NEWA

2.5MG/ML

N21272 002 MAY 21, 2002 MAY NEWA

5MG/ML

N21272 003 MAY 21, 2002 MAY NEWA

+

10MG/ML

N21272 004 MAY 21, 2002 MAY NEWA

* SEE SECTION 1.4 OF INTRODUCTION

TRETINOIN

GEL; TOPICAL

RETIN-A

AB	+	JOHNSON AND JOHNSON	0.01%	N17955 001		JUN	CFTG
		RETIN-A MICRO					
	+	JOHNSON AND JOHNSON	0.04%	N20475 002	MAY 10, 2002	SEP	NEWA
		TRETINOIN					
AB		SPEAR PHARMS	0.01%	N75589 001	JUN 11, 2002	JUN	NEWA

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

@ FUJISAWA HLTHCARE

1MG

N11161 009

JUL DISC

@

2MG

N11161 004

JUL DISC

@

8MG

N11161 011

JUL DISC

KENACORT

+ BRISTOL MYERS SQUIBB

8MG

N11283 010

AUG CTEC

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

KENALOG-10

APOTHECON

10MG/ML

N12041 001

JUN CRLD

KENALOG-40

BP + APOTHECON

40MG/ML

N14901 001

JUN CRLD

+

40MG/ML

N14901 001

SEP CTEC

TRIAMCINOLONE ACETONIDE

@ PARNELL

3MG/ML

N19503 001 OCT 16, 1987

JUN DISC

@ STERIS

40MG/ML

N85825 001

SEP DISC

SPRAY, METERED; NASAL

TRI-NASAL

@ MURO

0.05MG/SPRAY

N20120 001 FEB 04, 2000

JUN DISC

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

+ FUJISAWA HLTHCARE

25MG/ML

N11685 003

OCT CAHN

+

40MG/ML

N12802 001

OCT CAHN

+ LEDERLE

40MG/ML

N12802 001

SEP CTEC

TRIAMCINOLONE DIACETATE

@ STERIS

40MG/ML

N84072 001

SEP DISC

SYRUP; ORAL

ARISTOCORT

@ FUJISAWA HLTHCARE

2MG/5ML

N11960 004

JUL DISC

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+ FUJISAWA HLTHCARE

5MG/ML

N16466 001

OCT CAHN

+

20MG/ML

N16466 002

OCT CAHN

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

a APOTHECON 10MG/ML

N11325 004

JUN DISC

a 20MG/ML

N11325 001

JUN DISC

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

a BIOENVISION 30MG

N18719 002 DEC 31, 1984 JUN CAHN

a 60MG

N18719 001 DEC 31, 1984 JUN CAHN

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

a ABBOTT 300MG

N05856 005

JUN DISC

SOLUTION; ORAL

a ABBOTT 200MG/5ML

N05856 002

JUN DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

+ KING PHARMS 300MG

N17531 006 DEC 13, 2001 JAN NEWA

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

a STERIS 100MG/ML

N87939 001 DEC 28, 1982 FEB DISC

TRIMETHOPRIM

TABLET; ORAL

TRIMPEX

a ROCHE 100MG

N17952 001

AUG DISC

TRIOXSALEN

TABLET; ORAL

TRISORALEN

a ICN 5MG

N12697 001

JUN DISC

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

a NOVARTIS EQ 25MG HCL/5ML

N05914 004

JUN DISC

TRIPLENNAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

a NOVARTIS 100MG

N10533 001

JUN DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

TABLET; VAGINAL

SULTRIN

a ORTHO MCNEIL PHARM 184MG;143.75MG;172.5MG

N05794 002

JUN DISC

UREA, C-13

FOR SOLUTION; ORAL

PYLORI-CHEK BREATH TEST

@ ALIMENTERICS 100MG/VIAL

N20900 001 FEB 04, 1999 JUL DISC

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

BX + FERRING 75 IU/VIAL

N21289 001 MAY 06, 2002 MAY NEWA

INJECTABLE; SUBCUTANEOUS

FERTINEX

BX + SERONO 75 IU/AMP

N19415 005 AUG 23, 1996 MAY CTEC

@ 150 IU/AMP

N19415 004 AUG 23, 1996 JUN DISC

URSODIOL

CAPSULE; ORAL

ACTIGALL

@ WATSON PHARMS 150MG

N19594 001 DEC 31, 1987 FEB CAHN

AB + 300MG

N19594 002 DEC 31, 1987 FEB CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

@ GLAXOSMITHKLINE EQ 500MG BASE

N20487 001 JUN 23, 1995 MAR DISC

@ EQ 1GM BASE

N20487 002 JUN 23, 1995 MAR DISC

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACON

AP + ABBOTT EQ 100MG BASE/ML

N20593 001 DEC 30, 1996 NOV CFTG

VALPROATE SODIUM

AP BEDFORD EQ 100MG BASE/ML

N76295 001 NOV 14, 2002 NOV NEWA

VALSARTAN

CAPSULE; ORAL

DIOVAN

@ NOVARTIS 80MG

N20665 001 DEC 23, 1996 JUN DISC

@ 160MG

N20665 002 DEC 23, 1996 JUN DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

@ ORGANON 20MG/VIAL

N18776 003 JAN 03, 1992 JUN DISC

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH AYERST EQ 37.5MG BASE

N20699 001 OCT 20, 1997 MAY CRLD

EQ 150MG BASE

N20699 004 OCT 20, 1997 MAY CRLD

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

AB + ELAN DRUG	120MG	N19614 001	MAY 29, 1990	APR	CAHN
AB +	180MG	N19614 003	JAN 09, 1992	APR	CAHN
AB +	240MG	N19614 002	MAY 29, 1990	APR	CAHN
+	360MG	N19614 004	MAY 10, 1996	APR	CAHN

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE

>A> + AM PHARM PARTNERS	1MG/ML	N76296 001	DEC 20, 2002	DEC	NEWA
-------------------------	--------	------------	--------------	-----	------

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ AAIPHARMA	EQ 50,000 UNITS BASE/ML	N06823 001		JUL	CAHN
-------------	-------------------------	------------	--	-----	------

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

+ PFIZER	200MG/VIAL	N21267 001	MAY 24, 2002	MAY	NEWA
TABLET; ORAL					
PFIZER	50MG	N21266 001	MAY 24, 2002	MAY	NEWA
+	200MG	N21266 002	MAY 24, 2002	MAY	NEWA

XENON, XE-127

GAS; INHALATION

XENON XE 127

@ MALLINCKRODT	5mCi/VIAL	N18536 001	OCT 01, 1982	JUN	DISC
@	10mCi/VIAL	N18536 002	OCT 01, 1982	JUN	DISC

XYLOSE

POWDER; ORAL

XYLOSE

@ LYNE	25GM/BOT	N18856 001	MAR 26, 1987	JUL	DISC
--------	----------	------------	--------------	-----	------

ZILEUTON

TABLET; ORAL

ZYFLO

+ ABBOTT	300MG	N20471 001	DEC 09, 1996	JUN	CRLD
@	300MG	N20471 001	DEC 09, 1996	JUL	DISC

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+ PFIZER	EQ 20MG BASE/ML	N20919 001	JUN 21, 2002	JUN	NEWA
----------	-----------------	------------	--------------	-----	------

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

+ ASTRAZENECA	5MG	N21231 002	SEP 17, 2001	JUN	NEWA
---------------	-----	------------	--------------	-----	------

PRESCRIPTION DRUG PRODUCT LIST - 22ND EDITION
OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - DEC 2002

2-1

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

COREPHARMA 650MG

N76200 001 MAR 19, 2002 MAR NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ BECKLOFF 2%

N21555 001 OCT 07, 2002 OCT NEWA

SPONGE; TOPICAL

E-Z SCRUB

@ BECTON DICKINSON 4%

N73416 001 MAR 14, 2000 SEP DISC

>A> CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

>A> TABLET; ORAL

>A> ADVIL ALLERGY SINUS

>A> + WYETH CONS 2MG;200MG;30MG

N21441 001 DEC 19, 2002 DEC NEWA

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC 12 HOUR

@ GLAXOSMITHKLINE 8MG;75MG

N18099 001 JAN DISC

PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE

@ CENT PHARMS 8MG;75MG

N18809 001 MAY 07, 1984 FEB DISC

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

@ GLAXOSMITHKLINE 200MG/20ML

N20951 001 JUL 09, 1999 SEP DISC

TABLET; ORAL

CIMETIDINE

TORPHARM 200MG

N74948 002 JUL 26, 2002 JUL NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

EON 10MG

N76101 001 OCT 21, 2002 OCT NEWA

TORPHARM 10MG

N75610 001 MAR 12, 2002 MAR NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX

+ ADAMS LABS 600MG

N21282 001 JUL 12, 2002 NOV CRLD

600MG

N21282 001 JUL 12, 2002 JUL NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

BANNER PHARMACAPS 200MG

N21472 001 OCT 18, 2002 OCT NEWA

TABLET; ORAL

PERRIGO 200MG

N75995 001 MAR 14, 2002 MAR NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

WYETH CONS 200MG;30MG

N21374 001 MAY 30, 2002 MAY NEWA

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD

WYETH CONS 100MG/5ML;15MG/5ML

N21373 001 APR 18, 2002 APR NEWA

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HCL

PHARM FORM 200MG;30MG

N75588 001 APR 08, 2002 APR NEWA

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

REGULAR PURIFIED PORK INSULIN

@ NOVO NORDISK 100 UNITS/ML

N18381 001 FEB DISC

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

VELOSULIN BR

+ NOVO NORDISK 100 UNITS/ML

N21028 001 JUL 19, 1999 JUN CMS2

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

NPH PURIFIED PORK ISOPHANE INSULIN

@ NOVO NORDISK 100 UNITS/ML

N18623 001 FEB DISC

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE

@ NOVO NORDISK 100 UNITS/ML

N18383 001 FEB DISC

KETOPROFEN

TABLET; ORAL

KETOPROFEN

PERRIGO 12.5MG

N75364 001 FEB 07, 2002 FEB NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL

LOPERAMIDE HCL AND SIMETHICONE

PERRIGO 2MG;125MG

N76029 001 AUG 30, 2002 AUG NEWA

>A> LORATADINE

>A> TABLET, ORALLY DISINTEGRATING; ORAL

>A> ALAVERT

>A> + WYETH CONS 10MG

N21375 001 DEC 19, 2002 DEC NEWA

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

CLAY PARK 5%

N75737 001 MAR 15, 2002 MAR NEWA

NOVEX 5%

N75839 001 OCT 01, 2001 MAR CTNA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

DR REDDYS LABS INC EQ 200MG BASE

N75168 001 JUL 28, 1998 AUG CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

COMMIT

GLAXOSMITHKLINE CONS 2MG

N21330 001 OCT 31, 2002 OCT NEWA

+ 4MG

N21330 002 OCT 31, 2002 OCT NEWA

POTASSIUM IODIDE

TABLET; ORAL

THYROSAFE

>D> R R REGISTRATIONS 65MG

N76350 001 SEP 10, 2002 DEC CRLD

>A> + 65MG

N76350 001 SEP 10, 2002 DEC CRLD

65MG

N76350 001 SEP 10, 2002 SEP NEWA

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

SUDAFED 12 HOUR

+ WARNER LAMBERT 120MG

N73585 001 OCT 31, 1991 MAY CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

GENEVA PHARMS EQ 75MG BASE

N75519 001 SEP 26, 2002 SEP NEWA

PERRIGO EQ 75MG BASE

N76195 001 AUG 30, 2002 AUG NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER '02

NO DECEMBER 2002 APPROVALS

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

Orphan Products Designations and Approvals List

November 2002

(December update not available)

albuterol	DD: 3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc. 3 Pine View Road Mount Kisco NY 10549
	MA:		
allantoin	DD: 11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Alwyn Company, Inc. 2301 Highway 60 East Lake Crystal MN 56055
Alwextin	MA:		
antiangiogenic components extracted from marine cartilage Neovastat (AE-941)	DD: 10/16/2002	Treatment of renal cell carcinoma	AEterna Laboratories, Inc. Dr. Claude Hariton, Chief Medical Officer, VP, Clinical & Regulatory Affairs 1405 boul. Du Parc - Technologique Quebec G1P 4P5 CANADA
	MA:		
autologous antigen presenting cells pulsed with autologous tumor Ig idiotype Mylovenge	DD: 4/18/2002	Treatment of multiple myeloma	Dendreon Corporation 3005 First Avenue Seattle WA 98121
	MA:		
autologous tumor-derived gp96 heat shock protein-peptide complex Oncophage	DD: 7/11/2002	Treatment of metastatic melanoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
	MA:		
autologous tumor-derived gp96 heat shock protein-peptide complex Oncophage	DD: 5/10/2002	Treatment of renal cell carcinoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
	MA:		
aztreonam	DD: 3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Corus Pharma 2025 First Ave., Suite 800 Seattle WA 98121
	MA:		
Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	DD: 2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc. Suite 235 7200 Hudson Blvd. Oakdale MN 55128
	MA:		

Orphan Products Designations and Approvals List

November 2002

capsaicin	DD: 10/23/2002	Treatment of erythromelalgia	NeurogesX, Inc. 981F Industrial Road San Carlos CA 94070
	MA:		
carbamic acid, [[4-[[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-ethyl ester	DD: 1/15/2002	Management of cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc 900 Ridgebury Road
	MA:		P.O. Box 368 Ridgefield CT 06877
cells produced using the AastromRepliselle System and SC-I Therapy Kit	DD: 7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated P.O. Box 376 Ann Arbor MI 48106
	MA:		
clofarabine	DD: 2/7/2002	Treatment of acute lymphoblastic leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
Clofarex	MA:		
clofarabine	DD: 3/14/2002	Treatment of acute myelogenous leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
Clofarex	MA:		
creatine	DD: 2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc. 580 California St. Suite 1600 San Francisco CA 94104
Creapure	MA:		
D-peptide of the sequence AKRHHGYKRKFH - NH ₂ PulmaDex	DD: 10/23/2002	Treatment of cystic fibrosis	Demegen, Inc. 1051 Brinton Road Pittsburgh PA 15221
	MA:		
decitabine	DD: 9/9/2002	Treatment of sickle cell anemia	SuperGen, Inc. 4140 Dublin Blvd., Suite 200 Dublin CA 94568
	MA:		
Deferasirox	DD: 11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover NJ 07936-1080
	MA:		
DHA-paclitaxel	DD: 10/10/2002	Treatment of metastatic malignant melanoma	Protarga, Inc. 2200 Renaissance Boulevard Suite 450 King of Prussia PA 19406
Taxoprexin	MA:		

Orphan Products Designations and Approvals List

November 2002

G17DT Immunogen	DD: 7/18/2002	Treatment of gastric cancer	Aphtron Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
	MA:		
G17DT Immunogen	DD: 7/10/2002	Treatment of adenocarcinoma of the pancreas	Aphtron Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
	MA:		
genetically engineered herpes simplex virus (G207)	DD: 4/29/2002	Treatment of malignant glioma	MediGene, Inc. 9880 Campus Point Drive, Suite A San Diego CA 92121
	MA:		
heat killed mycobacterium with immunomodulator CADI Mw	DD: 11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc. 16020 Swingley Ridge Road Suite 145 Chesterfield MO 63017
	MA:		
Hepatitis C virus immune globulin (human)	DD: 11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	NABI 5800 Park of Commerce Blvd., N.W. Boca Raton FL 33487
	MA:		
homoharringtonine	DD: 2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc. 2730 Wilshire Blvd. #110 Santa Monica CA 90403
	MA:		
human anti-transforming growth factor beta 1 monoclonal antibody	DD: 1/11/2002	Treatment of systemic sclerosis	Genzyme Corporation One Kendall Square Cambridge MA 02139
	MA:		
human gammaglobulin	DD: 9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Protein Therapeutics, Inc. 9040 S. Rita Road Suite 1100 Tucson AZ 85747
	MA:		
hyaluronic acid	DD: 3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	Exhale Therapeutics, Inc. 1301 Shoreway Road Suite 320 Belmont CA 94002
	MA:		
I(131)-TM-601 (chlorotoxin)	DD: 2/14/2002	treatment of malignant glioma	TransMolecular, Inc. 3800 Colonnade Parkway Suite 240 Birmingham AL 35243
	MA:		
infliximab	DD: 10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc.
Remicade			200 Great Valley Parkway Malvern PA 19355-1307
	MA:		

Orphan Products Designations and Approvals List November 2002

inolimomab	DD: 10/23/2002	Treatment of graft versus host disease	Opi 6, Chemin de l'industrie 69570 DARDILLY - France
Leukotac	MA:		
interferon gamma-1b	DD: 9/12/2002	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc. 3280 Bayshore Boulevard Brisbane CA 94005
Actimmune	MA:		
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococci)	DD: 1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Avenue Gaithersburg MD 20877
	MA:		
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	DD: 1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Ave. Gaithersburg MD 20877
	MA:		
lintuzumab	DD: 9/9/2002	Treatment of acute myelogenous leukemia	Protein Design Labs, Inc. 34801 Campus Drive Fremont CA 94555
Zamyl	MA:		
lipase, amylase, and protease	DD: 1/23/2002	Treatment of pancreatic insufficiency	Altus Biologics Inc. 625 Putnam Avenue Cambridge MA 02139
TheraCLEC-Total	MA:		
meloxicam	DD: 11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road P. O. Box 368 Ridgefield CT 06877-0368
Mobic	MA:		
methylbicyclone	DD: 11/14/2002	Treatment of cystic fibrosis	Sucampo Pharmaceuticals, Inc. 4733 Bethesda Ave. Suite 450 Bethesda MD 20814
	MA:		
N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea	DD: 5/13/2002	Treatment of sickle cell disease	NeuroSearch A/S 93 Pederstrupvej DK-2750 Ballerup Denmark
	MA:		
N-acetylcysteine	DD: 9/9/2002	Treatment of acute liver failure	William M. Lee, MD, FACP University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Blvd Dallas TX 75390-9151
	MA:		
Natural human lymphoblastoid interferon-alpha	DD: 11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.

Orphan Products Designations and Approvals List

November 2002

	MA:		800 West 9th Avenue Amarillo TX 79101
nitazoxanide	DD: 2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607
Cryptaz	MA:		
octavalent Psuedomonas aeruginosa O-polysaccharide-toxin A Aerugen	DD: 5/16/2002	Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis	Orphan Europe Immeuble "Le Wilson"
	MA:		70 avenue du General de Gaulle, 92046 Paris La Defense France
phenylephrine	DD: 2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma Unit 3, Hill Farm Industrial Estate Leavesden, Watford United Kingdom WD25 7SA
	MA:		
polyinosinic-polycytidilic acid Poly-ICLC	DD: 11/19/2002	Treatment for orthopox virus infections	Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
	MA:		
polyinosinic-polycytidilic acid Poly-ICLC	DD: 8/2/2002	As an adjuvant to smallpox vaccination	Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
	MA:		
recombinant human endostatin protein	DD: 2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850
	MA:		
recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3 SomatoKine	DD: 5/17/2002	Treatment of growth hormone insensitivity syndrome	Celtrix Pharmaceuticals, Inc. a subsidiary of Insmad, Inc. 4851 Lake Brook Drive Glen Allen VA 23060
	MA:		
recombinant human monoclonal antibody to hsp90 Mycograb	DD: 9/16/2002	Treatment of invasive candidiasis	NeuTec Pharma plc 2dn floor, Clinical Sciences Bldg. Central Manchester Healthcare Trust, Oxford Rd., Manchester M139WL, UK
	MA:		
recombinant human porphobilinogen deaminase	DD: 9/9/2002	Treatment of acute intermittent porphyria attacks	HemeBiotech A/S Roskildevej 12C 3400 Hillerod Denmark
	MA:		
retroviral gamma-c cDNA containing vector	DD: 4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210
	MA:		

Orphan Products Designations and Approvals List

November 2002

rituximab	DD: 3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990
Rituxan	MA:		
rubitecan	DD: 7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
	MA:		
S(-)-3-[3-amino-phthalimido]-glutar amide	DD: 3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated 9640 Medical Center Dr. Rockville MD 20850
	MA:		
SS1(dsFv)-PE38	DD: 2/11/2002	Treatment of epithelial ovarian cancer	NeoPharm, Inc. 150 Field Drive Suite 195 Lake Forest IL 60045
	MA:		
SS1(dsFv)-PE38	DD: 2/11/2002	Treatment of malignant mesothelioma	NeoPharm Incorporated 150 Field Drive Suite 195 Lake Forest IL 60045
	MA:		
TGF(beta)2-specific phosphorothioate antisense oligodeoxynucleotide	DD: 6/5/2002	Treatment of malignant glioma	Antisense Pharma GmbH Josef-Engert-Str. 9 93053 Regensburg Germany
Oncomun	MA:		
tinidazole	DD: 4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc. 1607 N. Douglas Ave. Arlington Heights IL 60004
	MA:		
tirapazamine	DD: 10/23/2002	For the treatment of head and neck cancer	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355
	MA:		
toralizumab	DD: 3/14/2002	Treatment of immune thrombocytopenic purpura	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121
	MA:		

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2002 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	6417191	MAR 28, 2016	U-248		
		6417191*PED	SEP 28, 2016	U-248		
>ADD>	021478 001	ACYCLOVIR;ZOVIRAX			NDF	DEC 30, 2005
	021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6451340	JUL 23, 2018	U-470 NCE	SEP 20, 2007
		4808716	APR 25, 2006			
		5663159	SEP 02, 2014	U-470		
		4724233	APR 21, 2006	U-470		
		5695743	JUL 06, 2010	U-491		
		6352684	NOV 28, 2009			
>ADD>	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5565447	OCT 15, 2013		
	021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	OCT 15, 2013		
	021001 002	ALMOTRIPTAN MALATE;AXERT				
	021212 001	ALPROSTADIL;CAVERJECT			NP	JUN 11, 2005
	021212 002	ALPROSTADIL;CAVERJECT			NP	JUN 11, 2005
	020364 005	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003	NS	JUN 20, 2005
		4572909	JUL 31, 2006			
		4879303	MAR 25, 2007			
		6162802	DEC 19, 2017	U-367		
	021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	NOV 27, 2018		
	021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819	NOV 27, 2018	NDF	OCT 11, 2004
	021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	NOV 27, 2018		
	021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819	NOV 27, 2018	NDF	OCT 11, 2004
	021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	NOV 27, 2018		
	021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819	NOV 27, 2018	NDF	OCT 11, 2004
	011522 007	AMPHETAMINE ASPARTATE;ADDERALL 10	6384020	JUL 06, 2020		
	011522 012	AMPHETAMINE ASPARTATE;ADDERALL 12.5	6384020	JUL 06, 2020		
	011522 013	AMPHETAMINE ASPARTATE;ADDERALL 15	6384020	JUL 06, 2020		
	011522 008	AMPHETAMINE ASPARTATE;ADDERALL 20	6384020	JUL 06, 2020		
	011522 010	AMPHETAMINE ASPARTATE;ADDERALL 30	6384020	JUL 06, 2020		
	011522 009	AMPHETAMINE ASPARTATE;ADDERALL 5	6384020	JUL 06, 2020		
	011522 011	AMPHETAMINE ASPARTATE;ADDERALL 7.5	6384020	JUL 06, 2020		
	020541 001	ANASTROZOLE;ARIMIDEX			I-363	SEP 05, 2005
	020883 001	ARGATROBAN;ARGATROBAN	5925760	AUG 04, 2017	I-352	APR 03, 2005
	021436 001	ARIPIRAZOLE;ABILIFY			NCE	NOV 15, 2007
	021436 002	ARIPIRAZOLE;ABILIFY			NCE	NOV 15, 2007
	021436 003	ARIPIRAZOLE;ABILIFY			NCE	NOV 15, 2007
	021436 004	ARIPIRAZOLE;ABILIFY			NCE	NOV 15, 2007
	021436 005	ARIPIRAZOLE;ABILIFY			NCE	NOV 15, 2007
	021436 006	ARIPIRAZOLE;ABILIFY			NCE	NOV 15, 2007
>ADD>	021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA			NCE	NOV 26, 2007
>ADD>	021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA			NCE	NOV 26, 2007
>ADD>	021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA			NCE	NOV 26, 2007
>ADD>	021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA			NCE	NOV 26, 2007
>ADD>	021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA			NCE	NOV 26, 2007
>ADD>	021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA			NCE	NOV 26, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020702 001	ATORVASTATIN CALCIUM;LIPITOR				D-77 I-350 PED	APR 22, 2005 OCT 18, 2005 APR 18, 2006
020702 002	ATORVASTATIN CALCIUM;LIPITOR				D-77 I-350 PED	APR 22, 2005 OCT 18, 2005 APR 18, 2006
020702 003	ATORVASTATIN CALCIUM;LIPITOR				D-77 I-350 PED	APR 22, 2005 OCT 18, 2005 APR 18, 2006
020702 004	ATORVASTATIN CALCIUM;LIPITOR				D-77 I-350 PED	APR 22, 2005 OCT 18, 2005 APR 18, 2006
>ADD> 021470 001	AZELAIC ACID;FINACEA	4713394	JAN 17, 2006	U-492	NDF	DEC 24, 2005
020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	6352684	NOV 28, 2009		NP	SEP 15, 2003
020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	6352684	NOV 28, 2009		NPP NP NPP	MAY 10, 2005 SEP 15, 2003 MAY 10, 2005
>ADD> 020934 001	BETAMETHASONE VALERATE;LUXIQ	6126920	MAR 01, 2016	U-484		
021055 001	BEXAROTENE;TARGRETIN	5962731	OCT 05, 2016	U-475		
021275 001	BIMATOPROST;LUMIGAN	6403649	SEP 21, 2012	U-446		
020873 001	BIVALIRUDIN;ANGIOMAX	5196404	MAR 23, 2010			
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NPP PED	DEC 20, 2004 JUN 20, 2005
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6465464	JUN 28, 2015	U-394	NPP	DEC 20, 2004
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6465464*PED	DEC 28, 2015	U-394	PED	JUN 20, 2005
021324 001	BUDESONIDE;ENTOCORT EC	6465464	JUN 28, 2015	U-395	NPP	DEC 20, 2004
020441 002	BUDESONIDE;PULMICORT	6465464*PED	DEC 28, 2015	U-395	PED	JUN 20, 2005
		5643602	JUL 01, 2014		NP	OCT 02, 2004
		5643602*PED	JAN 01, 2015		PED	APR 02, 2005
		4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			
020441 003	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			
020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
020929 002	BUDESONIDE;PULMICORT RESPULES	4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
020929 003	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
020746 001	BUDESONIDE;RHINOCORT	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
		6291445	APR 29, 2017		NDF	OCT 01, 2002
		6291445*PED	OCT 29, 2017		M-22 PED PED	OCT 26, 2004 APR 26, 2005 APR 01, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020746 002	BUDESONIDE; RHINOCORT	6291445	APR 29, 2017		NDF	OCT 01, 2002
		6291445*PED	OCT 29, 2017		M-22	OCT 26, 2004
					PED	APR 26, 2005
					PED	APR 01, 2003
020733 001	BUPRENORPHINE HYDROCHLORIDE; SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020733 002	BUPRENORPHINE HYDROCHLORIDE; SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 002	BUPRENORPHINE HYDROCHLORIDE; SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 003	BUPRENORPHINE HYDROCHLORIDE; SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020358 004	BUPROPION HYDROCHLORIDE; WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
018731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 003	BUSPIRONE HYDROCHLORIDE; BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 004	BUSPIRONE HYDROCHLORIDE; BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
020954 001	BUSULFAN; BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
		5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
		5430057*PED	MAR 30, 2014	U-263	PED	AUG 04, 2002
		5559148*PED	NOV 24, 2015	U-264	PED	AUG 04, 2006
					NP	OCT 17, 2005
021408 001	BUTENAFINE HYDROCHLORIDE; MENTAX-TX					
019881 001	BUTOCONAZOLE NITRATE; GYNAZOLE-1	5266329	NOV 30, 2010	U-457		
		4551148	NOV 05, 2002			
020838 001	CANDESARTAN CILEXETIL; ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
020838 002	CANDESARTAN CILEXETIL; ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
020838 003	CANDESARTAN CILEXETIL; ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
020838 004	CANDESARTAN CILEXETIL; ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
021093 001	CANDESARTAN CILEXETIL; ATACAND HCT	5196444	JUN 04, 2012	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021093 002	CANDESARTAN CILEXETIL; ATACAND HCT	5196444	JUN 04, 2012	U-3		
021222 001	CEFDITOREN PIVOXIL; SPECTRACEF	4839350	JUN 13, 2006		I-364	AUG 21, 2005
		4918068	JUN 13, 2006			
		5958915	OCT 14, 2016			
020998 003	CELECOXIB; CELEBREX	5466823	NOV 30, 2013		I-284	DEC 23, 2002
		5563165	NOV 30, 2013		NCE	DEC 31, 2003
		5760068	JUN 02, 2015	U-19	I-338	OCT 17, 2004
		5760068	JUN 02, 2015	U-299		
		5972986	OCT 14, 2017	U-299		
020740 001	CERIVASTATIN SODIUM; BAYCOL	5006530	JUN 26, 2011			
020740 002	CERIVASTATIN SODIUM; BAYCOL	5006530	JUN 26, 2011			
020740 003	CERIVASTATIN SODIUM; BAYCOL	5006530	JUN 26, 2011			
020740 004	CERIVASTATIN SODIUM; BAYCOL	5006530	JUN 26, 2011			
020740 005	CERIVASTATIN SODIUM; BAYCOL	5006530	JUN 26, 2011			
020740 006	CERIVASTATIN SODIUM; BAYCOL	5006530	JUN 26, 2011			
019835 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
019835 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
020346 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
021555 001	CHLORHEXIDINE GLUCONATE; CHLORAPREP ONE-STEP				NP	OCT 07, 2005
>ADD>	021441 001				NP	DEC 19, 2005
>ADD>	019992 001	4670444	DEC 09, 2003			
>ADD>		4670444*PED	JUN 09, 2004			
>ADD>	020369 001	4670444	DEC 09, 2003	U-223		
>ADD>		4670444*PED	JUN 09, 2004	U-223		
>ADD>	020805 001	4670444	DEC 09, 2003			
>ADD>		4844902	FEB 11, 2008			
>ADD>		4670444*PED	JUN 09, 2004			
>ADD>		4844902*PED	AUG 11, 2008			
020822 001	CITALOPRAM HYDROBROMIDE; CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 002	CITALOPRAM HYDROBROMIDE; CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 003	CITALOPRAM HYDROBROMIDE; CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
021046 001	CITALOPRAM HYDROBROMIDE; CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
>ADD>	021142 001	6126920	MAR 01, 2016	U-484	I-374	DEC 20, 2005
	020839 001	6429210	JUN 10, 2019		I-349	FEB 27, 2005
	021141 001	6433026	JUN 10, 2014			
	021176 001	6433026	JUN 10, 2014			
>ADD>	020287 004	4303651	JAN 04, 2005			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021165 001	DES Loratadine; CLARINEX	6100274	JUL 07, 2019			
021312 001	DES Loratadine; CLARINEX				NCE	DEC 21, 2006
075863 001	DESOGESTREL; KARIVA				PC	JUN 04, 2002
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6355656	DEC 04, 2015			
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6355656	DEC 04, 2015			
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6355656	DEC 04, 2015			
021191 001	DIMYRISTOYL LECITHIN; IMAGENT	6280704	JUL 30, 2013		NCE	MAY 31, 2007
		6280705	JUL 30, 2013			
		6287539	JUL 30, 2013			
		5605673	FEB 25, 2014			
		5626833	MAY 16, 2014	U-458		
		5639443	JUN 17, 2014			
		5695741	DEC 09, 2014	U-458		
		5720938	FEB 24, 2015			
		5798091	AUG 25, 2015	U-458		
021168 001	DIVALPROEX SODIUM; DEPAKOTE ER	6419953	DEC 18, 2018			
021168 002	DIVALPROEX SODIUM; DEPAKOTE ER	4913906	APR 03, 2007		NP	AUG 04, 2003
		4988731	JAN 29, 2008			
>ADD>	DOCETAXEL; TAXOTERE				I-379	NOV 27, 2005
020690 001	DONEPEZIL HYDROCHLORIDE; ARICEPT	6372760	MAR 31, 2019			
020690 002	DONEPEZIL HYDROCHLORIDE; ARICEPT	6372760	MAR 31, 2019			
020862 001	DOXERCALCIFEROL; HECTOROL	5602116	FEB 11, 2014	U-278		
		5707980	AUG 17, 2010	U-278		
		5861386	AUG 02, 2008	U-278		
		5869473	AUG 02, 2008	U-278		
021027 001	DOXERCALCIFEROL; HECTOROL	5602116	FEB 11, 2014	U-321		
		5707980	AUG 17, 2010	U-321		
021098 001	DROSPIRENONE; YASMIN	5569652	OCT 29, 2013	U-1		
021319 001	DUTASTERIDE; AVODART	5565467	OCT 15, 2013			
		5846976	DEC 08, 2015	U-476		
		5998427	OCT 15, 2013	U-477		
020972 001	EFAVIRENZ; SUSTIVA	6238695	APR 06, 2019			
020972 002	EFAVIRENZ; SUSTIVA	6238695	APR 06, 2019			
020972 003	EFAVIRENZ; SUSTIVA	6238695	APR 06, 2019			
021360 001	EFAVIRENZ; SUSTIVA	5519021	MAY 21, 2013			
		5633169	SEP 02, 2014	U-248		
		5811423	AUG 07, 2012	U-256		
021360 002	EFAVIRENZ; SUSTIVA	5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U-248		
		5811423	AUG 07, 2012	U-256		
>ADD>	ELETRIPTAN HYDROBROMIDE; RELPAX	5545644	AUG 13, 2013		NCE	DEC 26, 2007
>ADD>	ELETRIPTAN HYDROBROMIDE; RELPAX	5545644	AUG 13, 2013		NCE	DEC 26, 2007
020796 001	ENTACAPONE; COMTAN	5446194	AUG 29, 2012			
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		5112861	MAY 12, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 021437 001	EPLERENONE; INSPRA	6495165	DEC 08, 2019	U-3	NCE	SEP 27, 2007
		6410054	DEC 08, 2019	U-3		
		6410524	NOV 05, 2019	U-467		
		4559332	APR 09, 2004			
>ADD> 021437 002	EPLERENONE; INSPRA	6495165	DEC 08, 2019	U-3	NCE	SEP 27, 2007
		6410054	DEC 08, 2019	U-3		
		6410524	NOV 05, 2019	U-467		
		4559332	APR 09, 2004			
>ADD> 021437 003	EPLERENONE; INSPRA	6495165	DEC 08, 2019	U-3	NCE	SEP 27, 2007
		6410054	DEC 08, 2019	U-3		
		6410524	NOV 05, 2019	U-467		
		4559332	APR 09, 2004			
020738 006	EPROSARTAN MESYLATE; TEVETEN	5185351	FEB 09, 2010	U-3	NCE	DEC 22, 2002
021268 001	EPROSARTAN MESYLATE; TEVETEN HCT	5656650	AUG 12, 2014	U-3		
021268 002	EPROSARTAN MESYLATE; TEVETEN HCT	5656650	AUG 12, 2014	U-3		
020718 001	EPTIFIBATIDE; INTEGRILIN	5968902	JUN 02, 2015	U-453		
		5747447	MAY 05, 2015			
020718 002	EPTIFIBATIDE; INTEGRILIN	5968902	JUN 02, 2015	U-453		
		5747447	MAY 05, 2015			
021323 001	ESCITALOPRAM OXALATE; LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
021323 002	ESCITALOPRAM OXALATE; LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
021323 003	ESCITALOPRAM OXALATE; LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
>ADD> 021365 001	ESCITALOPRAM OXALATE; LEXAPRO				NP	AUG 14, 2005
>ADD>					I-366	AUG 29, 2005
>ADD>					PED	FEB 14, 2006
>ADD>					PED	MAR 01, 2006
>ADD> 021153 001	ESOMEPRAZOLE MAGNESIUM; NEXIUM	4738974	APR 19, 2005	U-373	NP	FEB 20, 2004
>ADD>		5900424	MAY 04, 2016	U-373	PED	AUG 20, 2004
>ADD>		4786505	APR 20, 2007	U-373		
>ADD>		4853230	APR 20, 2007	U-373		
>ADD>		5714504	FEB 03, 2015	U-373		
>ADD>		5877192	MAY 27, 2014	U-373		
>ADD>		5690960	NOV 25, 2014	U-373		
>ADD>		6166213	OCT 09, 2018			
>ADD>		6191148	OCT 09, 2018			
>ADD>		6369085	MAY 25, 2018			
>ADD>		6428810	NOV 03, 2019	U-469		
>ADD>		4738974*PED	OCT 19, 2005	U-373		
>ADD>		4786505*PED	OCT 20, 2007	U-373		
>ADD>		4853230*PED	OCT 20, 2007	U-373		
>ADD>		5690960*PED	MAY 25, 2015	U-373		
>ADD>		5714504*PED	AUG 03, 2015	U-373		
>ADD>		5877192*PED	NOV 27, 2014	U-373		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>		5900424*	PED NOV 04, 2016	U-373		
>ADD>		6147103	OCT 09, 2018			
>ADD>		6147103*	PED APR 09, 2019			
>ADD>		6166213*	PED APR 09, 2019			
>ADD>		6191148*	PED APR 09, 2019			
>ADD>		6369085*	PED NOV 25, 2018			
>ADD>		6428810*	PED MAY 03, 2020	U-469		
>ADD>	021153 002	ESOMEPRAZOLE	MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U-373 NP FEB 20, 2004
>ADD>		5900424	MAY 04, 2016	U-373	PED	AUG 20, 2004
>ADD>		4786505	APR 20, 2007	U-373		
>ADD>		4853230	APR 20, 2007	U-373		
>ADD>		5714504	FEB 03, 2015	U-373		
>ADD>		5877192	MAY 27, 2014	U-373		
>ADD>		5690960	NOV 25, 2014	U-373		
>ADD>		6147103	OCT 09, 2018			
>ADD>		6166213	OCT 09, 2018			
>ADD>		6191148	OCT 09, 2018			
>ADD>		6369085	MAY 25, 2018			
>ADD>		6428810	NOV 03, 2019	U-469		
>ADD>		4738974*	PED OCT 19, 2005	U-373		
>ADD>		4786505*	PED OCT 20, 2007	U-373		
>ADD>		4853230*	PED OCT 20, 2007	U-373		
>ADD>		5690960*	PED MAY 25, 2015	U-373		
>ADD>		5714504*	PED AUG 03, 2015	U-373		
>ADD>		5877192*	PED NOV 27, 2014	U-373		
>ADD>		5900424*	PED NOV 04, 2016	U-373		
>ADD>		6147103*	PED APR 09, 2019			
>ADD>		6166213*	PED APR 09, 2019			
>ADD>		6191148*	PED APR 09, 2019			
>ADD>		6369085*	PED NOV 25, 2018			
>ADD>		6428810*	PED MAY 03, 2020	U-469		
>ADD>	020655 001	ESTRADIOL;ALORA			I-351	APR 05, 2005
>ADD>	020655 002	ESTRADIOL;ALORA			I-351	APR 05, 2005
>ADD>	020655 003	ESTRADIOL;ALORA			I-351	APR 05, 2005
>ADD>	020655 004	ESTRADIOL;ALORA			I-351	APR 05, 2005
>ADD>		5122383	MAY 17, 2011			
>ADD>		5227169	MAY 17, 2011			
>ADD>		5212199	MAY 17, 2011			
>ADD>		5164190	DEC 11, 2010			
>ADD>	020538 005	ESTRADIOL;VIVELLE-DOT			I-254	AUG 16, 2003
>ADD>	020538 006	ESTRADIOL;VIVELLE-DOT			I-254	AUG 16, 2003
>ADD>	020538 007	ESTRADIOL;VIVELLE-DOT			I-254	AUG 16, 2003
>ADD>	020538 008	ESTRADIOL;VIVELLE-DOT			I-254	AUG 16, 2003
>ADD>	020992 001	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015	I-359	JUN 21, 2005
>ADD>	021187 001	ETHINYL ESTRADIOL;NUVARING	5989581	APR 08, 2018		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021241 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN LO	4616006	SEP 26, 2003	U-112	NP	AUG 22, 2005
		6214815	JUN 09, 2019	U-112		
		4530839	SEP 26, 2003	U-112		
		4544554	SEP 26, 2003	U-112		
		4628051	SEP 26, 2003	U-112		
021445 001	EZETIMIBE; ZETIA	5846966	SEP 21, 2013	U-474	NCE	OCT 25, 2007
		RE37721	JUN 16, 2015	U-473		
075753 002	FENOFIBRATE; FENOFIBRATE (MICRONI				PC	SEP 15, 2002
075753 003	FENOFIBRATE; FENOFIBRATE (MICRONI				PC	SEP 15, 2002
020625 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	6399632	MAY 11, 2012	U-468		
020872 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	6399632	MAY 11, 2012	U-468		
020872 002	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	6399632	MAY 11, 2012	U-468		
020872 004	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	6399632	MAY 11, 2012	U-468		
020786 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA-D	6399632	MAY 11, 2012	U-468		
075442 001	FLECAINIDE ACETATE; FLECAINIDE ACETATE				PC	OCT 28, 2002
075442 002	FLECAINIDE ACETATE; FLECAINIDE ACETATE				PC	OCT 28, 2002
075442 003	FLECAINIDE ACETATE; FLECAINIDE ACETATE				PC	OCT 28, 2002
018936 001	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
>ADD>					NPP	JAN 03, 2006
>ADD>					PED	JUL 03, 2006
018936 003	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
>ADD>					NPP	JAN 03, 2006
>ADD>					PED	JUL 03, 2006
018936 004	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
>ADD>					NPP	JAN 03, 2006
>ADD>					PED	JUL 03, 2006
018936 006	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
>ADD>					NPP	JAN 03, 2006
>ADD>					PED	JUL 03, 2006
020101 001	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
020974 001	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
020974 002	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
018936 007	FLUOXETINE HYDROCHLORIDE; SARAFEM				D-75	JUN 12, 2005
018936 008	FLUOXETINE HYDROCHLORIDE; SARAFEM				D-75	JUN 12, 2005
020121 001	FLUTICASONE PROPIONATE; FLONASE				D-76	MAY 23, 2005
021192 001	FLUVASTATIN SODIUM; LESCOL XL	6242003	APR 13, 2020			
021345 001	FONDAPARINUX SODIUM; ARIXTRA	4818816	AUG 19, 2003			
021344 001	FULVESTRANT; FASLODEX	4659516	OCT 01, 2004		NCE	APR 25, 2007
020235 001	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
		5084479*PED	JUL 02, 2010	U-258		
020235 002	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
		5084479*PED	JUL 02, 2010	U-258		
020235 003	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
		5084479*PED	JUL 02, 2010	U-258		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020882 001	GABAPENTIN; NEURONTIN				I-354	MAY 24, 2005
020882 002	GABAPENTIN; NEURONTIN				I-354	MAY 24, 2005
021129 001	GABAPENTIN; NEURONTIN	6054482	APR 25, 2017		I-354	MAY 24, 2005
020131 001	GADOTERIDOL; PROHANCE	6054482*PED	OCT 25, 2017			
		5474756	DEC 12, 2012	U-480		
		5846519	DEC 08, 2015			
		6143274	DEC 12, 2012	U-480		
021061 001	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015		NCE	DEC 17, 2004
021061 002	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015		NCE	DEC 17, 2004
021062 001	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015			
021062 002	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015			
>ADD>	021062 003	GATIFLOXACIN; TEQUIN	4980470	DEC 25, 2007	NCE	DEC 17, 2004
>ADD>			5880283	DEC 05, 2015	D-69	OCT 12, 2004
>ADD>	021062 004	GATIFLOXACIN; TEQUIN	4980470	DEC 25, 2007	NCE	DEC 17, 2004
>ADD>			5880283	DEC 05, 2015	D-69	OCT 12, 2004
020622 001	GLATIRAMER ACETATE; COPAXONE	6342476	MAY 24, 2014	U-441		
		6362161	MAY 24, 2014	U-441		
021460 001	GLIPIZIDE; METAGLIP				NC	OCT 21, 2005
021460 002	GLIPIZIDE; METAGLIP				NC	OCT 21, 2005
021460 003	GLIPIZIDE; METAGLIP				NC	OCT 21, 2005
021178 001	GLYBURIDE; GLUCOVANCE				I-368	SEP 30, 2005
021178 002	GLYBURIDE; GLUCOVANCE				I-368	SEP 30, 2005
021178 003	GLYBURIDE; GLUCOVANCE				I-368	SEP 30, 2005
020239 001	GRANISETRON HYDROCHLORIDE; KYTRIL				I-369	AUG 16, 2005
020239 002	GRANISETRON HYDROCHLORIDE; KYTRIL				I-369	AUG 16, 2005
020305 002	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 20, 2007	U-105		
>ADD>	021282 001	GUAIFENESIN; MUCINEX	6372252	APR 28, 2020	U-489	
020125 001	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
		4743450	FEB 24, 2007		PED	JUN 28, 2003
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020125 002	HYDROCHLOROTHIAZIDE; ACCURETIC	4743450	FEB 24, 2007			
		4344949	OCT 03, 2002	U-3		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020125 003	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020758 001	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011			
020758 002	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011			
020758 003	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011			
020818 001	HYDROCHLOROTHIAZIDE; DIOVAN HCT	6294197	JUN 18, 2017	U-3		
020818 002	HYDROCHLOROTHIAZIDE; DIOVAN HCT	6294197	JUN 18, 2017	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020729 003	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	6348216	JUN 10, 2017			
021374 001	IBUPROFEN;ADVIL COLD AND SINUS	5071643	DEC 10, 2008			
		5071643*PED	JUN 10, 2009			
		5360615	DEC 10, 2008			
		5360615*PED	JUN 10, 2009			
021373 001	IBUPROFEN;CHILDREN'S ADVIL COL				NP	AUG 01, 2003
075874 001	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PED	FEB 01, 2004
075874 002	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
>ADD> 021335 001	IMATINIB MESYLATE;GLEEVEC				PC	OCT 05, 2002
>ADD> 021335 002	IMATINIB MESYLATE;GLEEVEC				I-376	DEC 20, 2005
020986 001	INSULIN ASPART;NOVOLOG				I-376	DEC 20, 2005
021172 001	INSULIN ASPART;NOVOLOG MIX 70/30	5618913	APR 08, 2014			
		5866538	JUN 20, 2017			
		5547930	SEP 28, 2013			
		5834422	SEP 28, 2013	U-471		
		5948751	JUN 19, 2017			
		5840680	SEP 28, 2013	U-471		
		5618913	APR 08, 2014			
>ADD> 021425 001	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005			
>ADD> 021425 002	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005			
019710 003	IOVERSOL;OPTIRAY 160	4396598	DEC 30, 2002	U-31		
019710 002	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002	U-30		
		4396598	DEC 30, 2002	U-29		
019710 004	IOVERSOL;OPTIRAY 300	4396598	DEC 30, 2002	U-29		
		4396598	DEC 30, 2002	U-30		
		4396598	DEC 30, 2002	U-464		
019710 001	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002	U-28		
		4396598	DEC 30, 2002	U-29		
		4396598	DEC 30, 2002	U-463		
019710 005	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002	U-62		
		4396598	DEC 30, 2002	U-464		
		4396598	DEC 30, 2002	U-465		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL./PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020757 001	IRBESARTAN; AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
020757 002	IRBESARTAN; AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
020757 003	IRBESARTAN; AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
020571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	6403569	APR 28, 2020	U-449		
018662 002	ISOTRETINOIN; ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 003	ISOTRETINOIN; ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 004	ISOTRETINOIN; ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
020657 001	ITRACONAZOLE; SPORANOX	6407079	JUN 18, 2019			
020966 001	ITRACONAZOLE; SPORANOX	6407079	JUN 18, 2019			
019700 001	KETOROLAC TROMETHAMINE; ACULAR				M-16	FEB 08, 2005
020811 001	KETOROLAC TROMETHAMINE; ACULAR PRESERVATIVE				M-16	FEB 08, 2005
020564 001	LAMIVUDINE; EPIVIR				D-2	JUN 24, 2005
020564 003	LAMIVUDINE; EPIVIR	5047407	NOV 17, 2009		NS	JUN 24, 2005
		5047407*PED	MAY 17, 2010		D-2	JUN 24, 2005
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020596 001	LAMIVUDINE; EPIVIR				D-2	JUN 24, 2005
020406 001	LANSOPRAZOLE; PREVACID	5013743	FEB 12, 2010	U-452	M-12	JUL 31, 2005
020406 002	LANSOPRAZOLE; PREVACID	5013743	FEB 12, 2010	U-452	M-12	JUL 31, 2005
021428 001	LANSOPRAZOLE; PREVACID	4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U-126		
		5013743	FEB 12, 2010	U-452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
		6328994	MAY 17, 2009			
021428 002	LANSOPRAZOLE; PREVACID	4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U-126		
		5013743	FEB 12, 2010	U-452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
		6328994	MAY 17, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020597 001	LATANOPROST; XALATAN	6429226	SEP 06, 2009	U-260	I-375	DEC 20, 2005
021343 001	LEUPROLIDE ACETATE; ELIGARD	5599552	FEB 04, 2014			
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
		4938763	OCT 03, 2008			
		5278201	JAN 11, 2011			
		5324519	OCT 20, 2011			
021379 001	LEUPROLIDE ACETATE; ELIGARD	5599552	FEB 04, 2014		NP	JUL 24, 2005
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
		4938763	OCT 03, 2008			
		5278201	JAN 11, 2011			
		5324519	OCT 20, 2011			
021088 001	LEUPROLIDE ACETATE; VIADUR	6375978	DEC 17, 2018			
		6395292	JAN 30, 2017			
020837 001	LEVALBUTEROL HYDROCHLORIDE; XOPENEX	6451289	MAR 21, 2021			
020837 002	LEVALBUTEROL HYDROCHLORIDE; XOPENEX	6451289	MAR 21, 2021			
020837 003	LEVALBUTEROL HYDROCHLORIDE; XOPENEX	5362755	NOV 08, 2011	U-332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
		6083993	JAN 05, 2010	U-332		
		6451289	MAR 21, 2021			
020182 001	LEVOCARNITINE; CARNITOR	6335369	JAN 18, 2021	U-433		
		6429230	JAN 18, 2021	U-433		
020634 001	LEVOFLOXACIN; LEVAQUIN				I-357	APR 08, 2003
					I-372	OCT 30, 2005
020634 002	LEVOFLOXACIN; LEVAQUIN				I-357	APR 08, 2003
					I-372	OCT 30, 2005
020634 003	LEVOFLOXACIN; LEVAQUIN				I-305	FEB 02, 2003
					I-357	APR 08, 2003
					I-372	OCT 30, 2005
020635 001	LEVOFLOXACIN; LEVAQUIN				I-357	APR 08, 2003
					I-372	OCT 30, 2005
020635 002	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				I-357	APR 08, 2003
					I-372	OCT 30, 2005
020635 003	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				I-357	APR 08, 2003
					I-372	OCT 30, 2005
021342 001	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020			
021342 002	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020			
021342 003	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020			
021342 004	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020			
021342 005	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020			
021342 006	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES CODE	EXCLUS CODE	EXCLUS EXPIRES
021342 007	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020		
021342 008	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020		
021342 009	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020		
021342 010	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020		
021342 011	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020		
>ADD> 020612 001	LIDOCAINE;LIDODERM	5589180	MAR 05, 2016	U-485	
>ADD>		5441738	MAY 01, 2012	U-485	
>ADD>		5827529	JUN 10, 2011	U-486	
>ADD>		5709869	DEC 23, 2016	U-487	
>ADD>		5601838	MAY 18, 2010	U-488	
021226 001	LOPINAVIR;KALETRA	6458818	NOV 07, 2017		
020470 001	LORATADINE;CLARITIN-D 24 HOUR	5314697	OCT 23, 2012		
020386 001	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009		
		5153197	OCT 06, 2009	U-3	
		5608075	MAR 04, 2014		
		5138069*PED	FEB 11, 2010		
		5153197*PED	APR 06, 2010	U-3	
		5608075*PED	SEP 04, 2014		
020386 002	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06, 2009	U-3	
		5138069	AUG 11, 2009		
		5608075	MAR 04, 2014		
		5138069*PED	FEB 11, 2010		
		5153197*PED	APR 06, 2010	U-3	
		5608075*PED	SEP 04, 2014		
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009		
		5153197	OCT 06, 2009	U-3	
		5608075	MAR 04, 2014		
		5138069*PED	FEB 11, 2010		
		5153197*PED	APR 06, 2010	U-3	
		5608075*PED	SEP 04, 2014		
021249 001	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447	
		6129930	SEP 20, 2013	U-448	
		6406715	OCT 31, 2017	U-450	
021249 002	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447	
		6129930	SEP 20, 2013	U-448	
		6406715	OCT 31, 2017	U-450	
021249 003	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447	
		6129930	SEP 20, 2013	U-448	
		6406715	OCT 31, 2017	U-450	
>ADD> 021316 001	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017	NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U-456	
>ADD> 021316 002	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017	NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U-456	
>ADD> 021316 003	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017	NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U-456	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 021316 004	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
019643 002	LOVASTATIN;MEVACOR	6080778	MAR 23, 2018	U-456	PED	AUG 14, 2005
019643 003	LOVASTATIN;MEVACOR				I-350	FEB 14, 2005
019643 004	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	NOV 27, 2011		I-350	FEB 14, 2005
076175 001	MEFLOQUINE HYDROCHLORIDE;MEFLOQUINE HCL				PED	AUG 14, 2005
020938 002	MELOXICAM;MOBIC				I-350	FEB 14, 2005
020922 001	MEQUINOL;SOLAGE				PED	AUG 14, 2005
020855 001	MESNA;MESNEX				I-350	FEB 14, 2005
>ADD>		6353029	AUG 24, 2020		PC	NOV 03, 2002
>ADD>		5252341	JUL 16, 2011		NCE	APR 13, 2005
		5262169	JUL 16, 2011		NDF	MAR 21, 2005
013217 001	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U-189		
013217 003	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U-189		
>ADD> 021410 001	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U-493		
>ADD>		5741803	APR 21, 2015	U-493		
>ADD>		6288095	FEB 11, 2017	U-493		
>ADD>		5965584	JUN 19, 2016	U-493		
>ADD>		6166042	JUN 19, 2016	U-493		
>ADD> 021410 002	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U-493		
>ADD>		5741803	APR 21, 2015	U-493		
>ADD>		6288095	FEB 11, 2017	U-493		
>ADD>		5965584	JUN 19, 2016	U-493		
>ADD>		6166042	JUN 19, 2016	U-493		
>ADD> 021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U-493		
>ADD>		5741803	APR 21, 2015	U-493		
>ADD>		6288095	FEB 11, 2017	U-493		
>ADD>		5965584	JUN 19, 2016	U-493		
>ADD>		6166042	JUN 19, 2016	U-493		
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED I-320 W W	JUN 15, 2004 DEC 15, 2003 DEC 15, 2003 JUN 15, 2004
021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6475521	MAR 19, 2018			
021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4519801 4612008 4783337 5082668	JUL 12, 2002 SEP 16, 2003 SEP 16, 2003 SEP 16, 2003		NP	AUG 01, 2003
021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020			
021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284 6228398	MAY 15, 2016 MAY 01, 2019	U-372 U-472	NP	JUN 07, 2005
021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284 6228398	MAY 15, 2016 MAY 01, 2019		NP	JUN 07, 2005
021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284 6228398	MAY 15, 2016 NOV 01, 2019	U-472	NP	JUN 07, 2005
>ADD>	019815 003	MIDODRINE HYDROCHLORIDE;PROAMATINE			ODE	SEP 06, 2003
	020415 001	MIRTAZAPINE;REMERON			M-18	APR 09, 2005
	020415 002	MIRTAZAPINE;REMERON			M-18	APR 09, 2005
	020415 003	MIRTAZAPINE;REMERON			M-18	APR 09, 2005
	021208 001	MIRTAZAPINE;REMERON SOLTAB			M-18	APR 09, 2005
	021208 002	MIRTAZAPINE;REMERON SOLTAB			M-18	APR 09, 2005
	021208 003	MIRTAZAPINE;REMERON SOLTAB			M-18	APR 09, 2005
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE			ODE	OCT 13, 2007
	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX			I-360 PED	JUL 17, 2005 JAN 17, 2006
>ADD>	020829 002	MONTELUKAST SODIUM;SINGULAIR			I-378	DEC 31, 2005
>ADD>	020830 001	MONTELUKAST SODIUM;SINGULAIR			I-378	DEC 31, 2005
>ADD>	020830 002	MONTELUKAST SODIUM;SINGULAIR			I-378	DEC 31, 2005
	021409 001	MONTELUKAST SODIUM;SINGULAIR	5565473 5565473*PED	FEB 03, 2012 AUG 03, 2012	NDF PED NCE PED I-378	JUL 26, 2005 JAN 26, 2006 FEB 20, 2003 AUG 20, 2003 DEC 31, 2005
>ADD>	021260 001	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017	NP	MAR 20, 2005
	021260 002	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017	NP	MAR 20, 2005
	021260 003	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017	NP	MAR 20, 2005
	021260 004	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017	NP	MAR 20, 2005
	019583 001	NABUMETONE;RELAFEN	4420639 4420639*PED	DEC 13, 2002 JUN 13, 2003		
	019583 002	NABUMETONE;RELAFEN	4420639 4420639*PED	DEC 13, 2002 JUN 13, 2003		
	020763 001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U-232	
	020763 002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U-232	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317 5256664 4338317*PED 5256664*PED	MAR 16, 2003 APR 28, 2012 SEP 16, 2003 OCT 28, 2012			
020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317 5256664 4338317*PED 5256664*PED	MAR 16, 2003 APR 28, 2012 SEP 16, 2003 OCT 28, 2012			
020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317 5256664 4338317*PED 5256664*PED	MAR 16, 2003 APR 28, 2012 SEP 16, 2003 OCT 28, 2012			
020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317 5256664 4338317*PED 5256664*PED	MAR 16, 2003 APR 28, 2012 SEP 16, 2003 OCT 28, 2012			
020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317 5256664 4338317*PED 5256664*PED	MAR 16, 2003 APR 28, 2012 SEP 16, 2003 OCT 28, 2012			
020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317 5256664 4338317*PED 5256664*PED	MAR 16, 2003 APR 28, 2012 SEP 16, 2003 OCT 28, 2012			
020778 001	NELFINAVIR MESYLATE;VIRACEPT	6162812	OCT 07, 2013	U-248		
020779 001	NELFINAVIR MESYLATE;VIRACEPT	6162812	OCT 07, 2013	U-248		
020381 001	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
020381 002	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
020381 003	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
020381 004	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
020381 005	NIACIN;NIASPAN TITRATION ST	6406715 6129930	OCT 31, 2017 SEP 20, 2013	U-450 U-354		
021330 001	NICOTINE POLACRILEX;COMMIT				NDF	OCT 31, 2005
021330 002	NICOTINE POLACRILEX;COMMIT				NDF	OCT 31, 2005
020076 004	NICOTINE;HABITROL				D-71	NOV 12, 2002
020076 005	NICOTINE;HABITROL				D-71	NOV 12, 2002
020076 006	NICOTINE;HABITROL				D-71	NOV 12, 2002
>ADD> 020356 001	NISOLDIPINE;SULAR	4703038	OCT 07, 2005	U-3		
>ADD> 020356 002	NISOLDIPINE;SULAR	4703038	OCT 07, 2005	U-3		
>ADD> 020356 003	NISOLDIPINE;SULAR	4703038	OCT 07, 2005	U-3		
>ADD> 020356 004	NISOLDIPINE;SULAR	4703038	OCT 07, 2005	U-3		
021498 001	NITAZOXANIDE;ALINIA				NCE ODE	NOV 22, 2007 NOV 22, 2009
>ADD> 021134 001	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021134 002	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018		
>ADD>	021134 003	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018		
	020555 001	NIZATIDINE;AXID AR	4375547	APR 12, 2002		
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	6395292	JAN 30, 2017		
	021286 001	OLMESARTAN MEDOXOMIL;BENICAR			NCE	APR 25, 2007
	021286 003	OLMESARTAN MEDOXOMIL;BENICAR			NCE	APR 25, 2007
	021286 004	OLMESARTAN MEDOXOMIL;BENICAR			NCE	APR 25, 2007
	019810 001	OMEPRAZOLE;PRILOSEC	6166213*PED	APR 09, 2019	M-19	JUL 12, 2005
					PED	JAN 12, 2006
	019810 002	OMEPRAZOLE;PRILOSEC	6166213*PED	APR 09, 2019	M-19	JUL 12, 2005
					PED	JAN 12, 2006
	019810 003	OMEPRAZOLE;PRILOSEC	6166213	OCT 09, 2018	M-19	JUL 12, 2005
			6166213*PED	APR 09, 2019	PED	JAN 12, 2006
	020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2009		
	021492 001	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013	NCE	AUG 09, 2007
			5338874	APR 07, 2013		
			5290961	JAN 12, 2013		
	021492 002	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013	NCE	AUG 09, 2007
			5338874	APR 07, 2013		
			5290961	JAN 12, 2013		
>ADD>	020776 001	OXAPROZIN POTASSIUM;DAYPRO ALTA			NE	OCT 17, 2005
	021285 001	OXCARBAZEPINE;TRILEPTAL			NCE	JAN 14, 2005
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006		
			5266331	OCT 26, 2007		
			5549912	OCT 26, 2007		
			5508042	APR 16, 2013	U-443	
			5656295	OCT 26, 2007	U-443	
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006		
			5266331	OCT 26, 2007		
			5549912	OCT 26, 2007		
			5508042	APR 16, 2013	U-443	
			5656295	OCT 26, 2007	U-443	
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006		
			5266331	OCT 26, 2007		
			5549912	OCT 26, 2007		
			5508042	APR 16, 2013	U-443	
			5656295	OCT 26, 2007	U-443	
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013		
			5656295	OCT 26, 2007	U-443	
			4970075	AUG 29, 2006		
			5266331	OCT 26, 2007		
			5549912	OCT 26, 2007		
	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006		
			5266331	OCT 26, 2007		
			5549912	OCT 26, 2007		
			5508042	APR 16, 2013	U-443	
			5656295	OCT 26, 2007	U-443	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020987 001	PANTOPRAZOLE SODIUM; PROTONIX	5997903	DEC 07, 2016		I-356	APR 19, 2005
020987 002	PANTOPRAZOLE SODIUM; PROTONIX	4758579	JUL 19, 2005		I-356	APR 19, 2005
		5997903	DEC 07, 2016		I-330	JUN 12, 2004
					NCE	FEB 02, 2005
020031 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020031 002	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 003	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020031 004	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6133289	MAY 15, 2015	U-358		
		6121291	MAR 17, 2017	U-286		
		6121291	MAR 17, 2017	U-431		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 005	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 15, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020710 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5811436	SEP 22, 2015		PED	NOV 17, 2002
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U-285	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	OCT 13, 2004
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007			
		5789449*PED	JUL 06, 2009	U-285		
		5811436*PED	MAR 22, 2016			
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		5900423*	PED NOV 19, 2015			
		6063927*	PED OCT 23, 2019			
		6080759*	PED NOV 19, 2015			
		6121291*	PED SEP 17, 2017	U-286		
		6121291*	PED SEP 17, 2017	U-431		
		6133289*	PED NOV 19, 2015	U-358		
		6172233*	PED JUL 15, 2018			
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6062927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*	PED JUN 29, 2007	U-12		
		5789449*	PED JUL 06, 2009	U-285		
		5872132*	PED NOV 19, 2015			
		5900423*	PED NOV 19, 2015			
		6063927*	PED OCT 23, 2019			
		6080759*	PED NOV 19, 2015			
		6121291*	PED SEP 17, 2017	U-286		
		6121291*	PED SEP 17, 2017	U-431		
		6133289*	PED NOV 19, 2015	U-358		
		6172233*	PED JUL 15, 2018			
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
		4721723*	PED JUN 29, 2007			
		4839177*	PED DEC 13, 2006			
		5422123*	PED DEC 06, 2012			
		5789449*	PED JUL 06, 2009	U-286		
		5872132*	PED NOV 19, 2015			
		5900423*	PED NOV 19, 2015			
		6063927*	PED OCT 23, 2019			
		6080759*	PED NOV 19, 2015			
		6121291*	PED SEP 17, 2017	U-286		
		6133289*	PED NOV 19, 2015	U-286		
		6172233*	PED JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES CODE	EXCLUS CODE	EXCLUS EXPIRES
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015	I-358	FEB 12, 2005
		4839177	JUN 13, 2006	PED	AUG 12, 2005
		5422123	JUN 06, 2012		
		4721723	DEC 29, 2006		
		5900423	MAY 19, 2015		
		5789449	JAN 06, 2009	U-286	
		6063927	APR 23, 2019		
		6080759	MAY 19, 2015		
		6121291	MAR 17, 2017	U-286	
		6133289	MAY 19, 2015	U-286	
		6172233	JAN 15, 2018		
		4721723*PED	JUN 29, 2007		
		4839177*PED	DEC 13, 2006		
		5422123*PED	DEC 06, 2012		
		5789449*PED	JUL 06, 2009	U-286	
		5872132*PED	NOV 19, 2015		
		5900423*PED	NOV 19, 2015		
		6063927*PED	OCT 23, 2019		
		6080759*PED	NOV 19, 2015		
		6121291*PED	SEP 17, 2017	U-286	
		6133289*PED	NOV 19, 2015	U-286	
		6172233*PED	JUL 15, 2018		
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006	I-358	FEB 12, 2005
		4839177	JUN 13, 2006	PED	AUG 12, 2005
		5422123	JUN 06, 2012		
		5789449	JAN 06, 2009	U-286	
		5872132	MAY 19, 2015		
		5900423	MAY 19, 2015		
		6063927	APR 23, 2019		
		6080759	MAY 19, 2015		
		6121291	MAR 17, 2017	U-286	
		6133289	MAY 19, 2015	U-286	
		6172233	JAN 15, 2018		
		4721723*PED	JUN 29, 2007		
		4839177*PED	DEC 13, 2006		
		5422123*PED	DEC 06, 2012		
		5789449*PED	JUL 06, 2009	U-286	
		5872132*PED	NOV 19, 2015		
		5900423*PED	NOV 19, 2015		
		6063927*PED	OCT 23, 2019		
		6080759*PED	NOV 19, 2015		
		6121291*PED	SEP 17, 2017	U-286	
		6133289*PED	NOV 19, 2015	U-286	
		6172233*PED	JUL 15, 2018		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020629 001	PENCICLOVIR SODIUM;DENA VIR	5075445	SEP 24, 2010			
021302 001	PIMECROLIMUS;ELIDEL	6352998	OCT 26, 2015			
		6352998*PED	APR 26, 2016			
		6423722	JUN 26, 2018			
		6423722*PED	DEC 26, 2018			
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
019898 002	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5180589	JUL 09, 2008		I-304	JAN 18, 2003
		5030447	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 003	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019898 008	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		NS	DEC 18, 2004
		5030447	JUL 09, 2008		D-70	DEC 18, 2004
		5180589	JUL 09, 2008		PED	JUN 18, 2005
		5622985	APR 22, 2014	U-335	PED	JUN 18, 2005
		4346227*PED	APR 20, 2006		I-281	JUN 09, 2003
		5180589*PED	JAN 09, 2009		PED	DEC 09, 2003
		5622985*PED	OCT 22, 2014	U-335	D-51	JAN 18, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					I-286	JAN 18, 2003
					PED	JUL 18, 2003
					I-287	FEB 10, 2003
					PED	AUG 10, 2003
					I-304	JAN 18, 2003
					PED	JUL 18, 2003
					I-370	OCT 29, 2005
019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3	PED	APR 29, 2006
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
		4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
		4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
		4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
		4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020973 001	RABEPRAZOLE SODIUM;ACIPHEX	5035899	APR 04, 2009	U-385	NCE	AUG 19, 2004
020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385	I-346	FEB 12, 2005
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2003		I-371	NOV 08, 2005
020741 001	REPAGLINIDE;PRANDIN	6458811	MAR 10, 2017			
		5312924	SEP 05, 2006		I-367	OCT 21, 2005
		6143769	SEP 05, 2006			
020741 002	REPAGLINIDE;PRANDIN	RE37035	MAR 14, 2009			
		5312924	SEP 05, 2006	U-214	I-367	OCT 21, 2005
		6143769	SEP 05, 2006			
020741 003	REPAGLINIDE;PRANDIN	RE37035	MAR 14, 2009			
		5312924	SEP 05, 2006	U-214	I-367	OCT 21, 2005
		6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
>ADD> 021511 001	RIBAVIRIN;COPEGUS				NP	DEC 03, 2005
020903 001	RIBAVIRIN;REBETOL	6177074	NOV 01, 2016	U-454		
		6177074*PED	MAY 01, 2017	U-454		
		6461605	NOV 01, 2016	U-478		
		6461605*PED	MAY 01, 2017	U-478		
		6472373	SEP 21, 2017	U-479		
		6472373*PED	MAR 21, 2018	U-479		
020599 001	RILUZOLE;RILUTEK	5527814	JUN 18, 2013			
020835 003	RISEDRONATE SODIUM;ACTONEL	5994329	JUL 17, 2018	U-353	NCE	MAR 27, 2003
		6015801	JUL 17, 2018	U-353	I-292	APR 14, 2003
					I-291	APR 14, 2003
					D-73	MAY 17, 2005
					D-74	MAY 17, 2005
					M-15	MAR 03, 2005
020272 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 002	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 003	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 004	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 005	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 007	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 008	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020588 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
021042 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
021042 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
021042 003	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021052 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
021052 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020692 001	SALMETEROL XINAFOATE;SEREVENT				I-348	MAR 22, 2005
020828 001	SAQUINAVIR;FORTOVASE	6352717	NOV 16, 2019			
		6008228	JUN 06, 2015			
021209 001	SECRETIN;SECREFLO				NP ODE	APR 04, 2005 APR 04, 2009
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
020478 001	SEVOFLURANE;ULTANE	6444859	JAN 27, 2017		M-17	MAR 30, 2004
		6444859*PED	JUL 27, 2017		PED	SEP 30, 2004
020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
		5436272	JUL 25, 2012	U-439		
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
		5436272	JUL 25, 2012	U-439		
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
		5436272	JUL 25, 2012	U-439		
020895 001	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U-155		
020895 002	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U-155		
020895 003	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U-155		
019766 001	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 002	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 003	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 004	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 005	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
>ADD>	021110 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U-290	NCE SEP 15, 2004
		5212155	MAY 18, 2010	U-291		
		5308847	MAY 03, 2011	U-292		
		5403833	APR 04, 2012	U-293		
		5989591	MAR 11, 2018			
021196 001	SODIUM OXYBATE;XYREM				ODE	JUL 17, 2009
					NCE	JUL 17, 2007
020572 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136		
020573 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136		
021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
020604 004	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
020677 001	SPARFLOXACIN;ZAGAM	4795751	FEB 04, 2010	U-160		
>ADD>	020132 001	SUMATRIPTAN SUCCINATE;IMITREX	5863559	JAN 26, 2016	U-72	
>ADD>		6020001	MAR 02, 2012	U-444		
		6368627	MAR 02, 2012	U-444		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020132 002	SUMATRIPTAN SUCCINATE; IMITREX	5863559	JAN 26, 2016	U-72	
>ADD>			6020001	MAR 02, 2012	U-444	
			6368627	MAR 02, 2012	U-444	
>ADD>	020132 003	SUMATRIPTAN SUCCINATE; IMITREX	5863559	JAN 26, 2016	U-72	
>ADD>			6020001	MAR 02, 2012	U-444	
			6368627	MAR 02, 2012	U-444	
	017970 001	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002	M-20	AUG 30, 2005
			4536516*PED	FEB 20, 2003	PED	MAR 01, 2006
	017970 002	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002		
			4536516*PED	FEB 20, 2003		
	021184 003	TAZAROTENE; AVAGE	5089509	JUN 13, 2011	U-481 NP	SEP 30, 2005
	020600 001	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U-193	
			5089509	JUN 13, 2011	U-481	
	020600 002	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U-193	
			5089509	JUN 13, 2011	U-481	
	021184 001	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U-481	
	021184 002	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U-481	
	019785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	DEC 21, 2004		
	019785 003	TECHNETIUM TC-99M SESTAMIBI KIT; MIRALUMA	4452774	DEC 21, 2004		
	021200 001	TEGASEROD MALEATE; ZELNORM	5510353	APR 26, 2013	U-466 NCE	JUL 24, 2007
	021200 002	TEGASEROD MALEATE; ZELNORM	5510353	APR 26, 2013	U-466 NCE	JUL 24, 2007
	021029 001	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010	NCE	AUG 11, 2004
			5260291*PED	MAY 09, 2011	ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
	021029 002	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010	NCE	AUG 11, 2004
			5260291*PED	MAY 09, 2011	ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
	021029 003	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010	NCE	AUG 11, 2004
			5260291*PED	MAY 09, 2011	ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
	021029 004	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010	NCE	AUG 11, 2004
			5260291*PED	MAY 09, 2011	ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
	020846 001	TERBINAFINE; LAMISIL	4755534	DEC 30, 2006	U-445	
			4680291	JUL 14, 2004	U-445	
	021318 001	TERIPARATIDE ACETATE; FORTEO			NP	NOV 26, 2005
>ADD>	021015 001	TESTOSTERONE; ANDROGEL	6503894	AUG 30, 2020	U-490	
>ADD>	021454 001	TESTOSTERONE; TESTIM	5023252	JUN 11, 2008	U-483	
	020791 001	TESTOSTERONE; TESTODERM TTS	6348210	NOV 10, 2019	U-440	
	020785 001	THALIDOMIDE; THALOMID	6315720	OCT 23, 2020	U-442	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
021447 001	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
021447 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
021447 003	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
020697 001	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
020697 002	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
021228 001	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318		
021228 002	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318		
020671 001	TOPOTECAN HYDROCHLORIDE;HYCANTIN	5004758	MAY 28, 2010			
		5004758*PED	NOV 28, 2010			
076110 001	TORSEMIDE;TORSEMIDE				PC	FEB 17, 2003
076110 002	TORSEMIDE;TORSEMIDE				PC	DEC 10, 2002
076110 003	TORSEMIDE;TORSEMIDE				PC	DEC 07, 2002
076110 004	TORSEMIDE;TORSEMIDE				PC	DEC 10, 2002
021272 001	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
021272 002	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
021272 003	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
021272 004	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
020475 002	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NS	MAY 10, 2005
		5955109	SEP 21, 2016	U-134		
021289 001	UROFOLLITROPIN;BRAVELLE				NP	MAY 06, 2005
					I-377	DEC 19, 2005
>ADD>						
>ADD>	019415 004	UROFOLLITROPIN;FERTINEX	4589402	JUL 26, 2004	U-482	
>ADD>	019415 005	UROFOLLITROPIN;FERTINEX	4589402	JUL 26, 2004	U-482	
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009		
			5879706	JAN 19, 2016		
			6107302	JAN 19, 2016		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020550 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	JUN 23, 2009			
		5879706	JAN 19, 2016			
		6107302	JAN 19, 2016			
021341 002	VALDECOXIB; BEXTRA	5633272	FEB 13, 2015	U-462		
021341 003	VALDECOXIB; BEXTRA	5633272	FEB 13, 2015	U-462		
020593 001	VALPROATE SODIUM; DEPACON				D-72	JAN 24, 2005
020665 001	VALSARTAN; DIOVAN				I-365	AUG 14, 2005
020665 002	VALSARTAN; DIOVAN				I-365	AUG 14, 2005
021283 001	VALSARTAN; DIOVAN	6294197	JUN 18, 2017	U-3	I-365	AUG 14, 2005
021283 002	VALSARTAN; DIOVAN	6294197	JUN 18, 2017	U-3	I-365	AUG 14, 2005
021283 003	VALSARTAN; DIOVAN	6294197	JUN 18, 2017	U-3	I-365	AUG 14, 2005
021283 004	VALSARTAN; DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U-3		
020151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
>ADD>	020699 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6419958*PED	SEP 20, 2017	U-459	I-325 MAY 02, 2004
>ADD>		4535186	DEC 13, 2007		PED	NOV 02, 2004
		6274171	MAR 20, 2017			
		5916923	JUN 28, 2013	U-398		
		6403120	MAR 20, 2017	U-451		
		6419958	MAR 20, 2017	U-459		
		6444708*PED	DEC 28, 2013			
		6444708	JUN 28, 2013			
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U-398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U-451		
>ADD>	020699 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6419958*PED	SEP 20, 2017	U-459	I-325 MAY 02, 2004
>ADD>		4535186	DEC 13, 2007		PED	NOV 02, 2004
		6274171	MAR 20, 2017			
		5916923	JUN 28, 2013	U-398		
		6403120	MAR 20, 2017	U-451		
		6419958	MAR 20, 2017	U-459		
		6444708*PED	DEC 28, 2013			
		6444708	JUN 28, 2013			
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U-398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U-451		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
<u>>ADD></u> <u>>ADD></u>	020699 003 VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6419958*PED	SEP 20, 2017	U-459	I-325	MAY 02, 2004
		4535186	DEC 13, 2007		PED	NOV 02, 2004
		6274171	MAR 20, 2017			
		5916923	JUN 28, 2013	U-398		
		6403120	MAR 20, 2017	U-451		
		6419958	MAR 20, 2017	U-459		
		6444708*PED	DEC 28, 2013			
		6444708	JUN 28, 2013			
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U-398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U-451		
<u>>ADD></u> <u>>ADD></u>	020699 004 VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6419958*PED	SEP 20, 2017	U-459	I-325	MAY 02, 2004
		4535186	DEC 13, 2007		PED	NOV 02, 2004
		6274171	MAR 20, 2017			
		5916923	JUN 28, 2013	U-398		
		6403120	MAR 20, 2017	U-451		
		6419958	MAR 20, 2017	U-459		
		6444708*PED	DEC 28, 2013			
		6444708	JUN 28, 2013			
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U-398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U-451		
021119 001	VERTEPORFIN;VISUDYNE	4883790	JAN 20, 2007			
020388 001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			
		4307100*PED	JAN 08, 2003			
021266 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
021266 002	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
021267 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
021036 001	ZANAMIVIR;RELENZA	6294572	DEC 15, 2014			
020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
020919 001	ZIPRASIDONE MESYLATE;GEODON	6399777	APR 01, 2017		NCE	FEB 05, 2006
		4831031	MAR 02, 2007		NDF	JUN 21, 2005
		6110918	MAR 26, 2017			
		6232304	APR 01, 2017			
021223 001	ZOLEDRONIC ACID;ZOMETA				I-361	FEB 22, 2005
021231 001	ZOLMITRIPTAN;ZOMIG-ZMT	5466699	NOV 14, 2012		NCE	NOV 25, 2002
020789 001	ZONISAMIDE;ZONEGRAN	6342515	DEC 21, 2018	U-438		

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 22ND EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.3 OF SUPPLEMENT WAIVED EXCLUSIVITY

REFERENCES

NEW DOSING SCHEDULE

D-71 EIGHT WEEK DOSING REGIMEN
 D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
 D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
 D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
 D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
 D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
 D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)

NEW INDICATION

I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
 I-349 ACUTE CORONARY SYNDROME
 I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
 I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
 I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
 I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
 I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
 I-355 PREMENSTRUAL DYSPHORIC DISORDER
 I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
 I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
 I-358 TREATMENT OF PANIC DISORDER
 I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
 I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE

- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
- I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
- I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- I-372 NOSOCOMIAL PNEUMONIA
- I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
- I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
- I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
- I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION

MISCELLANEOUS EXCLUSIVITY CODES

- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION

PATENT USE CODES

- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID

- DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
 - U-444 METHOD OF TREATING
 - U-445 USE AS AN ANTIMYCOTIC AGENT
 - U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
 - U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
 - U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
 - U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
 - U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
 - U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
 - U-452 USE OF LANSOPRAZOLE FOR COMBATING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
 - U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
 - U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
 - U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
 - U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
 - U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
 - U-458 METHOD OF USE OF IMAGENT
 - U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
 - U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
 - U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
 - U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
 - U-463 VENOGRAPHY
 - U-464 PERIPHERAL ARTERIOGRAPHY
 - U-465 CT IMAGING OF THE HEAD
 - U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME
 - U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
 - U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
 - U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
 - U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
 - U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
 - U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
 - U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
 - U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
 - U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
 - U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
 - U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
 - U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
 - U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
 - U-480 CONTRAST AGENT FOR MRI
 - U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-

- LIKE ACTIVITY
- U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
- U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
- U-489 EXPECTORANT
- U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-491 METHOD OF DELIVERING A DRUG TO THE LUNG
- U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
- U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

Superintendent of Documents Subscription Order Form

* 8392



Yes, enter my subscription as follows:

— subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for \$105.00 per year.

The total cost of my order is \$ _____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

Γ Check payable to Superintendent of Documents

Γ GPO Deposit Account ΠΠΠΠΠΠ-Γ

☐ VISA or MasterCard

[illegible]

Thank you for your order!

(Credit card expiration date)

(Authorizing Signature)

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954

To **FAX** your charge order, call (202) 512-2250.

To charge your subscription call (202) 512-1800.

